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1 Introduction 
 
 
1 INTRODUCTION 
1.1 The human immune system 
Our body’s integrity is constantly jeopardized by extrinsic and intrinsic threats such as 
microbiota and incipient cancer cells. As a result of evolutionary pressure, the human 
immune system has evolved into a complex network composed of different cell types, 
humoral factors and signaling pathways involved in the prevention and clearance of infective 
pathogens and in control of constant malignant transformation. A hallmark feature is the 
capability of discriminating “self” from “non-self” or “altered-self”: foreign pathogens or 
cancer cells have to be recognized and eliminated while remaining tolerant to the body’s own 
tissue and commensal microflora. Shifting this delicate balance in one direction or the other 
can lead to severe consequential damage such as neoplastic transformation, sepsis or 
autoimmune disease.   
In all jawed vertebrates, the immune system is classically comprised of two branches: innate 
and adaptive immunity. The innate immune system, as a phylogenetically ancious and 
evolutionary conserved system, serves as a first-line host defense of every multicellular 
organism. In mammals, its cellular basis is largely reflected by phagocytes such as 
neutrophils, monocytes/macrophages and dendritic cells that sense microbial infection or 
engulf pathogens and induce a subsequent immune answer. Furthermore, innate immunity 
is indispensable as driver for acquired immunity. In contrast, the adaptive (or acquired) 
immune system shows delayed responses to pathogens but allows for immunological memory 
and tailored response. Whereas innate immunity is not a single entity, the adaptive immune 
system is mainly reflected by highly specialized T and B cells. This specificity is ensured by 
antigen-specific receptors expressed on the cell surface as the result of somatic 
hypermutation and individual recombination of receptor-encoding genes during lymphocyte 
maturation. As a result, this assembly process generates an enormous diversity of receptors 
each specific to a single antigen and expressed on the surface of its corresponding 
lymphocyte. Only receptors that bind their matching antigen induce clonal expansion of the 
corresponding lymphocyte. 
In contrast to adaptive immunity, the molecular detection mechanisms of the innate immune 
system are mediated via germline-encoded and evolutionally highly conserved pattern 
recognition-receptors (PRR) [Zhang et al., 2010]. Thus, the specificity of any given PRR is 
genetically determined. Whereas the hereditability of such receptors is a decisive advantage, 
as no prior antigen exposure is necessary, the disadvantage is their limited diversity in 
comparison to the manifold repertoire of rearranged receptors used by the acquired system.      
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1.2 Pattern recognition receptor families 
Pattern recognition receptors (PRRs) are responsible for sensing the presence of 
microorganisms by recognizing invariant microbial structures termed pathogen-associated 
molecular patterns (PAMPs). Even before they have been discovered, Charles Janeway 
postulated the presence of such receptors [Janeway, 1992]. PRRs have common 
characteristics: First, they are germ-line encoded, non-clonal and constitutively expressed on 
all cells of a given type. Second, they sense specific molecular patterns that share a common 
motif. In microorganisms, those structures are essential for survival thus highly conserved 
and difficult to alter during evolution. Third, receptor-binding elicits a rapid reaction and 
upregulation of genes involved in inflammatory responses. In 1996, Matzinger already 
hypothesized that the activation of PRRs is not limited to exogenous PAMPs but that they also 
sense endogenous molecules released after cell stress and tissue damage, termed damage-
associated molecular patterns (DAMPs) (reviewed [Matzinger, 2002]). A concept that is 
nowadays well proven and clinically relevant in the pathogenesis of malignant, cardiovascular 
and autoimmune disease [Rakoff-Nahoum and Medzhitov, 2009; Frantz et al., 2007; Takeuchi 
and Akira, 2010].  
Until now, five different classes of PRR families have been identified. These families include 
transmembrane proteins such as Toll-like receptors (TLRs) [Kawai and Akira, 2010], C-type-
lectin receptors (CLRs) [Geijtenbeek and Gringhuis, 2009], scavenger receptors [Peiser et al., 
2002], cytosolic helicases such as (RIG)-I-like receptors (RLRs) [Yoneyama and Fujita, 2007] 
and NOD-like receptors (NLRs) [Chen et al., 2009]. With regard to the enormous spectrum of 
abovementioned PRRs, the following sections are limited to the detailed description of TLRs 
and RLRs. 
1.2.1 Toll-like receptors and their ligands 
The best characterized innate immune receptors are Toll-like receptors. TLRs are responsible 
for sensing pathogens on the cell surface and in intracellular endosomes and lysosomes 
[Akira et al., 2006]. They are evolutionally conserved from the worm Caenorhabditis elegans 
to mammals [Beutler and Rehli, 2002; Hoffmann 2003}. Toll, the eponymous member of the 
TLR family was initially described in Drosophila melanogaster as a gene product regulating 
dorsoventral polarity in Drosophila [Nusslein-Volhard and Wieschaus, 1980; Hashimoto et 
al., 1988]. Later, Hoffmann and colleagues showed that Toll is also essential for antifungal 
response in flies [Lemaitre et al., 1996]. The first human homologue of the Drosophila toll 
protein - Toll-like receptor 4 - was shown to induce the expression of proinflammatory 
cytokines and co-stimulatory molecules [Medzhitov et al., 1997].  
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To date, fourteen TLRs have been identified among different species [Kawai and Akira, 2010]. 
Ten TLRs have been found in human and twelve in mice. TLR1-9 are conserved among mice 
and human, although TLR8 is non-functional in mice and human TLR10 lacks subsequent 
signaling due to gene disruption by insertion of an endogenous retrovirus. TLR10-13 are not 
expressed in humans. Recently TLR14 has been described in fish [Palti, 2011].  
The cellular localization seems to play important roles in downstream signaling and 
maintaining tolerance to self-molecules such as nucleic acids. Some TLRs (TLR3, 7, 8 and 9) 
are exclusively located in intracellular compartments such as the endoplasmatic reticulum, 
endosomes and lysosomes where they sense nucleic acids. Another group of TLRs (TLR1, 2, 
4, 5, 6, 11) is expressed on cell surfaces and mainly recognizes microbial membrane 
components such as lipoproteins and carbohydrates. While TLR1, 2 and 6 recognize ligands 
by forming heterodimers, the remaining receptors seem to function as homodimers. 
Importantly, some TLRs have been shown to monitor the host’s internal environment to detect 
endogenous abnormal self-antigens. For instance, numerous endogenous TLR ligands have 
been identified so far such as heat-shock proteins, high-mobility group box-1 protein 
(HMGB1), extracellular matrix components as well as endogenous nucleic acids [Asea et al., 
2002; Park et al., 2004; Midwood et al., 2009; Kariko et al., 2004]. Endogenous TLR agonists 
are now thought to play an important role in regulating inflammation and seem to be involved 
in the pathogenesis of certain non-infectious disease such as autoimmune disorders, cancer 
and atherosclerosis [Piccinini and Midwood, 2010]. Table 1 gives an overview of different 
TLRs with their respective exogenous and endogenous ligands.  
TLR PAMP/DAMP Origin Reference 
TLR1+2 
Triacetylated lipopeptide 
β-defensin-3 
(Myco-)bacteria 
Self 
[Takeuchi et al., 1999] 
[Funderburg et al., 2007] 
TLR2+6 
Diacetylated lipopeptide 
Zymosan 
HMGB-1 
Heat-shock proteins 
Mycoplasma 
Fungus 
Self 
Self 
[Takeuchi et al., 2001] 
[Ozinsky et al., 2000] 
[Park et al., 2004] 
[Asea et al., 2002] 
TLR3 
dsRNA 
mRNA 
Virus 
Self 
[Alexopoulou et al., 2001] 
[Kariko et al., 2004] 
TLR4 
Lipopolysaccharide 
Envelope proteins 
Mannan 
Taxol 
Heat-shock proteins 
HMGB-1 
Fibrinogen 
Bacteria 
Virus 
Fungus 
Plants 
Self 
Self 
Self 
[Poltorak et al., 1998] 
[Kurt-Jones et al., 2000] 
[Tada et al., 2002] 
[Byrd-Leifer et al., 2001] 
[Asea et al., 2002] 
[Park et al., 2004] 
[Smiley et al., 2001]  
TLR5 Flagellin Bacteria [Hayashi et al., 2001] 
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Table 1.1. Overview of Toll-like receptors and their main endogenous and exogenous ligands 
(modified from Ishii et al., 2006; Piccinini and Midwood, 2010; Takeuchi and Akira, 2010).  
TLRs are differentially expressed depending on tissue and cell type. Moreover, most tissues 
express at least one TLR with predominance in cells associated with immune function. As an 
example, splenic cells and peripheral blood leukocytes express almost all TLRs as well as 
immune-associated tissue such as epithelial cells and fibroblasts [Zarember and Godowski, 
2002]. Focusing on expression patterns in immune cells, myeloid cells constitutively express 
TLR1 and 6, whereas macrophages preferentially express TLR2, 3, 4 and 8. Cells of acquired 
immunity  have been shown to express different TLRs, namely TLR2, 3, 5 and 9 on T cells 
[Kabelitz, 2007] and TLR1, 7, 9 and 10 on B cells [Bourke et al., 2003; Dasari et al., 2005]. 
Notably, the expression pattern of TLRs in dendritic cells significantly differs between mice 
and human: human myeloid DC express all TLRs with the exception of TLR9 while 
plasmacytoid DC express TLR1, 6, 7 and 9. In contrast, murine plasmacytoid DC express 
almost all TLR but TLR3 and 4. In addition, the expression level of TLR7 and 9 in murine DC 
is generally higher than in human DC [Muzio et al., 2000; Hornung et al., 2002]. These 
differences in expression patterns might explain why several studies using TLR7 and TLR9 
agonists as adjuvants in cancer immunotherapy did not produce the expected results 
generated from preclinical studies performed in mice. 
1.2.2 RIG-I-like receptors 
Retinoic acid-inducible gene I (RIG-I)-Iike receptors (RLRs) are a family of cytoplasmic 
DExD/H box RNA helicases that play a major role in sensing of RNA viruses to initiate and 
modulate antiviral immunity. The downstream signaling cumulates in the induction of a type 
I interferon response and antiviral gene expression. To date, three RIG-I-like helicases have 
TLR7  
ssRNA 
Imiquimod/Resiquimod 
Antiphospholipid antibody 
RNA virus/self 
Synthetic 
Self 
[Vollmer et al., 2005] 
[Hemmi et al., 2002] 
[Hurst et al., 2009] 
hTLR8 
ssRNA 
Antiphospholipid antibody 
RNA virus/self 
Self 
[Heil et al., 2004] 
[Doring et al., 2010] 
TLR9 
CpG DNA 
DNA 
Malaria hemozoin 
IgG-chromatin complexes 
Bacteria  
DNA virus 
Plasmodia 
self 
[Hemmi et al., 2000] 
[Lund et al., 2003] 
[Coban et al., 2005] 
[Leadbetter et al., 2002] 
hTLR10 Unknown Unknown  
mTLR11 
Unknown 
Profilin-like molecule 
Uropath. bacteria 
Toxoplasma 
[Zhang et al., 2004] 
[Yarovinsky et al., 2005] 
mTLR12 Unknown Unknown  
mTLR13 Unknown Unknown  
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been discovered: RIG-I (retinoic acid-inducible gene I), which is the first and therefore best 
characterized RLR, MDA5 (melanoma differentiation associated factor 5) and LGP2 
(laboratory of genetics and physiology 2) [Kang et al., 2002; Yoneyama et al., 2005]. RLRs 
are broadly expressed in most tissues and their expression is greatly enhanced with IFN 
exposure and after viral infection. Whereas in many cell types they play a dominant role in 
triggering antiviral immune defenses, plasmacytoid dendritic cells mainly use other RNA-
sensors such as TLR3, 7 and for IFN production [Kato et al., 2005].  
RIG-I and MDA-5 preferentially sense dsRNA either from dsRNA viruses or as an intermediate 
from ssRNA viruses. In addition, both are able to induce a potent IFN response following 
stimulation with synthetic polyinosinic:polycytidylic acid poly(I:C), especially when 
transfected intracellularily. In its low molecular form (0.2-1.0 kb) it mainly induces RIG-I 
activation, whereas high molecular weight poly(I:C) (1.5-8.0 kb) has been shown to be 
preferentially sensed by MDA-5 [Kato et al., 2008]. Furthermore, RIG-I detects RNA 
sequences marked with a 5’triphosphorylated (5’ppp) moiety which defines a non-self PAMP 
[Hornung et al., 2006]. Endogenous RNA also contains 5’ppp structures but is either capped 
or modified in the nucleus before it reaches the cytosol. Recent discoveries extended the 
spectrum of possible RIG-I substrates. As an example, Ablasser and colleagues showed a 
potent RIG-I response to dsDNA poly(dA:dT) from intracellular pathogens through 
recognition of a non-self product of polymerase III transcription [Kumar et al., 2006; Ablasser 
et al., 2009]. LGP2 is implicated in regulating the function of both of its family members 
depending on the type of RNA virus [Rothenfusser et al., 2005; Venkataraman et al., 2007]. 
Structurally, LGP2 is a homolog of RIG-I and MDA-5 but lacks the CARD domain and thus 
has no signaling ability but likewise has been shown to detect dsRNA [Li et al., 2009]. 
Notably, it is important to recognize that pathogens mostly do not activate one single PRR. 
The beginning of an innate immune answer and subsequent shaping of acquired immunity 
reflects an interplay between various PRRs in order to orchestrate a coordinated 
inflammatory response (reviewed in [Mogensen, 2009; Broz and Monack, 2013]. Accordingly, 
the current view on pathogen recognition has been shaped during the last two decades, 
initiated by Janeway’s hypothesis and stimulated by the identification of over 100 PRRs to 
date. Unraveling the complex interplay between different PRRs and the network of innate and 
adaptive immunity is subject of intensive and ongoing research activity thus our 
understanding of this interplay might improve substantially in the next years. 
Introduction  6 
1.2.3 Signaling of pattern recognition receptors 
Downstream signaling of RIG-I-like helicases, TLRs, NOD-like receptors and C–type lectin 
receptors is mediated via some central proteins and transcription factors, the most popular 
being nuclear factor (NF-)κB, activated protein 1 (AP-1) and mitogen-activated protein 
kinases (MAPK) - together dozens of transcription factors are cooperating in the upregulation 
of inflammatory genes. More specifically, TLRs initiate common NFκB/AP-1 whereas others 
have shown to initiate the expression of type I IFN via interferon regulatory factor (IRF)3 and 
IRF7 [Kawai and Akira, 2006; Thompson et al., 2011]. CARD-domain containing helicases 
such as RIG-I and MDA-5 trigger the induction of interferons via the adaptor protein 
interferon promoter stimulator 1 (IPS-1). Nucleotide oligomerization domain (NOD)-like 
receptors (NLRs) also signal via NFκB but share a second innate immune pathway by 
activating inflammasomes [Martinon et al., 2002]. Dectin-1 as a prototype for C-type lectins 
is important in triggering antifungal immunity and activates NFκB. Figure 1.1 summarizes 
main signaling pathways of PRRs targeted in this work; details are given in the text. 
 
Figure 1.1. Major signaling pathways of TLRs and RLRs with main target transcription factors relevant 
in this work (own drawing, adapted from Kawai and Akira, 2010; Geijtenbeek and Gringhuis, 2009; 
Yoneyama and Fujita, 2007). 
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1.2.3.1 Signal transduction via Toll-like receptors 
All TLRs are integral transmembrane glycoproteins that belong to a superfamily called the 
Toll/IL-1 receptor (TIR) family. The cytoplasmic TIR-domain shares considerable homology 
with Interleukin-1 receptors (IL-1Rs) and is required for mediating downstream signaling. 
The extracellular domain of TLRs contains variable leucine-rich repeats (LRR) motifs 
responsible for ligand recognition [Akira and Takeda, 2004]. TLRs share common and distinct 
signaling pathways: following LRR domain ligand recognition, TLRs dimerize and undergo 
conformational changes which is an essential step in the recruitment of cytoplasmic TIR-
domain-containing adaptor molecules to the intracellular TIR domain of the activated TLR. 
Five adaptor molecules have been described yet: the myeloid differentiation primary 
response gene 88 (MyD88), TIR-containing adapter inducing IFN-β (TRIF), TIR-associated 
protein (TIRAP)/MyD88-adaptor-like (MAL), TRIF-related adapter molecule (TRAM) and 
Sterile-alpha and Armadillo motif-containing protein (SARM) [O'Neill et al., 2003; Oshiumi et 
al., 2003; Kawai and Akira, 2006]. Together these signaling pathways activate the 
transcription factors NFκB and AP-1, leading to the production of various pro-inflammatory 
cytokines and chemokines as well as the upregulation of co-stimulatory molecules in order 
to facilitate an adaptive immune response [Iwasaki and Medzhitov, 2004]. In addition, the 
inflammatory response is further amplified by recruiting innate immune cells such as 
monocytes, neutrophils and natural killer (NK) cells to the site of inflammation. They also 
lead to production of type I interferons via IRF3/7 upon activation of TLRs 3, 4, 7, 8, 9 and 
RLRs.  
TLR signaling is divided into two pathways depending on the adaptor molecule used, MyD88 
or TRIF. The MyD88-dependent pathway is used by all TLRs with the exception of TLR3. In 
detail, upon PAMP recognition, MyD88 associates with the cytoplasmic portion of TLRs 
though homophilic TIR-TIR domain interaction. TLR2 and TLR4 signaling additionally 
requires the adaptor protein TIRAP/MAL for bridging between the TLR and MyD88 [Horng 
et al., 2002]. Once activated, MyD88 recruits IL-1R associated kinases (IRAK)-1 and IRAK 4. 
Subsequent signaling eventually leads to the phosphorylation of the IκB kinase (IKK)-β and 
MAP kinase 6. The IKK complex (composed of IKKα, IKKβ and NFκB essential modulator 
[NEMO]), phosphorylates IκB, an inhibitory protein NFκB. IκB then undergoes degradation 
and releases NFκB for translocation into the nucleus. In turn, activation of the MAP kinase 
cascade activates another major transcription factor complex, AP-1. Both transcription 
factors elicit an upregulation of inflammatory genes leading to the induction of a variety of 
chemokines and cytokines such IL-1β, IL-6, IL-10, IL-12, IP-10, TNFα and IFNγ [Barr et al., 
2007; Makela et al., 2009]. 
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As mentioned before, TLR2 and 4 require the presence of MAL for MyD88-dependent 
downstream signaling. In addition, Kawai and colleagues have shown that MyD88-deficient 
mice do not suffer from septic shock following treatment with high doses of LPS [Kawai et 
al., 1999]. However, neither NFκB nor MAPK showed abrogated activity which suggests a 
second signaling pathway independent of MyD88. This MyD88-independent signaling 
pathway has been well described during the last decade and termed TRIF-dependent 
pathway. It gets activated via TLR3 as well as TLR4. In TLR4 signaling requires the 
recruitment of TRAM as a bridging adaptor to the TIR domain of TLR4 [Fitzgerald et al., 2003; 
Yamamoto et al. 2003]. In addition to the activation of the canonical NFκB pathway and the 
activation of MAP kinases, downstream signaling of TRIF induces phosphorylation of IRF3 
and IRF7 which form homodimers, translocate into the nucleus and induce the transcription 
of type I interferons [Fitzgerald et al., 2003]. 
TLR-dependent type I IFN induction uses different signaling pathways and key molecules 
depending on the stimulated TLR, co-stimulatory effects of other PRRs and the cell-type 
stimulated. TLR4 as LPS-sensing molecule and TLR3 as sensor for dsRNA mainly activate 
IRF3 and 7 via the adaptor proteins TRAM/TRIF [Doyle et al., 2002]. TLR7, 8 and 9 in turn 
activate IRF5 and 7 in a TRIF-independent and MyD88-dependent manner with a central role 
for IRAK-1 downstream of MyD88 and IRAK-4 [Schoenemeyer et al., 2005; Uematsu et al., 
2005]. IRF7 plays an essential role as transcription factor in the IFN induction following 
stimulation with CpG-DNA as TLR9 agonist and R848 as TLR7 agonist [Honda et al., 2005].  
Notably, IFN induction upon TLR stimulation considerably differs between 
myeloid/conventional dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs). 
Conventional DCs mainly use the TLR3/4-TRIF dependent pathway for the induction of IFNβ 
that leads to upregulation of IRF-7 in an autocrine manner [Au et al., 1998]. In addition, TLR7 
and 9 expression levels as well as that of IRF7 as key transcription factor for IFNα production 
are significantly lower in cDCs. Honda and colleagues could unravel an additional 
mechanism, namely that CpG-DNA rapidly lysosomally degrades in cDCs, but is retained 
much longer in the endosome of pDCs thus facilitating the encounter between ligand and 
receptor-complex [Honda et al., 2005]. Interestingly, in human pDCs it has been shown that 
TLR9 exhibits a unique feature: knowing that TLR9 activation can result in a potent IFNα 
response and/or in triggering an adaptive immune response via IL-6 and TNFα secretion, this 
dual function has been attributed to the intracellular location where TLR9 encounters its 
ligand. Whereas in early endosomes TLR9 signaling primarily elicits the production of type I 
IFN, triggering TLR9 in late endosomes has been shown to mainly result in the production of 
inflammatory cytokines [Gilliet et al., 2008]. 
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1.2.3.2 Signal transduction via RIG-I-like receptors 
The RIG-I-like helicases MDA-5 and RIG-I recognize long dsRNA such as poly(I:C) and short 
dsRNA with 5’ppp moiety [Seth et al., 2005]. Once activated, both signal through homophilic 
interaction via CARD domains with a mitochondrial associated protein named IFNβ promotor 
stimulator 1 (IPS-1). IPS-1 has also been designated as mitochondrial anti-viral signaling 
(MAVS), CARD adapter inducing IFN-β (Cardif) or virus-induced signaling adapter (VISA) 
]Loo and Gale, 2011]. Downstream signaling results in a potent type I IFN response via 
TRAF3, TBK 1 and the already mentioned IRF3 and 7. Simultaneously, IPS-1-dependent 
signaling also mediates the nuclear translocation of NFκB via its non-CARD region which 
involves the activation of caspase-8. Nevertheless, the biological significance of that 
alternative pathway needs to be determined [Seth et al., 2005]. 
1.3 The human immune system and cancer 
1.3.1 Cancer Immunology: Immunosurveillance and Immunoediting  
Burnet and Thomas hypothesized 1957 that our immune system is capable of recognizing 
and eliminating nascent and continuously arising transformed cells; a concept which has 
been termed immunosurveillance [Burnet, 1957]. Already in 1909, Paul Ehrlich envisioned 
that our immune system is able to suppress and monitor neoplastic transformation. Notably, 
at that time Ehrlich already worked on sarcoma vaccination in rodents. Burnet’s and Thomas’ 
hypothesis gained further interest when the first tumor-associated antigens were discovered 
[Feldman, 1963; Old and Boyse, 1964; Rosenberg, 1999]. The concept of immunosurveillance 
ultimately gained acceptance in the 1990s with rising technological advances when DC 
vaccination with tumor-antigens and adoptive T-cell transfer showed significant immune 
responses against malignant cells and pivotal studies identified key effector molecules such 
as IFNγ [Kaplan et al., 1998; Shankaran et al., 2001] and perforin [van der Bruggen et al., 
1991; Smyth et al., 2001] in protecting the host in both chemically induced and spontaneous 
tumors. Furthermore, extensive research of the last two decades revealed that 
immunosurveillance seems to be only one dimension in the complex relationship of cancer 
and our immune system [Smyth et al., 2001; Dunn et al., 2002; Dunn et al., 2004]. Tumor-
immunologists learned that immunity not only protects the development of neoplastic lesions 
in terms of immunosurveillance, but also sculpts tumor immunogenicity and eventually can 
support tumor growth by selecting for more aggressive tumor escape variants with reduced 
immunogenicity - a concept that has been termed immunoediting [Dunn et al., 2004]. Cancer 
immunoediting resembles a three-step process: The first step is ` the elimination phase’ which 
resembles above described immunosurveillance by a cooperative action of innate and 
acquired immunity. The second phase has been named ‘equilibrium phase’; genetically 
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unstable and rapidly mutating tumor cells that withstood the elimination’s phase selection 
pressure enter this latency period as an intermediate between elimination phase to the 
emergence of clinically detectable malignant disease which defines the ‘escape phase’ as last 
phase (see below). Particularly, it is important to recognize that the process of immunoediting 
is not an inevitable linear process. Incipient malignant transformation can be cleared in the 
elimination phase and cancer cells that have entered the equilibrium phase can eventually 
still get eliminated by the immune system.  
1.3.2 Tumor-escape mechanisms 
To become clinically relevant in immunocompetent hosts, tumor cells must overcome innate 
and adaptive detection mechanisms. The failure of this immune recognition is arguably due 
to its inability to recognize cancer cells in an immunologic context which can be due to 
induction of immunogenic tolerance [Willimsky and Blankenstein, 2005] or by avoiding 
immune recognition; the concept of avoiding immune destruction has even pronounced as 
one of the emerging hallmarks of cancer [Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011].  
First evidence for the role of defective immunological monitoring in the context of tumor 
formation was made by clinical epidemiologists in the late 1980s to 1990s when a striking 
increase of certain cancers such as Kaposi’s sarcoma, Hodgkin’s and non-Hodgkin’s 
lymphoma in HIV/AIDS patients and immunocompromised patients following solid organ or 
bone marrow transplantation was observed [Farge, 1993; Lai et al., 1997; Vajdic and van 
Leeuwen, 2009]. However, the majority of these tumor entities were viral-induced cancers 
and given that over 80% of human malignancies are of non-viral etiology the conclusion of a 
general role of an over-alert immune system limiting the formation of nascent cancer cells 
into clinically evident tumors is not justified. Nevertheless, further research with genetically 
engineered mouse models as well as clinical evidence has warranted that our immune system 
indeed acts in limiting tumor formation and that neoplastic growth, in terms of a Darwinian 
fashion, triggers a variety of immunosuppressive features to avoid detection and to foster its 
own survival [Rabinovich et al., 2007; Hanahan and Weinberg, 2011]. 
1.3.2.1 Tumor cell-intrinsic traits 
Tumor cells can alter distinct genes and signaling pathways to effectively avoid immune 
recognition. Several groups have shown that human cancer cells either downregulate or loose 
their HLA class I expression thus limiting the activation and cytotoxic effect of tumor-specific 
CD8+ T cells [Ferrone and Marincola, 1995; Algarra et al., 2000]. Likewise, mutations in the 
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β2-microglobulin locus and loss-of-function mutations in the TAP1 locus lead to defects in 
signaling pathways involved in processing and presentation of antigens on tumor cells 
[Maeurer et al., 1996; Marincola et al., 2000; Rivoltini et al., 2002]. Other genetic lesions 
include the absence of IFNγ receptors on the surface which has been demonstrated for lung 
carcinoma cell lines [Kaplan et al., 1998] and melanoma cells [Wong et al., 1997] rendering 
them unresponsive to IFNγ-induced upregulation of HLA molecules.  
Another striking mechanism is the expression of factors involved in modulating antitumor 
responses by negative co-stimulatory pathways with the programmed cell death protein 1 
(PD-1) / programmed cell death protein 1 ligand (PD-L1) system as a prime example. PD-1 
and PD-L1 are both membrane-bound proteins with PD-1 expressed on T cells and known 
for its regulatory effect on T cell receptor signaling. In turn, PD-L1 as its ligand has been 
shown to be expressed by almost all murine and a variety of human cancer cells playing a 
pivotal role in the escape from host immune response by blocking the effector phase of 
specific T cell antigen receptor mediated lysis of tumor cells [Blank et al., 2004]. Anti-PD-L1 
antibodies were already evaluated in phase-I-trial for patients with selected advanced stage 
cancer [Brahmer et al., 2012]. 
Another mechanism contributing to immune evasion is the microenvironmental influence on 
amino acid metabolism. Uyttenhove and colleagues identified the enzyme indoleamine 2,3-
dioxygenase (IDO) to induce T cell tolerance by oxidative breakdown of tryptophan 
[Uyttenhove et al., 2003]. Apart from its production in tumor cells, IDO has been found to be 
expressed by tolerogenic antigen-presenting cells (APCs) thus amplifying the suppression of 
T cell immunity and the recruitment of regulatory T cells (Treg) [Prendergast, 2008]. 
A counterintuitive feature of cancer cells is using the immune system’s own antitumoral 
defense mechanisms to evade immune destruction. Fas ligand or CD95L as a type II 
transmembrane protein is expressed by T cells and NK cells. By binding to its receptor 
FasR/CD95 it triggers an intracellular cascade leading to apoptotic cell death; a mechanism 
essential in mounting an effective T cell response in antitumor immunity [Siegel et al., 2000; 
Shanker et al., 2009]. Cancer cells twist around this feature by acquiring FasL on their cell 
surface making them capable of delivering death signals to Fas-positive cytotoxic T 
lymphocytes and NK cells. [Hahne et al., 1996; Andreola et al., 2002]. In accordance with 
this, the secretion of soluble CD95 in tumor patients abolishes antitumor response and 
significantly correlates with a poorer outcome [Ugurel et al., 2001; Igney and Krammer, 
2002].  
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Finally, even highly immunogenic cancer cells may avoid immune destruction by 
overproduction of immunosuppressive factors such as transforming growth factor-β, IL-10, 
galectin-1 and PGE2 [Yang et al., 2010]. IL-10 can impair adequate DC responses by impairing 
TAA cross-presentation [Gerlini et al., 2004]. TGFβ in turn has been shown to exert 
pleiotropic effects on tumor formation and tumor-associated immunosuppression. In early 
phases of tumor formation, TGFβ functions as a regulator of tissue homeostasis and acts as 
an inhibitor of tumor-progression via TGFβ Receptor II (TGFβ RII) and SMAD-dependent 
induction of apoptosis [Arteaga et al., 1990; Edlund et al., 2003]. That has been demonstrated 
in multiple mouse models and supported by clinical studies showing mutations of TGFβ RII 
and SMAD proteins in human lung, prostate, colon and breast cancer [Markowitz et al., 1995; 
Jakowlew, 2006]. On the other hand, numerous other studies outlined the detrimental effect 
of TGFβ in cancer biology. Alongside non-immunological and pro-tumoral mechanisms like 
activation of epithelial-to-mesenchymal transition [Ellenrieder et al., 2001; Drabsch and ten 
Dijke; 2012] and fostering tumor angiogenesis [Roberts et al., 1986], TGFβ is commonly 
known as a potent and naturally occurring suppressor of the immune system - a function 
generously used by tumor cells to facilitate their immune escape. Secreted by tumor or 
bystander cells of the microenvironment, TGFβ blocks the production of perforin, granzymes 
and IFNγ thus inducing T cell anergy of CTLs [Fukunaga et al., 2004; Thomas and Massague, 
2005]. In addition, TGFβ shifts a TH1-skewed immune response to a tumor-promoting TH2 
phenotype and participates in the induction of Tregs and recruitment and activation of 
myeloid-derived suppressor cells into the tumor-microenvironment [Chen et al., 2003; Li et 
al., 2012].  
1.3.2.2 Tumor cell-extrinsic traits 
In addition to intrinsic immune evasive mechanisms, more subtle mechanisms of 
immunosuppression in cancer operate together in order to recruit immunosuppressive 
bystander cells to the tumors immediate microenvironment and draining lymph nodes where 
tumor neoantigens scavenged by antigen-presenting cells are cross-presented to the adaptive 
immune system.  
An increasing body of evidence shows that neoplastic immune escape is also mediated by 
regulatory T cells (TRegs). Regulatory T cells have initially been described by Sakaguchi and 
colleagues as naturally occurring CD4+CD25+ forkhead box p3 (Foxp3) expressing cells in the 
context of immune homeostasis and in preventing autoimmunity by suppressing autoreactive 
T cells [Sakaguchi et al., 1995; Vieweg et al., 2007]. The proof-of-principle on the role of TRegs 
in tumor immunity was made by Curiel in 2004 when he and colleagues found that tumor-
associated TRegs were recruited to tumor sites in a CCL22 dependent fashion and specifically 
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inhibited T cell-mediated antitumor immunity in patients with advanced stage ovarian cancer. 
In addition, on an individual base, they demonstrated that an increase in the amount of tumor-
infiltrating TRegs predicts for poorer survival [Curiel et al., 2004]. Since then, multiple other 
studies in mice and human cancer have provided mechanistic insights into the 
immunosuppressive capabilities of TRegs. On a cellular basis they inhibit antigen-presenting 
cells, NK cells and T cells in the tumor microenvironment or systemically. They do so via the 
expression of TGFβ, IL-10, IL-35 [O'Garra et al., 2004; Collison et al., 2007], induction of IDO-
expression in APCs [Fallarino et al., 2003; Vignali et al., 2008], or via the expression of 
cytotoxic T lymphocyte antigen 4 (CTLA4) thus shutting down the costimulatory pathway in 
APCs by inhibitory binding to B7-H1 or B7-H2 [Waterhouse et al., 1995]. 
Dendritic cells (DCs) are critically important in mounting an effective antitumoral response 
via uptake and presentation of tumor-associated antigens to effector cells [Guermonprez et 
al., 2002]. Cancer patients, however, show decreased numbers of functionally active DCs in 
lymph nodes, spleen and peripheral blood [Almand et al., 2000; Hoffmann et al., 2002]. DCs 
loose their functionality during tumor progression as evidenced by studies in patients with 
prostate cancer, malignant glioma and breast cancer showing marked reduction in antigen-
presentation and induction of IFNγ secretion by T cells [Pinzon-Charry et al., 2005]. 
Additionally, cancer cells induce expansion and accumulation of tolerogenic dendritic cells 
(tDCs). In 2003, Steinmann and colleagues described a physiologically occurring population 
of dendritic cells that bear an antigen-specific tolerogenic role in limiting autoimmunity and 
overwhelming immune responses by presenting antigens without concurrent co-stimulatory 
signals and simultaneous paracrine secretion of immunosuppressive molecules [Steinman et 
al., 2003]. Tolerogenic DCs, phenotypically matching pDCs, have been found in a variety of 
human malignancies and have been well studied in murine tumors models [Hartmann et al., 
2003; Vermi et al., 2003]. By mechanisms depending on a tumor-induced differentiation 
blockage and increase in STAT3 expression, tDCs are kept immature and acquire 
immunosuppressive features such as IL-10, TGFβ and IDO-expression [Gabrilovich et al., 
1996; Geissmann et al., 1999; Gabrilovich, 2004; Lob and Konigsrainer, 2008]. When T cells 
encounter tDCs that lack co-stimulatory receptors, surrounded by a suppressing cytokine 
milieu, they are either rendered anergic or even differentiate into regulatory T cells.  
In addition to the above-mentioned immunosuppressive cells, other regulatory cell 
populations also contribute to impaired tumor surveillance including regulatory B cells (Bregs) 
[Mauri and Bosma, 2012], regulatory NK cells [Deniz et al., 2008], tumor-associated 
macrophages (TAMs) [Mantovani et al., 2002] and tumor-associated neutrophils (TANs) 
[Fridlender and Albelda, 2012]. Recently a population of immature myeloid cells termed 
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MDSC (myeloid derived suppressor cells) has been described which will be further discussed 
in detail below.   
1.4 Myeloid-derived suppressor cells: Innate regulators of the immune 
system 
Cancer-associated immunosuppressive myeloid cells were already described over 30 years 
ago [Duwe and Singhal, 1979; Young et al., 1987]. The appreciation of their functional 
importance only recently became apparent when researchers demonstrated that the 
administration of anti-Gr1 antibodies could significantly slow tumor growth by eliminating 
myeloid cells circulating in the blood of tumor-bearing mice [Seung et al., 1995] and when 
clinicians discovered CD34+ cells in tumors and lymph nodes of patients with head and neck 
cancer [Pak et al., 1995]. Recently, these cells were generally termed myeloid-derived 
suppressor cells (MDSC) to reflect the abnormal nature of myelopoiesis during tumor 
formation [Gabrilovich and Nagaraj, 2009].  
MDSC resemble a heterogeneous group of myeloid cells comprised of macrophage 
precursors, immature granulocytes and dendritic cells as well as myeloid cells at earlier 
stages of differentiation, all of which have been prevented from fully differentiating into 
myeloid cells by tumor-derived factors [Gabrilovich and Nagaraj, 2009]. By definition, this 
group shares two distinct features: their myeloid origin and potent immunosuppressive 
function. In addition, MDSC have been found in numerous human malignancies and in almost 
all murine cancer models tested [Nagaraj and Gabrilovich, 2010; Rodrigues et al., 2010; Sun 
et al., 2012]. MDSC have been detected in bone marrow, blood, spleen, tumor-draining lymph 
nodes as well as the tumor microenvironment of tumor-bearing mice and human cancer 
patients [Sinha et al., 2005; Serafini et al., 2006; Vincent et al., 2010]. Notably, a recent study 
by Jordan and colleagues showed MDSC accumulation in peripheral blood as an individual 
prognostic factor of poor outcome in patients with melanoma [Jordan et al., 2013].  
MDSC employ multiple immunosuppressive features including their remarkable ability to 
suppress T cell responses as well as non-immunological functions such as promotion of 
angiogenesis, tumor invasion and metastasis. During the last decade, tumor immunologists 
started to further characterize MDSCs in the context of human and murine malignancies and 
begin to dissect molecular pathways regulating their expansion and activation thereby 
opening the doors for a new potential target in immunotherapy of malignant disease 
[Talmadge and Gabrilovich, 2013].   
15 Introduction 
 
1.4.1 Origin of MDSC 
Immature myeloid cells (iMCs) are an integral part of the normal process of myelopoiesis. 
Myelopoiesis in the bone marrow is a tightly regulated process and controlled by a complex 
network of soluble factors including cytokines such as IL-3, stem-cell derived factor (SDF), 
granulocyte/macrophage colony-stimulating factor (GM-CSF), FMS-related tyrosine kinase 
and a myriad of growth-factor receptors [Moore, 1979, Bender et al., 1987; Friedman, 2002]. 
Hematopoietic stem cells differentiate into common myeloid progenitor cells and then into 
immature myeloid cells. Normally iMCs constitute about 20 to 30% bone marrow cells, 2 to 
4% splenic cells and approximately 0.5% of peripheral blood mononuclear cells, quickly 
migrating into peripheral organs and differentiating into macrophages, dendritic cells and 
mature granulocytes [Almand et al., 2001; Movahedi et al., 2008]. However, during trauma, 
inflammation and tumor formation they accumulate, become activated and migrate to sites 
of inflammation, alongside with further blockage of their differentiation. When these cells 
have finally acquired immunosuppressive properties they are further termed myeloid-derived 
suppressor cells (MDSC).   
Notably, the importance of MDSC accumulation has also been described in a variety of other 
disease as cancer: bacterial, viral and parasite infections [Brys et al., 2005; Delano et al., 
2007; Dietlin et al., 2007; De Santo et al., 2008], sepsis [Cuenca et al., 2011], chemotherapy 
[Angulo et al., 2000], traumatic stress [Makarenkova et al., 2006], autoimmunity [Zhu et al. 
2007; Kerr et al., 2008] and in the setting of bone marrow transplantation [Highfill et al., 
2010]. In cancer, MDSC play a detrimental role by immunosuppression of the host and 
simultaneously represent major obstacles for effective immunotherapy approaches. However, 
in the setting of hyperinflammation or autoimmunity such as autoimmune encephalitis, 
fulminant sepsis or graft-versus-host disease their presence might be ultimately beneficial by 
limiting immune-mediated damage to the host. 
1.4.2 Phenotype and MDSC heterogeneity  
In mice, MDSC are phenotypically characterized by the co-expression of the granulocyte  
differentiation antigen Gr-1 (constituted by the 2 epitopes Ly6G and Ly6C) and the αM- 
integrin CD11b or macrophage-1 antigen (Mac-1) [Kusmartsev and Gabrilovich, 2002]. MDSC 
are further divided into two major subpopulations with respect to their morphologic 
appearance and their differential expression of the Ly6G and Ly6C antigen: 
polymorphonuclear Gr1+CD11b+Ly6GhighLy6Clow MDSC (PMN-MDSC) and monocytic 
Gr1+CD11b+Ly6GnegLy6Chigh MDSC (MO-MDSC). Both subsets were found to potently inhibit 
antigen-specific T-cell responses in vitro and in vivo. Notably, PMN- and MO-MDSC further 
differ in their expression of specific enzymes involved in their immunosuppressive function: 
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While PMN-MDSC express high levels of arginase-1, MO-MDSC contain both arginase and 
inducible nitric oxide synthase (iNOS) (Figure 2.2). 
          DAPI    Arginase-1     iNOS              Merged 
 
Figure 2.2. Immunofluorescence of Arg1 and iNOS of magnetically purified murine MDSC-
subpopulations. 
Other phenotypical markers have been described differing on murine MDSC-subpopulations 
such as CD71 (transferrin receptor), CD115 (macrophage colony-stimulating factor 
receptor/M-CSFR), CD31 (PECAM-1), CD1d which are more prominent or exclusively 
expressed on MO-MDSC [Movahedi et al., 2008].  
Human MDSC were initially identified as HLA-DR-CD33+ or CD14-CD11b+ populations, both 
of which were able to suppress T cell activity [Almand et al., 2001]. Currently, the human 
equivalents of MDSC are commonly defined as CD34+CD11b+LIN-HLA-DR-CD14- cells, or 
more narrowly as cells expressing either one or both of the common myeloid markers CD33 
or CD11b, lack lineage markers of mature myeloid or lymphoid cells (LIN-) such as CD3, 
CD19, CD56 and CD13 and do not express the MHC class II molecule HLA-DR [Talmadge 
and Gabrilovich, 2013]. However, the expression of CD14 in human MDSC is still a matter of 
debate, as different groups reported the expression of CD14 on MO-MDSC [Zea et al., 2005; 
Filipazzi et al., 2007]. As human MDSC lack a phenotypical equivalent to the murine Gr1-
antgen and likewise lack Ly6G/C equivalents, efforts have been made to differentiate between 
MO-MDSC and PMN-MDSC in the human setting either on the basis of their maturity or by 
phenotypical means [Dumitru et al., 2012]. So far, MO-MDSC have been found to have a 
CD14high phenotype whereas PMN-MDSC are CD14neg/low. In addition, some groups used 
CD15 to discriminate between granulocytic CD15+ and monocytic myeloid cells [Rodriguez 
et al., 2009]. Additional markers are under investigation such as differential expression of 
CD66b which seems to be more prominent on PMN-MDSC. Phenotypes of human and mouse 
MDSC and as well as variable mechanisms of immunosuppression of MDSC subpopulations 
are further reviewed here [Serafini et al., 2006; Gabrilovich and Nagaraj, 2009].  
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1.4.3 MDSC expansion and activation in cancer 
Cancer patients show a four- to tenfold increase in peripheral MDSC numbers [Filipazzi et 
al., 2007; Hoechst et al., 2008; Diaz-Montero et al., 2009]. Likewise, MDSC levels in murine 
tumor models are significantly increased up to 70% of bone marrow cells, 10 to 20% 
peripheral blood mononuclear cells (PBMCs) and 5 to 40% of splenic leukocytes depending 
on the respective tumor model [Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and 
Sinha, 2009]. During tumor formation they also home to tumor-draining lymph nodes and 
represent a major cell type within the tumor microenvironment [Meyer et al., 2011].  
In order to completely fulfill their immunosuppressive function, MDSC first need to be 
expanded and then activated [Gabrilovich and Nagaraj, 2009]. The past decade of research 
has failed to identify a single factor or signaling pathway that simultaneously mediates both 
necessary steps. Moreover, their accumulation is rather seen as a result of an interaction 
between different soluble molecules and receptors that are hypersecreted under pathological 
conditions, the lion’s share being inflammatory mediators thereby linking MDSC with the old 
concept of chronic inflammation and cancer [Coussens and Werb, 2002]. Not surprisingly, 
the list of driver molecules for MDSC expansion seen in acute and chronic inflammatory 
conditions significantly overlaps with those identified in serum and tumor microenvironment 
of cancer patients and murine tumor models. This concept is supported by the fact that 
pharmacological inhibition of inflammatory mediators that drive and support tumor formation 
such as cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), vascular endothelial growth 
factor (VEGF), IL-6, IL-1β and others, has concurrently shown to inhibit MDSC expansion 
and/or their activation [De Santo et al., 2005; Kusmartsev et al., 2008; Sumida et al., 2012; 
Zitvogel et al., 2012].  
Several tumor-derived factors either directly secreted by tumor cells or released by 
microenvironmental bystander cells can induce a marrow expansion of MDSC and 
subsequently track them to the tumor site or other lymphoid organs such as tumor-draining 
lymph nodes and spleen [Gabrilovich, 2004]. The biological impact of these tumor-derived 
factors on myeloid cells was already shown in 1987, when researchers described that normal 
bone marrow cells gather an immunosuppressive phenotype and properties in vitro when 
cultured together with tumor-conditioned medium [Young et al., 1987]. Additional support 
came from studies in cancer patients revealing a significant decline in peripheral MDSC 
frequencies following cytoreductive surgery [Diaz-Montero et al., 2009]. More narrowly, GM-
CSF has been shown to be a major promotor of MDSC accumulation in human as well as in 
murine cancer models [Pak et al., 1995]. In addition, complement factor 5a (C5a) contributes 
to tumor growth by inducing MDSC. C5aR-deficient mice showed impairment of T cell 
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suppression by MDSC accompanied by a greater influx of intratumoral CTLs. Myeloid 
progenitors express receptors for S100 calcium-binding protein family members. S100A8/9 
proteins are released during inflammation and signal via TLR4 and the receptor for advanced 
glycation endproducts (RAGE) [Ehrchen et al., 2009; Leclerc et al., 2009] and have been 
linked to tumorigenesis [Ichikawa et al., 2011]. Notably, S100A9-deficient mice fail to 
increase MDSC numbers after challenging them with complete Freud’s adjuvant [Cheng et 
al., 2008]. Complementarily, IL-1β as the first cytokine to be described, has been shown to 
mobilize and activate MDSC in a mouse model of gastric cancer [Tu et al., 2008]. Table 1.2. 
depicts soluble factors known to drive accumulation or activation of MDSC. 
Tumor-derived factor Reference 
Granulocyte-colony stimulating factor (G-CSF) [Sawanobori al., 2008] 
Granulocyte/macrophage-colony stimulating 
factor (GM-CSF) 
[Bronte et al., 1999; Filipazzi et al., 2007] 
Vascular endothelial growth factor (VEGF) [Kusmartsev et al., 2008] 
Transforming growth factor beta (TGFβ) [Terabe et al., 2003; Li et al., 2012] 
Interleukin-1β (IL-1β) [Tu et al., 2008] 
Interleukin-6 (IL-6) [Bunt et al., 2007] 
Interleukin-10 (IL-10) [Huang et al., 2006] 
Interleukin-12 (IL-12) [Li et al., 2004] 
Interleukin-13 (IL-13) [Terabe et al., 2003] 
Interferon-γ (IFNγ) [Gallina et al., 2006] 
Tumor necrosis factor α (TNF-α) [Zhao et al., 2012] 
Stem cell factor (SCF) [Pan et al., 2008] 
Prostaglandins [Sinha et al., 2007] 
Complement factor 5a (C5a) [Markiewski et al., 2008] 
Matrix metalloproteinase 9 (MMP9) [Melani et al., 2007] 
S100A8 and S100 A9 [Cheng et al., 2008] 
Heat-shock protein 72 (Hsp72) [Chalmin et al., 2010] 
CC-chemokine ligand 2 (CCL2) [Fridlender et al., 2010] 
CXC-chemokine ligand 5 (CXCL5) [Toh et al., 2011] 
CXC-chemokine ligand 15 (CXCL12) [Obermajer et al., 2011] 
Table 1. 2. Factors implicated in the expansion or activation of MDSC in cancer.  
Upon differential activation, MDSC express a number of cytokines and proinflammatory 
molecules producing an autocrine feedback loop that triggers their own activation or sustains 
MDSC within the tumor microenvironment. 
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MDSC secreted cytokines Reference 
Transforming growth factor beta (TGFβ) [Terabe et al., 2003] 
Interleukin-1β (IL-1β) [Bruchard et al., 2013] 
Interleukin-10 (IL-10) [Chen et al., 2001] 
Interleukin-13 (IL-13) [Gallina et al., 2006] 
Tumor necrosis factor α (TNFα) [Umemura et al., 2008] 
Table 1. 3. Cytokines released by MDSC. 
Most of the factors described above converge in common signaling pathways, some of which 
have been implicated in regulating MDSC expansion such as Janus kinase 2 (JAK2) and signal 
transducer and activator of transcription 3 (STAT3). Engagement of cytokine receptors 
activates JAKs that subsequently induce phosphorylation of STAT protein family members 
[Rawlings et al., 2004]. Whereas constitutive activation of STAT3 in cancer cells and other 
tumor-infiltrating cells is well documented [Catlett-Falcone et al., 1999; Hu et al., 2014], 
Kusmartsev and colleagues could demonstrate a pivotal role for STAT3 in the expansion of 
MDSC by showing that STAT3 is persistently activated in MDSC and prevents myeloid cells 
from further differentiating [Kortylewski et al., 2005]. Blockage of STAT3 with selective 
inhibitors resulted in stronger antitumoral T cell responses and a significant decrease in 
MDSC frequency [Nefedova et al., 2007].   
1.4.4 Mechanisms of immunosuppression exerted by MDSC 
Myeloid derived suppressor cells use multiple mechanisms to suppress antitumor immunity. 
Their main feature is preventing the host from mounting an effective T cell response by 
inhibiting the proliferation of CD8+ cytotoxic T lymphocytes, inducing T cell anergy or 
apoptosis, perturbing T cell activation or downregulation of IFNγ secretion by T cells. Most 
studies showed the necessity of direct cell-cell interaction with target cells implicating that 
MDSC function either via cell surface receptors and/or via the release of soluble short-lived 
mediators.  
MDSC effectively suppress antigen-specific T cell responses by amino acid metabolism. In 
particular, both MDSC subsets express high levels of arginase 1 (Arg1) which allows them to 
metabolize L-arginine to L-ornithine and urea resulting in depletion of L-arginine from the 
microenvironment [Bronte and Zanovello, 2005; Rodriguez et al., 2009]. T cells in turn lack 
L-arginine and then fail to express CD3ζ-chain, which keeps them in the G0-G1 cell cycle 
phase thus repressing protein synthesis [Baniyash, 2004; Rodriguez and Ochoa, 2008]. 
Simultaneously, L-arginine is the substrate for another enzyme: inducible nitric oxide 
synthase (iNOS) that is mainly expressed by MO-MDSC and catalyzes the conversion of L-
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arginine to L-citrulline and nitric oxide (NO). NO operates through various mechanism to 
suppress T cell function such as interfering with the IL-2 signaling pathway, preventing TCR 
activation and eventually leading to apoptosis [Fischer et al., 2001; Ferlito et al., 2006]. 
Another mechanism that has been recently described is the sequestration of cysteine. T cells 
lack the machinery to generate cysteine, thus it represents an essential amino acid for them. 
During activation, T cells especially require cysteine for protein synthesis and differentiation. 
Under steady-state conditions it is provided by antigen-presenting cells via direct import 
during antigen presentation. However, MDSC are unable to export cysteine thus depleting it 
from the environment.  
Increased production of reactive oxygen species (ROS) has emerged as one of the main 
factors by which MDSC contribute to immunosuppression in tumor-bearing mice and patients 
with cancer [Schmielau and Finn, 2001; Kusmartsev et al., 2004]. ROS are derived from 
metabolism of cellular oxygen and include highly reactive species such as super oxide O2-, 
hydrogen peroxide H2O2 and peroxynitrite (ONOO-) as the product of NO and superoxide   
O3-. ROS are involved in both cancer initiation as well as progression and directly associated 
with T cell unresponsiveness and immunosuppression in patients with advanced disease 
[Mantovani et al., 2003]. Peroxynitrite induces nitrosylation of amino acids of the TCR 
complex during cell-cell contact which blocks the formation of CD8/MHC-I complexes 
rendering T cells unresponsive to antigen-specific stimulation [Nagaraj et al., 2007]. Several 
known tumor-derived factors induce ROS generation by MDSC such as TGFβ, IL-10, IL-6 and 
GMCSF (Table 1.3). 
Other described mechanisms of MDSC mediated immunosuppression include the 
downregulation of L-selectin, also known as CD62L, on naïve T cells. CD62L acts as a homing-
receptor by promoting extravasation and tracking of naïve T cells to antigen-containing sites 
such as lymph nodes and the tumor mircroenvironment [Tedder et al., 1995]. L-selectin 
expression on T lymphocytes is inversely correlated with MDSC frequency in tumor-bearing 
mice and cancer patients. Additionally, co-culture of MDSC with CD4+ and CD8+ T cells results 
in downregulation of L-selectin expression [Hanson et al., 2009]. The induction of Tregs by 
MDSC as a contributing factor for tolerance to tumor-specific antigens in vivo has been 
described by several groups [Serafini et al., 2006; Movahedi et al., 2008]. However, due to 
conflicting reports, the physiological relevance and presence of this mechanism needs further 
scientific proof. Additional mechanisms described are the induction of NK cell anergy via a 
mechanism involving MDSC-bound TGFβ [Li et al., 2009]. Interestingly, Park and colleagues 
showed that a specific subset of CD11b+ NK cells within the tumor microenvironment can be 
converted into GR1+CD11b+ MDSC ex vivo in a GM-CSF-dependent manner.  
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MDSCs also exhibit several non-immunological features to promote tumorigenesis. They 
foster tumor invasion and metastasis by expression of matrix metalloproteinases (MMPs) 
such as MMP9, a process that has shown to depend on the upregulation of hypoxia-inducible 
factor 1-α and microRNA-494 [Du et al., 2008; Liu et al., 2012]. Via secretion of VEGF, MDSC 
also promote tumor angiogenesis [Lechner et al., 2010]. Furthermore, one study 
demonstrates that splenic Gr1+CD11b+ cells can directly differentiate into endothelial 
progenitor cells and thereby contribute to de novo vasculogenesis of tumors [Yang et al., 
2004].  
Given the complexity of the described mechanism regulating MDSC accumulation, activation 
and the variety of immunosuppressive mechanism they exploit, it will be essential to 
determine which conditions and factors are dominant in order to specifically target MDSC-
associated immunosuppressive features. 
1.5 Immunotherapy of cancer 
1.5.1 Overview  
Most cancer patients are treated with a conventional combination of surgery, radio- and 
chemotherapy. Nevertheless, the primary failure in reducing cancer-related mortality is the 
insufficient control of advanced disease, metastatic spread and the presence of 
micrometastases or minimal residual disease which are not recognized by diagnostic 
imaging. As cancer becomes a chronic disease, another issue obtaining increasing attention 
is therapy-related mortality. In the last two decades multiple attempts have been made in 
order to eradicate clinically non-detectable disease and reducing therapy-related mortality. 
Meanwhile, besides surgery, chemotherapy and radiation, immunotherapy of cancer is 
already established as a fourth mainstay in clinical oncology.  
Clinically established approaches include the administration of cytokines: a number of 
cytokines including GM-CSF, IL-7, IL-12, IL-15, IL-18 and IL-21 have been evaluated in 
preclinical studies and are now entering clinical trials for patients with advanced stage 
disease. To date, two cytokines have been FDA-approved, namely IL-2 for treatment of 
metastatic melanoma and renal cell cancer [Coppin et al., 2005] and IFNα for stage III 
melanoma and a number of hematologic neoplasms such as chronic myeloid leukemia 
[Talpaz et al., 1986; Golomb et al., 1986].  
A second approach involves the use of monoclonal antibodies (mAb) targeting disease-related 
proteins for degradation. Monoclonal antibodies have achieved considerable success in 
recent years: over 30 mAbs are currently FDA-approved, the most popular in oncology being 
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rituximab, bevacizumab and trastuzumab [Scott et al., 2012]. Future trends facilitate the 
development of bifunctional antibodies such as bispecific T cell engagers (BiTEs) or 
trifunctional bispecific antibodies (trAb) aiming to bring cytotoxic T-cells, tumor cells and 
eventually innate immune effector cells into close proximity. Catumaxomab was the first trAb 
receiving FDA-approval in 2009 for treatment of malignant ascites [Heiss et al., 2005]. 
Considerable progress has been made in the last decade by using oncolytic viruses, adoptive 
T cell transfer or using cancer vaccines for cancer immunotherapy (reviewed by [Parato et 
al., 2005; Rosenberg et al., 2008]). Adoptive T cell transfer has being successfully studied in 
mice [Bourquin et al., 2010] and is now evaluated in various clinical trials in patients with 
advanced stage disease with our without dendritic cell vaccination (cp. 
http://www.clinicaltrials.gov/ct2/results?term=T+cell+transfer). Cancer vaccines are one of 
the latest strategies in immunotherapy. They include the use of tumor-associated antigens in 
combination with adjuvants for induction of a long-lasting and antigen specific immune 
response [Baxevanis et al., 2009]. Dendritic cell-based vaccines are currently under 
evaluation. Autologous DC are stimulated ex vivo and provided with the tumor-antigen via 
peptide-uptake, mRNA or cDNA. Autologous DC are a then reinjected into the patient with or 
without an additional adjuvant or disease specific therapy. Those approaches show promising 
results both in preclinical studies in mice as well as in clinical trials mice [Wurzenberger et 
al., 2009]. 
A novel therapeutic approach with remarkable antitumor potential that has been already 
evaluated in large scale clinical trials during the last years is targeting immune checkpoints. 
Tumors co-opt signaling pathways that normally avoid overactivation of T cells and maintain 
self-tolerance in healthy individuals. Many of these “immunological breaks” are initiated by 
distinct ligand-receptor interactions and can be targeted by so-called immune checkpoint 
inhibitors (ICIs). Thus far, these antibody-based treatment strategies target programmed cell 
death ligand 1 (PD-L1), programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 
4 (CTLA4). Importantly, ICIs have shown significant and durable responses not only in highly 
immunogenic malignancies such as malignant melanoma and renal cell carcinoma but also 
in a number of solid cancer entities that were previously not believed to be accessible to 
immune-based therapies [Brahmer et al, 2012; Brahmer and Pardoll, 2013]. 
The increasing knowledge in tumor immunology, namely the strong immunosuppressive 
paramalignant environment leading to inability of the immune system to recognize cancer 
cells, has led to the concept of activating the immune system in order to restore its 
functionality.  Concurrent growing inside into the signaling and biological function of pattern 
recognition receptors and their central involvement in the initiation of innate and adaptive 
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immunity, has moved PRRs into the field of immunotherapy. However, there are conflicting 
reports questioning the use of PRR ligands, bearing in mind that TLRs and other PRRs are 
also expressed in tumor cells which might limit their clinical use in anticancer treatment 
[Huang et al., 2008].  
1.5.2 Pattern recognition receptor ligands: a double-edged sword in cancer 
Tumor cell signaling pathways that trigger essential malignant features such as uncontrolled 
proliferation, resistance to apoptosis, induction of angiogenesis and escape from immune 
evasion are partially understood. Recent work revealed that some of the signaling pathways 
coincide with those initiated by PRR ligands. Despite the use of PRR ligands in anti-cancer 
immunotherapy, various PRR receptors, especially TLRs are also expressed on a variety of 
tumors suggesting that TLR signaling may play important roles in tumor biology and thus 
limiting the effect of PRR-based immunotherapy.  
1.5.2.1 PRR signaling and tumor progression 
The initial idea that TLR stimulation may drive tumorigenesis came from reports 
demonstrating that systemic TLR4 and TLR5 activation unexpectedly augmented tumor 
growth in adoptively transferred murine tumor models [Pidgeon et al., 1999; Sfondrini et al., 
2006]. Researchers from Mount Sinai Hospital and others have shown that human and murine 
cancer cell lines express multiple functionally active TLRs compared to the respective non-
neoplastic tissue [Huang et al., 2005]. For instance, human lung, cervical and prostate cancer 
cells have been found to express high levels of TLR9 [Droemann et al., 2005; Ilvesaro et al., 
2007; Lee et al., 2007], whereas TLR2, 3 and 4 expression has been found on laryngeal 
carcinoma, melanoma, multiple myeloma and leukemic cells [Bohnhorst et al., 2006; Molteni 
et al., 2006; Szczepanski et al., 2007]. Accumulating evidence now suggests that neoplastic 
transformation may usurp the signaling pathways used by TLRs and other pattern recognition 
receptors to favor cancer progression and facilitate the evasion of immune surveillance. In 
line with this, key transcription factors in TLR-dependent signaling pathways such as NFκB 
proteins, MyD88 and PI3K/AKT have been found to directly mediate survival, proliferation 
and increased angiogenesis during tumor progression [Karin and Greten, 2005; Rakoff-
Nahoum and Medzhitov, 2007]. Notably, TLR signaling and NFκB activation may even play a 
more important role on the tumor microenvironment. By secreting inflammatory cytokines 
and chemokines, sometimes elicited by TLR activation, tumor cells attract non-malignant 
cells which foster local immunosuppression by upregulation of crucial factors like vascular-
endothelial growth factor (VEGF) and immunosuppressive cytokines like IL-10 or TGFβ [Sato 
et al., 2009]. Given that tumor growth can mimic tissue damage, the studies discussed above 
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indicate TLRs might serve as a link between tissue repair, inflammation and tumorigenesis. 
Further dissection of associated signaling pathways and delineation of differences between 
microenvironmental versus systemic PRR stimulation should provide interesting insights into 
cancer development and the use of PRR ligands in immunotherapy.  
1.5.2.2 Use of PRR ligands in the immunotherapy of cancer 
Over a century ago, the New York surgeon William Coley showed that intratumoral injection 
of streptococcus pyogenes and later a mixture of heat-killed streptococcus pyogenes and 
serratia marcescens (Coley’s toxin) can induce significant regression of soft tissue sarcoma 
[Coley, 1991]. Without understanding the underlying biologic mechanisms, he has set the 
cornerstone for modern immunotherapy. Today we know that such approaches function by 
stimulating PRR signaling and activate both innate and adaptive immune responses.  
The idea of PRR agonists to provide a “danger signal” and break tolerance to tumor antigens 
has been well embraced by tumor immunologists. They make up attractive targets in cancer 
immunotherapy because of different reasons: in contrast to the application of distinct 
cytokines alone, PRR signaling induces a coordinated immune response, more resembling 
the natural situation. Furthermore, several PRR ligands have shown to induce co-stimulatory 
molecules (CD80, CD86, CD40) on dendritic cells and inflammatory cytokines such as TNFα 
and IL-12 both of which polarize a TH1-skewed immune response. Finally, a number of PRR 
ligands generate a potent type I IFN response which is essential against intracellular 
pathogens and immunological defense against host tumor cells. 
Because TLRs were the first PRRs to be described and their ligands and signaling pathways 
have been well elucidated, they were the first to be studied in anti-cancer immunotherapy 
and to enter clinical trials. Our group is especially interested in using different PRR ligands 
in murine tumors models. During the last years, we could show in vivo tumoricidal efficacy 
of different TLR and RLR ligands such as poly(I:C), R848, CpG-ODN  and ppp-RNA that signal 
via TLR3/MDA-5, TLR7, TLR9 and RIG-I, respectively [Bourquin et al., 2006; Bourquin et al., 
2009; Bourquin et al., 2011; Zoglmeier et al., 2011]. Whitmore and colleagues showed that 
administration of CpG-DNA complexed with cationic liposome-based lipoplexes elicits a 
potent induction of TH1 cytokines (TNFα, IFNγ and IL-12) and showed tumoricidal NK cell 
activity in a murine model of pulmonary metastasis [Whitmore et al., 2001]. The same group 
reported in 2004 that dsRNA and CpG can synergistically enhance antitumor activity 
[Whitmore et al., 2004]. Multiple other studies during the last decade have proven that TLR 
ligands can have potent antitumor activity in murine tumor models [Okamoto et al., 2006; 
Sfondrini et al., 2006; Favaro et al., 2012; Stier et al., 2013]. Current efforts are mainly focused 
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on TLR7 and TLR9 [Lee et al., 2003; Pashenkov et al., 2006; Krieg, 2007]. However, the 
promise of TLR agonist-based immunotherapy remains to be realized in clinical practice. To 
date, there are only a few FDA-approved TLR agonists. As an example, bacillus Calmette-
Guerin (BCG) and imiquimod are approved as monotherapy for urothelial carcinoma and 
basal cell carcinoma. Clinical trials have shown promising results for CpG-DNA in 
combination therapies for B-cell lymphoma [Brody et al., 2011], non-Hodgkin’s lymphoma 
[Friedberg et al., 2005] and non-small cell lung cancer [Manegold et al., 2008]. Finally, recent 
reports also underline the role of Pattern recognition receptors in a process called 
immunogenic cell death (ICD). ICD is described as a cell death modality that stimulates an 
immune response against dead-cell antigens that function as damage-associated molecular 
patterns (DAMPs). Via TLR4, DAMPs induce a tumor-antigen specific immune response via 
TLR4 which requires cross-presentation of tumor antigens to DCs on MHC class I to generate 
CTLs [Apetoh et al., 2007]. Two years later the same group showed that NLRP3-dependent 
release of IL-1β links innate and adaptive immune responses against dying tumor cells 
[Ghiringhelli et al., 2009]. A current search on ClinicalTrials.gov using the key words “TLR” 
and “cancer” returned 35 listings. Despite promising results in some studies to date, some of 
which are still recruiting, quite a few have been withdrawn showing no benefit of 
conventional therapy versus conventional therapy plus the use of TLR agonists.  
Other PRRs that gained interest as a target for tumor immunotherapy are the RLRs RIG-I and 
MDA-5. A prior study by Besch and colleagues showed potent induction of apoptosis when 
human melanoma cells were transfected with HMW-poly(I:C) as ligand for MDA-5 and 
pppRNA as ligand for RIG-I in vivo. Those results were confirmed in a humanized mouse 
model of lung metastasis in NOD/SCID mice showing potent antitumoral activity of both 
ligands by induction of apoptosis in line with a pronounced type I IFN response [Besch et al., 
2009]. Researchers, including our own group now started to combine the effect of the ppp-
moiety on RIG-I activation with siRNAs against known tumor-promoting factors such as B-
cell lymphoma 2 protein (Bcl-2) or transforming growth factor beta (TGFβ) [Petrocca and 
Lieberman, 2008; Poeck et al., 2008]. 
These opposing roles of TLRs in immunotherapy delineate the need of research in order to 
elucidate how to overcome potentially harmful effects on PRR-expressing tumor cells while 
maintaining beneficial antitumoral activity and to minimize the therapy-limiting effect of a 
strong immunosuppressive environment.  
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1.6 Objectives 
Overcoming the ability of malignant tumors to evade and suppress host immune responses 
is vital for successful immunotherapy approaches. Various immune suppressor cells have 
been identified as key mediators of such immune dysfunction in cancer patients. In particular, 
myeloid-derived suppressor cells (MDSC) have emerged as major regulators of immune 
tolerance, because they do not only enable and sustain malignant growth and metastatic 
disease, but also represent a major obstacle for effective immunotherapies. MDSC are a 
heterogenous population accumulating in cancer patients defined by their immature state 
due to a partial differentiation block. Little is known about the phenotypical difference of non-
immunosuppressive immature myeloid cells in tumor-free hosts versus myeloid-derived 
suppressor cells in tumor-bearing hosts. Furthermore, it remains largely obscure if reversing 
this paramalignant differentiation block is feasible in order to enable a more vigorous anti-
tumor immune response.  
Activation of the innate immune system by stimulation of pattern recognition receptors has 
been evaluated as a potent approach in cancer immunotherapy protocols, thereby minimizing 
toxic side effects of chemotherapy alone. Specifically therapeutic oligonucleotides, such as 
CpG-ODN, have been intensively studied as immune adjuvants for cancer therapy. Previous 
studies, including work from our own group, have shown that innate immune activation with 
the TLR9 agonist CpG-ODN evokes efficient antitumor immune responses in mice with 
significant decrease in tumor load and prolonged survival [Heckelsmiller et al., 2002; 
Bourquin et al., 2008]. However, some studies suggest a pivotal role of Toll-like receptor 
activation in the expansion and/or activation of MDSC, calling the clinical utility of such 
approaches into question.  
By using Toll-like receptor ligands to induce innate immune activation in tumor-free and 
tumor-bearing mice, this work was designed to answer the following questions: 
 
(a) Does stimulation of TLR9 and other innate immune receptors in vivo affect phenotype 
and function of Gr1+CD11b+ immature myeloid cells? 
 
 
(b) If so, does the same holds true for Gr1+CD11b+ myeloid-derived suppressor cells in 
tumor-bearing hosts? 
 
 
(c) Which cellular or soluble factors following in vivo stimulation of pattern recognition 
receptors might be crucial for the observed effects?
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Technical equipment 
Balance (LP 6209)  Sartorius, Göttingen, Germany 
Confocal fluorescence microscope Leica TCS SP5, Wetzlar, Germany 
Cell culture CO2 incubator (BD 6220)  Heraeus, Hanau, Germany 
Cell culture laminar flow  Heraeus, Hanau, Germany 
Centrifuge 5417 R  Eppendorf, Hamburg, Germany 
Centrifuge 5424  Eppendorf, Hamburg, Germany 
DynaMag 15/50 magnet  Invitrogen Dynal, Carlsbad, USA 
EasySep©Magnet StemCell Technologies, Grenoble, France 
FACS Canto II BD Biosciences, San Diego, USA 
Lab Water Purification Direct-Q 3 UV Millipore, Billerica, Massachusetts, USA 
Microscope Axiovert 25  Zeiss, Jena, Germany 
MiniMACS, QuadroMACS, LS columns Miltenyi, Bergisch Gladbach, Germany 
Mithras LB940 multilabel plate reader  Berthold, Bad Wildbad, Germany 
Multifuge 3L-R  Heraeus (Hanau, D)  
Multifuge 4KR  Heraeus (Hanau, D) 
Nanodrop ND-1000 NanoDrop, Wilmington, USA 
Neubauer hemocytometer Optik Labor Frischknecht, Balgach, Germany 
pH meter  WTW, Weilheim, Germany 
Refrigerators (4°C, -20°C)  Bosch, Gerlingen, Germany 
Refrigerators (-80°C)  Thermo Scientific, Waltham, USA 
Shaker  NeoLab, Heidelberg, Germany 
Thermocycler T3  Biometra, Göttingen, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
Vortex VF2  Janke & Kunkel, Staufen, Germany 
2.1.2 Chemicals, reagents and buffers 
Agarose LE  Biozym, Hess. Oldendorf, Germany 
Aqua ad injectabilia  Braun AG, Melsungen, Germany 
Bovine serum albumine (BSA)  Sigma Aldrich, Steinheim, Germany 
Collagenase D  Sigma Aldrich, Steinheim, Germany 
Chloroform  Sigma Aldrich, Steinheim, Germany 
DNAse I  Sigma Aldrich, Steinheim, Germany 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich, Steinheim, Germany 
Dulbecco’s PBS (1x)  PAA, Pasching, Germany 
Dynabeads® T-Activator Invitrogen Dynal AS, Oslo, Norway 
Ethylenediaminetetraacetic acid (EDTA)  Sigma Aldrich, Steinheim, Germany 
FACSFlow, FACSClean  Becton Dickinson, San Jose, USA 
H2SO4 Sigma Aldrich, Steinheim, Germany 
Heparin-Natrium 25000 I.E./5 ml  Braun AG, Melsungen, Germany 
in vivo-JetPEI Peqlab, Erlangen, Germany 
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Isoflurane (Forene®)  Abbott, Zug, Switzerland 
Isopropanol (70 Vol%)  Apotheke Innenstadt, LMU Munich 
PharmLyse (10x) RBS lysis Becton Dickinson, Heidelberg, Germany 
Paraformaldehyde (PFA)  Sigma Aldrich, Steinheim, Germany 
Sodium azide (NaN3)  Sigma Aldrich, Steinheim, Germany 
Sodium chloride (NaCl 0.9%)  Apotheke Innenstadt, LMU Munich 
Sulfuric acid H2SO4, 2N) Apotheke Innenstadt, LMU Munich 
Trypan blue Sigma  Aldrich, Steinheim, Germany 
Tris-HCL (pH 7,4) Sigma-Aldrich, Steinheim, Germany 
Trypan blue Sigma-Aldruch, Steinheim, Germany 
Trypsin (10x)  PAA, Pasching, Austria 
Tween 20 (pH 7,0) Sigma-Aldrich, Steinheim, Germany 
 
Erythrocyte lysis buffer Dissection buffer (tumors) 
10% PharmLyse  1 mg/ml Collagenase D 
in PBS 0.05 mg/ml DNAse I 
 10% FCS 
 In RPMI 
 
MACS buffer StemCell buffer Gr1-PE positive sort  
10% FCS or 0.5 Vol% BSA 2% FCS  
2 mM EDTA 1 mM EDTA  
in PBS in PBS  
FACS buffer  Cell fixation buffer 
5% FCS 2% PFA 
in PBS in PBS 
ELISA coating buffer 1 ELISA coatin buffer 2 
0.2 M sodium phosphate 0.1 mM sodium carbonate 
in water in water 
pH 6.5 pH 9.5 
(variations according to manufacturer) (variations according to manufacturer)  
ELISA assay diluents ELISA washing buffer  
10% FCS 0.05% Tween 20 
in PBS in PBS 
pH 7.0 
(variations according to manufacturer) 
2.1.3 Cell culture materials, reagents and media 
β-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany 
DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-   
3N-trimethylammonium-methylsulfate Roche, Mannheim, Germany 
Dulbeccos’s modified Eagle’s medium 
(DMEM), high glucose PAA, Pasching, Austria 
Dynabeads® Mouse T-Activator CD3/CD28 GibcoBRL, Karlsruhe, Germany 
Fetal Calf Serum (FCS) GibcoBRL, Karlsruhe, Germany 
HEPES Buffer Sigma Aldrich, Steinheim, Germany 
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Iscove’s modified Dulbecco’s medium PAA, Pasching, Austria  
L-glutamine 200 mM PAA, Pasching, Austria 
LipofectamineTM 2000 Invitrogen, Karlsruhe, Germany 
Minimum essential medium with  
non-essential amino acids (MEM-NEAA) GibcoBRL, Karlsruhe, Germany 
Opti-MEM® Reduced Serum Medium Gibco, Life Technologies, Frankfurt 
Phosphate buffered saline (PBS) PAA, Pasching, Austria 
Penicillin, Streptomycin (100x) PAA, Pasching, Austria  
Ciprofloxacin (2 mg/ml) Bayer Pharma AG, Berlin, Germany  
Rat serum StemCell Technologies, Grenoble, France 
Roswell Park Memorial Institute (RPMI) 
1640 medium PAA, Pasching, Austria 
RPMI VLE PAA, Pasching, Austria 
Sodium pyruvate Biochrom, Berlin, Germany 
 
RPMI complete medium DMEM complete medium 
10% FCS 10% FCS 
2 mM L-glutamine 2 mM L-glutamine 
100 IU/ml penicillin 100 IU/ml penicillin, 100 µg/ml streptomycin 
100 µg/ml streptomycin  
1 mM sodium pyruvate Cryo medium 
1% MEM-NEAA 40% DMEM complete medium 
3.75 x 10-4 β-mercaptoethanol 50% FCS 
In RPMI 1640 10% DMSO 
 
T-cell medium (TCM) Bone marrow-derived macrophage  
10 % FCS  medium (BMDM medium)  
2 mM L-glutamine  10% FCS  
100 IU/ml penicillin  30% L929-cell-conditioned medium (LCCM) 
100 μg/ml streptomycin  0.5% Ciprofloxacin 100x 
1 mM sodium pyruvate in RPMI 
1% MEM-NEAA  
1 x 10-4 % β-mercaptoethanol 
 in RPMI 1640 VLE  
Disposable plastic materials for cell culture experiments were purchased from Becton 
Dickinson (Heidelberg, Germany), Bibby Sterrilin (Stone, Staffordshire, Great Britain), 
Corning (Corning, USA), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, Germany), 
Greiner (Frickenhausen, Germany), Henke-Sass Wolf (Tuttlingen, Germany), Nunc 
(Rochester, USA) or Sarstedt (Nümbrecht, Germany).   
2.1.4 PRR ligands, cytokines and growth factors 
All following stimuli are displayed with used concentration in vitro or in vivo unless indicated 
otherwise. Special methodical remarks (e.g. complexation of RNA) are displayed below the 
respective list. 
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Recombinant cytokines 
Cytokine In vitro [c] Distributor 
IFNα, recombinant, human 1000 U/ml Miltenyi, Bergisch-Gladbach, GER 
IFNγ, recombinant, mouse 100 U/ml  eBioscience, San Diego, CA, USA 
TGFβ1, recombinant, mouse 20 ng/ml R&D Systems, Wiesbaden, GER 
Table 2.1. List of recombinant cytokines with concentrations used in vitro. 
Pattern recognigtion receptor (PRR) ligands 
Ligand Receptor In vitro [c] In vivo [c] Distributor 
Pam3CSK TLR1/2 2 µg/ml - InvivoGen, Toulouse, France 
Poly I:C  TLR3 200 µg/ml 250 µg i.p. InvivoGen, Toulouse, France 
LPS E.coli K12 TLR4 1 µg/ml 100 µg i.p. InvivoGen, Toulouse, France 
Flagellin TLR5 1 µg/ml - InvivoGen, Toulouse, France 
R848 TLR7 2 µg/ml - InvivoGen, Toulouse, France 
9.2dr RNA* TLR7      - 20 µg i.v. CureVac, Tübingen, Germany 
CpG 1826 TLR9 5 µg/ml 100 µg s.c. Coley, Langenfeld, Germany 
5‘-triphosphate  
2.2 dsRNA* 
RIG-I 1 µg/ml 50 µg i.v. 
Eurogenentech, Köln, 
Germany 
Poly dA:dT* AIM2 2 µg/ml - 
Sigma Aldrich, Steinheim, 
GER 
Curdlan Dectin-1 20 µg/ml - InvivoGen, Toulouse, France 
Table 2.2. List of pattern recognition receptor ligands, corresponding receptor and concentrations 
used for in vitro stimulation experiments or in vivo therapy. * indicated oligonucleotides are complexed 
with DOTAP, LipofectamineTM 2000 or in vivo-JetPEI before in vitro or in vivo usage. For more detailed 
methodical explanations see chapter 2.2.3 and 2.3.4. 
List of oligonucleotide sequences 
Oligonucleotide Nucleotide sequence 5’     3’ 
CpG-B-ODN 1826 (CpG)* TCCATGACGTTCCTGACGTT 
9.2 double right RNA (9.2dr RNA)* UGUCCUUCAAUGUCCAA 
5‘-triphosphate 2.2 dsRNA (3pRNA)* GCAUGCGACCUCUGUUUGA 
Murine siRNA against TGFβ1 GAACUCUACCAGAAAUAUA 
Control siRNA GAUGAACUUCAGGGUCAGC 
Table 2.3. List of selected oligonucleotide sequences shown from 5-prime to 3-prime end.  
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Indicated oligonucleotides (*) carry a PTO-modification. PTOs contain one sulfur atom 
instead of an oxygen atom in the internucleotidic linkage resulting in higher stability and less 
enzymatic degradation. siRNAs against TGFβ1 were designed according to published 
guidelines including a 3´-dTdT overhang and were purchased from Eurofins MWG Operon, 
Ebersberg, Germany. 
2.1.5 Tumor cell lines 
Cell line Background Disease Origin Reference 
B16-F10 C57Bl/6 Melanoma 
Prof. T. Brocker, Institut für 
Immunologie, LMU Munich 
(Fidler 1975) 
C26 Balb/c 
Colon 
cancer 
CLS, Eppelheim, Germany 
(Corbett, Griswold 
et al. 1975) 
E.G7 C57Bl/6 Thymoma ATCC, Manassas, USA 
(Moore, Carbone et 
al. 1988) 
EL-4 C57Bl/6 Thymoma ATCC, Manassas, USA 
(Ralph and 
Nakoinz 1973) 
mGC8 C57Bl/6 
Gastric 
cancer 
Prof. W. Zimmermann, LIFE 
Center, LMU Munich 
(Nockel, van den 
Engel et al. 2006) 
RMA-S C57Bl/6 Lymphoma 
Dr. J. Charo, Max-
Dellbrück- Center, Berlin 
(Karre, Ljunggren 
et al. 1986) 
Panc02 C57Bl/6 
Pancreatic 
cancer 
National Cancer Institute 
(NCI) 
(Corbett, Griswold 
et al. 1975) 
Table 2.4. List of tumor cell lines used in this work with listed mouse background, origin and reference. 
2.1.6 Kits 
Magnetic Cell Sorting 
EasySep© Gr1-PE positive sort Gr-1-PE-conjugated antibody, murine 
(StemCell Technologies, Grenoble, France) PE selection cocktail 
 Magnetic NanoParticles 
 
MDSC Isolation Kit, murine Anti-Ly-6G- Biotin, murine 
(Miltenyi Biotec, Bergisch Gladbach, GER) Anti-Gr-1-Biotin, murine 
 Anti-Biotin and Streptavidin MicroBeads 
 FcR Blocking Reagent, murine 
 
Anti-CD19 Microbeads, murine Miltenyi Biotec, Bergisch Gladbach, GER 
Anti-CD3-Biotin, murine Miltenyi Biotec, Bergisch Gladbach, GER 
Anti-Biotin-MicroBeads Miltenyi Biotec, Bergisch Gladbach, GER 
 
CD8 T-Cell Isolation Kit, murine Miltenyi Biotec, Bergisch Gladbach, GER 
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Cytokine ELISA sets 
IL-1β, murine BD Biosciences, San Diego, USA 
IL-6, murine BD Biosciences, San Diego, USA 
IL-10, murine BD Biosciences, San Diego, USA 
IL-12p40, murine BD Biosciences, San Diego, USA 
CXCL10 / IP-10, murine R&D Systems, Wiesbaden, Germany 
IFNγ, murine R&D Systems, Wiesbaden, Germany 
Cytokine ELISA antibodies 
Detection of murine IFNα: 
Capture-Ab: Anti-IFNα (RMMA-1) PBL, New Brunswick, USA 
Detection-Ab: Anti-IFNα  
(polyclonal, rabbit anti-mouse) PBL, New Brunswick, USA 
HRP-conjugated F(ab´)2 fragments 
(donkey anti-rabbit) Biomeda, Foster City, USA 
MDSC Suppression Assay  
Cell Proliferation ELISA, BrdU  
(chemiluminescent) Roche Diagnostics, Mannheim, Germany 
Apoptosis Assay 
FAM Flica TM Caspase 3 & 7 Assay Kit ImmunoChemistry, Bloomington, USA 
3p-RNA Transcription Kit 
MEGAshortscriptTM T7 Kit  Ambion, Austin, Texas, USA 
2.1.7 Antibodies: FACS and Immunofluorescence 
Flow cytometry antibodies 
All antibodies used in this work were either purchased from BD/Pharmingen (Heidelberg, 
GER) or BioLegend (San Diego, CA, USA). Following fluorochromes were used depending on 
the experimental setup: FITC, PE, PeCy7, PerCP, APC, APC-Cy7, PacificBlue, PacificOrange. 
Description Isotype Clone 
Anti-CD3 Rat IgG2b 17A2 
Anti-CD4 Rat IgG2b GK 1.5 
Anti-CD8a Rat (LOU/Ws1/M) IgG2a, κ 53-6.7 
Anti-CD11b Rat (DA) IgG2b, κ M1/70 
Anti-CD11c Armenian Hamster IgG1a N418 
Anti-CD19 Rat, IgG2a, κ 1D3 
Anti-CD45/B220 Rat IgG2a, κ RA3-6B2 
Anti-CD45 Rat IgG2b 30-F11 
Anti-CD80 (B7-1) Armenian Hamster IgG2, κ 16-10A1 
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Anti-CD86 (B7-2) Rat (Louvain) IgG2a, κ GL1 
Anti-F4/80 Rat IgG2a, κ BM8 
Anti-Gr-1 Rat IgG2b, κ RB6-8C5 
Anti-Ly-6C Rat IgM, κ AL-21 
Anti-Ly-6G Rat IgG2a, κ 1A8 
Anti-MHC I Mouse IgG2a, κ H-2Db 
Anti-MHC II Rat IgG2b, κ M5/114.15.2 
Anti-Sca-1 (Ly6A/E) Rat IgG2a, κ E13.161.7 
Isotype controls   
Table 2.5. Fluorochrome-conjugated antibodies for flow cytometry with isotype and clone.  
Fluorescence microscopy antibodies 
Primary antibodies 
Polyclonal rabbit anti-mouse CD3 (Abcam®) 
Rat anti-mouse CD3 (clone 53-6.7) (BioLegend®) 
Secondary antibodies 
Cy3 Goat anti-rabbit IgG (H+L) (BioLegend®) 
Polyclonal Cy2 Goat anti-Rat IgG Secondary Antibody (ThermoScientific®) 
2.1.8 Software 
Adobe Illustrator CS5  Adobe System, San Jose, USA 
CellQuest  BD Biosciences, San Diego, USA 
Endnote X2  Thompson Reuter, Carlsbad, USA 
FlowJo  Tree Star, Ashland, USA 
GraphPad Prism® GraphPad Software, San Diego, CA, USA 
Microsoft Office  Mircosoft, Redmond, USA 
2.2 Animal experiments 
2.2.1 Animals 
Female Balb/c or C57BL/6 mice were obtained from Harlan-Winkelmann (Borchen, 
Germany). IFNα receptor (IFNαR)-deficient mice and Stem Cell Antigen-1 (Sca-1)-deficient 
mice were kindly provided by Dr. Z. Waibler (Paul-Ehrlich Institute, Langen, Germany) and 
Prof. William Stanford (Institute of Biomaterials and Biomedical Engineering, University of 
Toronto, ON, Canada). CEA424-Tag mice [Thompson et al., 2000], kindly provided by W. 
Zimmermann (LIFE Center, LMU Munich, Germany) were bred heterozygously from 
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transgenic male mice. Mice were 8 – 12 weeks of age at the onset of experiments. All animal 
studies were performed according to ethical guidelines and approved by the local regulatory 
agency (Regierung von Oberbayern, Munich, Germany).  
2.2.2 Tumor induction and measurement 
In order to study the phenotype and function of myeloid-derived suppressor cells we 
compared various tumor models and different PRR ligands. The main tumor model used in 
this work was the CT26 subcutaneously induced colon cancer model (Balb/c background) 
which yielded high numbers of MDSC following tumor engraftment and is a well established 
and analyzed tumor model in the setting of CpG therapy in our laboratory [Bourquin et al., 
2006]. We also studied and compared our observations in other available mouse tumor 
models and various IFNα-inducing PRR ligands (see chapter 2.2.3), not least because some 
gene-deficient mice were only available on C57BL/6 background. 
For induction of subcutaneous tumors, tumor cells were centrifuged, washed twice, 
suspended in 100 µl PBS and injected into the right flank of C57BL/6 mice or Balb/c mice 
(CT26). The concentration of tumor cells per 100 µl as well as the approximate date of tumor 
onset varied between the respective cell lines (see table 2.5 below). The day of tumor onset 
was defined as formation of a palpable nodule (5 – 8 mm in diameter) subcutaneously or in 
sacrificed control mice (orthotopic Panc02). For orthotopic Panc02 tumor development, the 
left flank of anaesthetized mice was opened and the spleen mobilized to access the pancreas. 
A total of 2 x 105 Panc02 cells were then injected into the pancreas. 
Cell line [c] of cells / 100 µl ~ day of tumor onset 
B16-F10 1 x 106 Day 7 - 10 
CT26 2,5 x 105 Day 7 - 10 
E.G7 1 x 106 Day 7 - 10 
EL-4 1 x 106 Day 7 - 10 
mGC8 2 x 106 Day 15 - 18 
RMA-S 1 x 105 Day 8 - 12 
Panc02  1 x 106 Day 12 - 14 
Panc02 orthotopic*  2 x 105 Day 10 - 12 
Table 2.5. List of different tumor cell lines used for subcutaneous or orthotopic tumor induction 
(Panc02) with corresponding concentration for tumor induction and day of tumor onset. *Orthotopic 
tumor induction was kindly performed by co-workers of  the research group of Prof. Dr. med. M. 
Schnurr. 
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CEA424-Tag mice [Thompson et al., 2000] bearing autochthonous gastric tumors were used 
at the age of 85 – 100 days for analysis of myeloid-derived suppressor cells.  
For subcutaneous tumors, tumor area is expressed as the product of perpendicular diameters 
of individual tumors. The tumor volume was measured thrice per week unless indicated 
otherwise. The volume of CEA424-Tag-derived gastric tumors (SV40) was calculated as the 
product of 3 perpendicular diameters. When tumor volume exceeded 225 mm2 or when signs 
of animal distress were observed twice in 48 hours, mice were anaesthetized and sacrificed 
by cervical dislocation.  
2.2.3 Therapy with PRR ligands 
In order to determine the role of systemic Toll-like receptor and RIG-I activation on phenotype 
and function of myeloid-derived suppressor cells as well as on Stem Cell Antigen-1 
expression, mice were treated with different immunostimulants. Tumor-free and tumor-
bearing mice underwent the same treatment protocol unless indicated otherwise. The 
different treatment protocols used in this work as well as sites of injection are depicted in 
Table 2.6. Treatment of tumor-bearing mice was initiated following establishment of tumors 
(tumor area > 25 mm2 or age of CEA424-TAg mice > 85 days) unless indicated otherwise. 
Therapy of orthotopic Panc02 tumor-bearing mice started on day 12, when sacrificed control 
mice showed visible tumor nodules (5 – 8 mm diameter). In general, 100 µg LPS, 100 µg CpG-
oligodesoxyribonucleotides (ODN) and 250 µg poly(I:C) were dissolved in 100 µl PBS and 
injected subcutaneously or intraperitoneally as indicated in table 2.6. Immunostimulatory 
RNA was injected intravenously after complexation with DOTAP - a liposomal transfection 
reagent - or in vivo-jetPEI in order to prevent degradation and to improve rate of transfection. 
In detail, for treatment with 3pRNA or siRNA, 8 µl of in vivo-jetPEI were mixed with 50 µg of 
nucleic acid at an N:P ratio of 8:1 (8 nitrogen residues of jetPEI per RNA phosphate) in a 
volume of 200 µl 5% glucose solution, incubated 15 minutes at room temperature and 
injected intravenously into the retro-bulbar venous plexus or tail vein [Poeck et al., 2008; 
Ellermeier et al., 2013]. For in vivo administration of 9.2dr RNA, 20 µg of RNA were incubated 
with 100 µg DOTAP and 40 µl PBS for 20 minutes and injected into the retro-bulbar venous 
plexus. Depending on the experimental setup, 24 – 48 hours after the last treatment, mice 
were sacrificed, organs removed and prepared for further analysis as described below 
(chapter 2.2.4).  
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Table 2.6. Treatment protocols and injections sites for in vivo administration with PRR ligands unless 
indicated otherwise. * Day 1 is defined as first day of treatment depending on tumor volume in mm². 
Day 0 or 12 are defined as days after tumor inoculation. 
2.2.4 Organ and single cell preparation 
2.2.4.1 Blood collection and serum analysis 
For analysis of MDSC phenotype with or without PRR ligand therapy, blood cells were 
analyzed via flow cytometry. Mice were anesthetized with isoflurane and sacrificed via 
cervical dislocation. In order to receive a maximum of blood, the left chamber of the heart 
was punctured with a heparin coated syringe right after cervical dislocation. The blood was 
then transferred into 15 ml Falcon tubes, washed with 13 ml PBS, centrifuged (400 x G, 7 
minutes) and resuspended in 3 ml erythrocyte lysis buffer. After incubation for 5 min at room 
temperature, reaction was stopped with 14 ml PBS. Red blood cell debris was removed by a 
second centrifugation step. The resulting cell pellet was then resuspended in 1 ml FACS 
buffer for further analysis. 
To determine serum levels of interleukins, 24 hours after PRR ligand therapy, the retro-bulbar 
venous plexus of mice was punctured with heparinized capillary tubes until a minimum of 
500 µl blood was obtained. Blood was allowed to coagulate for 20 minutes and then 
centrifuged at 13.000 x G for another 20 minutes. The resulting serum in the supernatant was 
collected and stored at -20°C for subsequent evaluation of interleukin serum levels via ELISA.  
2.2.4.2 Tumor removal and digestion 
Mice bearing established subcutaneous tumors (tumor volume at least > 100 mm²) were 
anesthetized with isoflurane and sacrificed via cervical dislocation. Tumors were dissected 
and the skin was carefully removed. The resulting tumor tissue was dissected into small 
PRR ligand Injection site 
        Days of treatment 
Tumor-free      Tumor-bearing* 
organ removal 
after last 
course 
LPS intraperitoneally    0 – 3 – 7                - 24 hours 
CpG-ODN subcutaneously    0 – 3 – 6          1 – 4 – 7  24 hours 
Poly I:C intraperitoneally    0 – 3 – 6          1 – 4 – 7  24 hours 
3p-RNA intravenously    0 – 3 – 6          1 – 4 – 7  24 hours 
9.2dr RNA intravenously          - 0 – 2 – 4 – 6 – 8 – 12  48 hours 
(3p-)siTGFβ intravenously          -          12 – 14  24 hours 
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pieces and incubated in dissection buffer at moderate stirring for 30 – 45 minutes at 37°C. 
The digested tumor tissue was then passed through a 100 µm-pore cell strainer, followed by 
a second passage through a 40 µm-pore mesh. Single cell suspensions were then washed 
twice, resuspended in FACS buffer and analyzed via flow cytometry.  
2.2.4.3 Isolation of splenocytes 
Mice were anesthetized with isoflurane and sacrificed via cervical dislocation. Spleens were 
resected and passed with PBS through a 40 µm-pore cell strainer for mechanical tissue 
disintegration. The resulting single cell suspension was centrifuged (400 x G, 7 minutes) and 
resuspended in erythrocyte lysis buffer. After incubation for 3 minutes at room temperature, 
reaction was stopped by adding PBS and red cell debris was removed by a second 
centrifugation step. Splenocytes were then resuspended in either RPMI complete medium or 
FACS buffer for further analysis.  
2.2.4.4 Preparation of lungs and lymph nodes 
Mice were anesthetized with isoflurane and sacrificed via cervical dislocation. Lungs, 
peripheral lymph nodes (axillary or inguinal) or tumor-draining lymph nodes were removed. 
Single cell suspensions of lungs were prepared as described above (chapter 2.2.4.2) and 
analyzed via flow cytometry. Lymph nodes of individual mice were pooled and directly passed 
through a 40 µm-pore cell strainer. After washing twice with PBS, single cell suspensions 
were resuspended in FACS buffer and analyzed via FACS.   
2.2.4.5 Bone marrow isolation  
Mice were anesthetized with isoflurane and sacrificed via cervical dislocation. Femur and 
tibia were dissected bilaterally. The remaining muscle tissue was carefully removed with 
small scissors and scalpel followed by external cleaning with 70% isopropanol and complete 
RPMI medium. Each end of bone was then cut off and bone marrow was expelled using a 
27G needle / 1 ml syringe filled with complete RPMI medium. After passage through a 40 
µm-pore cell strainer, single cell suspensions were washed once with complete RPMI medium 
and resuspended in erythrocyte lysis buffer. After lysis, cells were washed again and 
resuspended in RPMI complete medium for later experiments.  
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2.3 Cell culture experiments 
2.3.1 General culture conditions and cell viability 
All cell culture experiments were performed with sterile technique and under sterile 
conditions using a laminar air flow hood. Culture of cell lines or primary cells was performed 
in incubators under 37°C, 5% CO2/air mixture and 95% air humidity. Cell viability was tested 
using trypan blue exclusion test: whereas the outer membrane of dying cells loses its integrity 
and absorbs trypan blue, it cannot enter the cell through intact membranes. Thus, the 
cytoplasm of dead or dying cells stains dark blue, whereas viable cells remain golden under 
light microscopy. Thus, after appropriate dilution, cell numbers of viable cells could be 
determined by using a Neubauer hemocytometer.  
2.3.2 Tumor cell cultures 
Tumor cell lines were obtained as described above (chapter 2.1.5). In general, cell lines were 
cultured in T75-T175 culture flasks in cell culture medium according to the respective cell 
line (see table 2.7). Cells were continuously checked via light microscopy for level of cell 
growth, signs of cell death and bacterial contamination. Medium was replaced regularly every 
two to three days depending on cell growth. In addition, adherent cell lines were splitted at 
a ratio of 1:2 – 1:10 at least twice a week and transferred to new culture flasks according to 
level of cell confluence and rate of cell growth. Therefore, medium was discarded and cells 
were gently detached either with a cell-scraper or by using 1 % trypsin-EDTA solution. Cells 
were then washed twice with PBS and re-disseminated in appropriate medium at lower 
concentrations. Non-adherent cell lines were splitted continuously two to three times a week. 
For in vivo tumor engraftment, tumor cells were splitted one day before injection to ensure 
optimal growth conditions. On day of tumor inoculation, tumor cells were harvested as 
described, re-suspended in PBS and separated by flushing through a 27G needle for three 
times.  
Cell line Cell growth Culture medium Split frequency 
B16-F10 adherent 10% FCS, 1% P/S, 1% L-glu in DMEM 2-3 x per week, 1:10 
CT26 adherent 10% FCS, 1% P/S, 1% L-glu in DMEM 2-3 x per week, 1:2 
E.G7 suspension 
10% FCS, 1% P/S, 1% L-glu, 1% So-
Pyr, 1% NEAA in DMEM 
3 x per week, 1:3 
EL-4 suspension 10% FCS, 1% P/S, 1% L-glu in DMEM 3 x per week, 1:3 
mGC8 adherent 
10% FCS (Gold), 1% P/S, 1% L-glu, 
1% So-Pyr , 1% NEAA in DMEM 
1 x per week, 1:2 
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Table 2.7. List of used tumor cell lines in this work and appropriate medium and split frequency for in 
vitro culture. P/S = penicillin/streptomycin, L-glu = L-glutamine, So-Pyr = sodium pyruvate. 
2.3.3 Generation of bone marrow-derived macrophages 
Bone marrow-derived macrophages (BMDM) were generated as described previously with 
some modifications [Zanoni et al., 2009; Marim et al., 2010]. M-CSF is a lineage-specific 
growth factor that is responsible for the differentiation from myeloid progenitors into 
macrophages. We used M-CSF transfected L929 cells which secret high amounts of M-CSF 
into the supernatant in order to obtain enough M-CSF for BMDM generation ex vivo [Englen 
et al., 1995]. L929 cells were kindly provided by Prof. Veit Hornung (University of Bonn, 
Germany). For generation of L929-conditioned medium (LCM), 2 x 107 L929 cells were 
seeded in T175 tissue flasks in 20 ml L929 culture medium. After one week of culture, 
supernatant was collected, sterile filtered and stored at -20°C until usage. For generation of 
murine BMDM, bone marrow was prepared as described above (chapter 2.2.4.5). Following 
washing with PBS, bone marrow cells of individual mice were splitted in half, suspended in 
25 ml of BMDM medium containing 30% LCM and seeded onto two T175 culture flasks, 
resulting in a concentration of approximately 1 x 106 cells/ml. After one week of culture, 
BMDM were harvested, washed twice in PBS and further used for in vitro stimulation with 
PRR ligands. Purity of BMDM was analyzed with flow cytometry via F4/80 expression and 
was typically over 90%. 
2.3.4 In vitro stimulation with PRR-ligands 
For in vitro stimulation of immature myeloid cells (iMC), myeloid-derived suppressor cells 
(MDSC) and bone marrow-derived macrophages (BMDM), single cells suspensions were 
prepared as described. Cells were then resuspended in RPMI complete medium and seeded 
on 96-well plates at a concentration of 2 x 105 MDSC/iMC per well or 1.5 x 105 BMDM per 
well in 200 µl medium. Experimental conditions were always performed in triplicates. Cells 
were allowed to attach to the well bottom for 1 hour before immunostimulants and cytokines 
were added to the culture. The respective cytokines and PRR ligands are described in chapter 
2.1.4 with their respective concentrations unless indicated otherwise. 
RMA-S suspension 
10% FCS, 1% P/S, 1% L-glu, 1% So-
Pyr, 1% NEAA in RPMI 
2-3 x per week, 1:5 
Panc02  adherent 10% FCS, 1% P/S, 1% L-glu in DMEM 2-3 x per week, 1:10 
L929  adherent 
10% FCS, 0.5 % Cipro, 1% So-Pyr in 
DMEM 
1 x per week, 1:5 
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As mentioned in chapter 2.2.3, RNA has to be complexed before in vivo and in vitro usage in 
order to prevent degradation and ensure optimal transfection rate. For in vitro experiments, 
LipofectamineTM 2000 - a polycationic lipid - was used for transfection of RNA. In this work, 
poly(dA:dT) and ppp-RNA had to be transfected for in vitro stimulation. Both, the appropriate 
amount of RNA as well as Lipofectamine were incubated in two separated tubes in the same 
volume of OptiMem at room temperature. After 5 minutes, both tubes were added together 
and incubated for another 20 minutes, before adding the desired amount into culture. 
After addition of cytokines and PRR ligands, cells were regularly cultured at 37°C for 24 hours 
unless indicated otherwise. For measurement of cytokine induction, 96-well plates were 
centrifuged (400 x G, 7 minutes), supernatant was collected and stored at -20°C for later 
analysis via ELISA. In some experiments, the remaining cell pellet was washed twice with 
PBS and resuspended in FACS buffer for flow cytometric analysis. 
2.3.5 MDSC isolation via magnetic-activated cell sorting 
2.3.5.1 Principle of magnetic-activated cell sorting 
Magnetic-activated cell sorting (MACS) is used for isolation of viable and functionally active 
cells via labeling with magnetic particles. The technique of magnetic cell separation was first 
described in 1990 by Miltenyi Biotec. A mixture of cells is incubated with supraparamagnetic 
particles (MicroBeads) of approximately 50 nanometers in diameter, which are composed of 
a biodegradable matrix. Thus, it is not necessary to detach them after the purification process 
resulting in minimal interference with subsequent experiments. These MicroBeads are 
coated with antibodies against a particular cell surface antigen that attach them to cells 
expressing the desired antigen. After incubation, the labeled cell solution is transferred in a 
column and placed in a strong static magnetic field induced by a permanent magnet. Antigen-
expressing and bead-bound cells are retained in the column, whereas cells not expressing 
the particular antigen pass through the column and can be collected. The retaining cell 
population is eluted from the column after removal of the magnetic field. With this method, 
cell can be positively and negatively separated depending on the particular antigen. Positive 
selection means, that a target population of cells expressing the desired antigen is retained 
in the column, eluted and then used for further experiments. Negatively selected cells are 
isolated by depletion of undesired non-target cells, often via incubation with multiple non-
target antibodies. Hence, only the non-magnetic and untouched target population rinses 
through and can be used for subsequent experiments. 
In this work, two different purification methods were used for isolation of Gr1+CD11b+ MDSC 
and their respective subpopulations. Unless stated otherwise, materials and reagents from 
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StemCell Technologies were used to isolate the total population of Gr1+CD11b+ MDSC. In 
order to separate MDSC subpopulations from each other, the MDSC Isolation Kit from 
Miltenyi Biotec was used with some modification. For some proliferation assays, CD8+ T Cells 
were purified with a CD8 T-Cell Isolation Kit (Miltenyi Biotec) and used as responder cells 
instead of splenocytes (see chapter 2.2.4). In general, magnetic cell separation technologies 
required fast working on ice and the use of pre-cooled solutions. Incubation periods were 
always performed at 4°C under gentle tilting. Rotation and centrifugation was done at 300 x 
G for 10 minutes, instead of the usual 400 x G for 7 minutes, all to ensure optimal cell viability. 
2.3.5.2 Miltenyi protocol for isolation of MDSC subpopulations 
As mentioned above (chapter 1.4.2), myeloid-derived suppressor cell subpopulations can be 
phenotypically distinguished via their expression of the Ly-6G antigen (Figure 2.1). Whereas 
polymorphonuclear MDSC (PMN-MDSC) are Gr1+CD11b+Ly6Ghigh, monocytic MDSC (MO-
MDSC) are Gr1+CD11b+Ly6Gneg. In order to analyze and compare the function of MDSC 
subsets, we used a mixture of positive and negative selection methods for magnetic 
enrichment based on their differential expression of Ly-6G.  
Therefore, we used the Miltenyi MDSC Isolation Kit with previous depletion of CD19+ and 
CD3+ cells (mainly B and T cells) to improve cell purity. After preparation of single-cell 
suspensions cells were adjusted to 108  per 350 µl MACS buffer. To prevent unspecific binding 
sites during the following incubation periods, cells were first incubated with 50 µl FcR 
Blocking Reagent for 10 minutes. After incubation with 50 µl anti-CD3-Biotin for another 10 
minutes, cells were washed and readjusted to 350 µl starting volume. Then the cells were 
incubated simultaneously with 100 µl Anti-CD19- and 100 µl Anti-Biotin-Microbeads for 10 
minutes and washed afterwards. LS columns were rinsed with 3 ml MACS buffer and loaded 
with labeled cells diluted in 500 µl MACS buffer. Columns were washed three times and the 
flow-through was gathered as CD3/CD19-depleted cell suspension.  
For magnetic separation of PMN-MDSC, these cells were first diluted in 400 µl MACS buffer 
and incubated with 100 µl of Anti-Ly6G-Biotin for 10 minutes. After a washing step, cells 
were resuspended in 800 µl buffer and 200 µl Anti-Biotin-Microbeads were added. Following 
incubation for 15 minutes, cells were washed, diluted in 500 µl MACS buffer and added onto 
pre-rinsed LS columns. Columns were washed three times with 3 ml MACS buffer. The flow 
through was gathered as Ly-6G negative fraction. After removal of the magnetic field,            
Ly-6Gpos PMN-MDSC were eluted by flushing the column with 2 ml MACS buffer by using 
the provided plunger. PMN-MDSC were centrifuged and kept in complete RPMI medium until 
further usage.  
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To purify MO-MDSC, the Ly-6G depleted flow through was centrifuged and diluted in 400 µl 
MACS buffer per total 108 cells. Cells were incubated with 100 µl Anti-Gr1-Biotin for 10 
minutes, washed and further incubated with 100 µl Streptavidin MicroBeads in 900 µl MACS 
buffer for another 10 minutes. According to remaining cell numbers, either LS or MS-columns 
were pre-rinsed again with buffer. In most experiments, MS columns were rinsed, loaded, 
washed thrice and after removal of the magnetic field, the column was flushed with 1 ml of 
buffer. To increase the purity of the eluted Gr1+Ly6Gneg MO-MDSC, they were rinsed over a 
second MS column. MO-MDSC were centrifuged and kept in complete RPMI medium until 
further usage. 
Cell purity was checked regularly via flow cytometry and always between 85 to 95% for PMN-
MDSC and 75 to 85% for MO-MDSC (Figure 2.1 B). The purity of each subpopulation varied 
depending on MDSC numbers in the starting population, e.g. purity was always slightly 
higher in tumor-bearing mice with respect to higher amounts of MDSC in spleens or bone 
marrow. 
2.3.5.3 Stem cell protocol for isolation of Gr1+CD11b+ MDSC 
For isolation of the whole population of splenic or bone marrow MDSC, we used a novel 
separation method developed by StemCell Technologies. The difference between Miltenyi 
and StemCell protocols was that the latter did not require passage through magnetic columns. 
Instead, a FACS tube was placed in a strong magnet (EasySep®) with accumulation of 
magnetically labeled cells at the surrounding inner surface.  According to the manufacturer, 
this techniques’ advantages are higher cell viability and function due to less mechanical cell 
stress. In detail, single-cell suspensions of splenocytes or bone marrow cells were washed 
once with StemCell buffer and adjusted to a concentration of 108 per ml. After incubation 
with 25 µl/ml of Anti-Gr1-PE-conjugated antibody for 7 minutes at 4°C, cells were washed 
with StemCell buffer and readjusted to the starting volume. The Gr-1-PE labeled cell 
suspension was then incubated with 50 µl/ml PE-selection-cocktail for another 7 – 10 minutes 
at 4°C followed by direct addition of 25 µl NanoParticles. Following incubation for another 7-
10 minutes at 4°C and volume adjustment up to 2.5 ml, the tube was placed into the EasySep® 
magnet for 5 minutes resulting in accumulation of Gr-1+, NanoParticle-bound cells at the 
inner surface of the tube. For cell separation, the supernatant was discarded containing non-
labeled, non-magnetic cells while the tube was still placed in the magnetic field. For further 
enrichment, previous steps were repeated two times with already purified target cells. 
Purified MDSC were centrifuged and kept in complete RPMI medium for subsequent 
experiments. The purity of Gr1+CD11+ cells was verified via flow cytometry and was typically 
over 90% (Figure 2.1 A). 
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2.4 Immunological methods 
2.4.1 Fluorescent-activated cell sorting (FACS) 
2.4.1.1 Principle 
Flow cytometry or fluorescence-activated cell sorting (FACS) is a laser based method that 
allows the analysis of properties of single cell suspensions or particles suspended in a liquid 
phase. A suspension of cells is surrounded by a sheath fluid stream and aspirated with high 
velocity through a capillary into a flow chamber. By forcing the cells to enter a small nozzle 
one at a time, they are hydrodynamically focused and pass through a focused laser one by 
one. At the point where the laser is hitting the cell stream, the illuminating light is either 
scattered or absorbed. Simultaneously, cells can be stained with an antibody linked 
fluorescent dye, which absorbs light of a particular wavelength and emits light at a longer 
wavelength. The scattered light and emitted fluorescence are measured by a number of 
detectors. The detector in line with the light beam is called Forward Scatter (FSC). Several 
other detectors are arranged perpendicular to it - one that measures a parameter which is 
logged as Side Scatter (SSC) and multiple fluorescence detectors. FSC estimates the cell 
volume by analyzing the angle light that is scattered in straight direction. SSC correlates with 
inner cell complexity such as membrane structure and the amount of cytoplasmatic granules. 
Thus, SSC roughly serves as a proxy for cell granularity. The detected fluorescence and light 
scatter signals are amplified by multiple photodiodes and converted into electrical signals 
that are electronically processed. Unwanted light emission is blocked by several optical 
filters.  
Each fluorochrome has to be excited by a laser of particular wavelength and measured by 
detectors appropriate for the emitted spectrum of light. All flow cytometric analyses were 
performed with a FACSCanto II (BD Biosciences) which allowed simultaneous examination 
of up to eight different antigens. 
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Table 2.9. Dyes (A) and laser of FACSCanto II with corresponding excited dyes (B).  
2.4.1.2 Analysis of cell surface antigens 
For analysis of cell surface antigens, single cell suspensions were prepared as described 
previously (chapter 2.2.4). Depending on the experiment, cells were diluted at 2 x 105 up to 
1 x 106 in 200 µl ice-cold FACS buffer or cell culture medium. Single cell suspensions were 
then incubated with the desired fluorochrome-conjugated antibodies for 30 minutes at 4°C 
with minimum light exposure (for overview of used FACS antibodies see Table 2.5). Cells 
were washed twice with PBS and re-suspended in 200 µl FACS buffer. If not analyzed 
immediately, cells were fixed in 200 µl fixation buffer and kept cold at 4°C until data 
acquisition. Each experimental condition was at least analyzed in triplets.  
2.4.1.3 Flow cytometry and gating of MDSC  
MDSC were analyzed from primary organs or following in vitro culture of purified MDSC or 
iMC, respectively. Given that MDSC subpopulations differ in their expression of the Ly-6G 
antigen, each staining contained at least the phenotypical marker Gr-1, CD11b and Ly-6G 
with additional maturation and differentiation markers (see chapter 1.4.2). The main gating 
strategy of MDSC subsets is illustrated below. 
Laser Wave length Dye 
Blue 488 nm 
FITC 
PE 
PerCP 
Pe-Cy7 
Red 633 nm 
APC 
APC-Cy7 
Violet 405 nm 
PacBlue 
PacOrange 
Dye Exmax Emmax 
FITC 495 nm 519 nm 
PE 565 nm 575 nm 
PerCP 490 nm  675 nm 
Pe-Cy7 
480 nm 
565 nm 
743 nm 
767 nm 
APC 650 nm 660 nm 
APC-Cy7 650 nm 785 nm 
PacBlue 410 nm 455 nm 
PacOrange 410 nm 551 nm 
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Figure 2.1. Representative flow cytometry data of MDSC with corresponding subpopulations.  
Dead splenocytes were excluded via scatter discrimination (not shown) and MDSC were gated on their 
status as Gr1+CD11b+ (left panel, A). MDSC were further divided into the major subpopulations of MO-
MDSC and PMN-MDSC with respect to their differential expression of the Ly-6G antigen (right panel, 
A). B shows backgating of MDSC subsets and illustrates subset-related differences in cell size and 
granularity by variable appearance on forward (FSC) and sideward scatter (SSC) analysis.  
2.4.1.4 Detection of apoptosis 
For evaluation of apoptosis in myeloid-derived suppressor cells, the FAM FLICA TM Caspase 
3&7 Assay Kit (Immunochemistry) was used. Therefore, after staining of surface antigens, 
primary cells were diluted in 290 µl complete RPMI with addition of 10 µl FLICA (Fluorescent 
Labeled Inhibitors of Caspases) that covalently bind with active caspase enzymes. Cells were 
than incubated at 37°C for 45 minutes and washed twice with 2 ml 1 X Apoptosis Wash Buffer. 
After resuspension in 300 µl Apoptosis Wash Buffer, cells were ready for colorimetric 
analysis. In some experiments, propidium iodine (PI) was used to discriminate between early 
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(FLICAposPIneg) and late apoptotic cells (FLICAposPIpos) as well as exclusion of necrotic cells 
which than appear as FLICAnegPIpos). 
2.4.2 Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay, or ELISA, is a technique used to analyze a specific 
antigen in a liquid sample. The method is based on binding of enzyme-linked antibodies 
against the desired antigen leading to subsequent conversion of a colorless substrate to a 
colored reagent. The color change is detected and converted into a quantifiable electrical 
signal that correlates to the initial amount of antigen.  
Different cytokine levels in serum of mice as well as from murine cell supernatants were 
measured in this work. The particular ELISA kits are listed in chapter 2.1.6. For cytokine 
detection, plates are coated with a capture antibody specific for the target cytokine. After 
addition of the sample, any given cytokine present is bound by the capture antibody. Plates 
are incubated again with biotinylated detection antibody which in turn is bound by 
streptavidin coupled to a peroxidase. By adding 3,3’,5,5’ – tetramethylbenzidine (TMB) as a 
substrate, this enzyme catalyzes a reaction that entails a blue color change. The reaction is 
stopped by addition of H2SO4 and read in a multiplate reader at 450 nm wavelength with a 
wavelength correction subtraction at 590 nm. All cytokines in this work except IFNα were 
measured by using commercially available kits according to the manufacturer’s protocol. 
Depending on the expected amount of cytokines present in supernatant or serum, the 
samples were generally diluted 1:2; for the detection of IL-12p40 and IFN, samples were 
diluted 1:5 or 1:10. 
Detection of IFNα was performed by using a set of antibodies listed in chapter 2.1.6: Plates 
were coated overnight at 4°C with 50 µl/well coating buffer containing 1 µg/ml of capture 
antibody. In order to block unspecific binding sites, plates were then blocked for 3 hours with 
150 µl of assay diluent per well at room temperature. After intensive washing for several times 
with washing buffer, plates were incubated overnight with sample and standard protein at 
4°C. The highest level of standard was generally set at 105 IU/ml, samples were loaded 
undiluted. After several washing steps, 50 µl/well of detection antibody at a concentration of 
625 ng/ml was added and incubated again for 3 hours at room temperature. Following 
extensive washing, horseradish peroxidase (HRP)-conjugated F(ab’)2 fragments were used 
at a concentration of 15 µg/ml and incubated for 3 hours in order to detect antigen-bound 
detection antibody. After extensive washing 50 µl of substrate solution were added to each 
well to induce a colored reaction. The reaction was stopped by addition of 2N H2SO4 and read 
in a multiplate reader at 450 nm with correctional subtraction at 590 nm.  
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2.4.3 Immunofluorescence of tumor slices 
Immunofluorescence of tumor slices was performed together with Tina Adunka and Jonathan 
Ellermeier (AG Prof. Dr. med. M. Schnurr). Briefly, for evaluating influx of tumor-infiltrating 
cytotoxic T-lymphocytes (CTLs), immunofluorescence was performed on frozen tissue 
sections. Following removal of Panc02 tumors, tissue was immediately stored in cryotubes, 
shock frozen in liquid nitrogen and stored at -80°C. Consecutive cryostat tissue sections (5 
μm) were mounted on glass slides and fixed in cold acetone (-20°C) for 10 minutes. Sections 
were blocked with 10% goat serum in PBS for 20 minutes followed by labeling with primary 
antibody overnight at 4°C (for antibodies see section 2.1.7). After washing with PBS, tumor 
slices were stained with the respective secondary antibodies diluted in 10% donkey serum 
for another 45 minutes and washed again with PBS. Slices were mounted with Aqua-
PolyMount (Polysciences) and then stored at -20°C for analysis of tumor-infiltrating CTLs. 
2.4.4 BrdU suppression assay 
To access the immunoregulatory capacity of myeloid-derived suppressor cells on antigen-
specific and -unspecific proliferation of T cells, we used a 5’Bromo-2’deoxy-uridine (BrdU) 
incorporation assay. The principle of measuring T cell proliferation in the presence of MDSC 
in vitro, as a surrogate for MDSC-mediated suppressivity, has been well described in 
literature (Dolcetti, Peranzoni et al. 2010). In detail, 1 x 105 splenocytes or 7.5 x 104 splenic 
T cells (Dynal Mouse Negative T Cell Isolation Kit, Invitrogen, Carlsbad, CA) from naïve mice 
were cultured with different ratios of MDSC in complete RPMI medium. Cultures were 
incubated in triplicate at 37°C and 5% CO2 in flat-bottom 96-well plates. T cell proliferation 
was stimulated by the addition of anti-CD3/anti-CD28 coated microbeads (Invitrogen) at a 
bead-to-cell ratio of 1:75.  Cells were co-cultured for 60 hours before 7.5 µM BrdU was added 
for another 12 hours. Cell culture plates were then centrifuged (300 x G, 10 minutes), medium 
was discarded and stored for further analysis before plates were dried with a hairdryer. Cell 
fixation, incubation with anti-BrdU-antibody and substrate reaction were done according to 
the manufacturer’s protocol. BrdU incorporation was detected by chemiluminescence-based 
assay and was measured in relative light units (rlu) with a multiple plate reader.  
Suppression of T cell proliferation in the presence of MDSC in increasing concentration was 
calculated relative to stimulated responder cells alone (MDSC-splenocyte-ratio 1:16, 1:8, 1:4, 
1:2 with anti-CD3/CD28-stimulated SC or T cells as positive control). Percentage suppression 
of proliferation was calculated as 
(1 −
𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑤𝑖𝑡ℎ𝑀𝐷𝑆𝐶
𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑤𝑖𝑡ℎ𝑜𝑢𝑡𝑀𝐷𝑆𝐶
) 𝑥 100. 
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Figure 2.2 shows a typical bar graph used in this work to display the results of a T cell 
proliferation assay with or without co-culture of T cell suppressing immature myeloid cells 
(iMC) or MDSC. As increasing concentration of iMC/MDSC in the culture are depressing T 
cell proliferation, the relative proliferation rate decreases. Negative controls are exemplary 
illustrated once and left out in other figures. 
 
 
 
Figure 2.2. Example of a standard BrdU incorporation assay for measuring MDSC-mediated 
suppression of T cell proliferation ex vivo. The y-axis shows the relative percentage of T cell or 
splenocyte (SC) proliferation with or without co-culture of immature myeloid cells (iMC). Therefore, a 
100% proliferation rate as positive control is defined as proliferation of anti-CD3/CD28-stimulated 
splenocytes alone. X-axis shows the different experimental conditions with internal controls (left side, 
white bars) and with co-culture of T cell suppressing immature myeloid cells or MDSC in ascending 
concentration (iMC-splenocyte-ratio 1:16, 1:8, 1:4, 1:2; black bars). SC = splenocytes; stim = anti-
CD3/CD28-stimulation. * Relative light units (rlu) ** depending on the experimental setup MDSC-like 
immature myeloid cells or myeloid-derived suppressor cells were used *** iMC-splenocyte-ratio 1:16, 
1:8, 1:4, 1:2 unless indicated otherwise. 
2.5 Generation of ppp-RNA 
In vitro transcription of ppp-RNA was performed using the MEGAshortscriptTM T7 Kit 
(Ambion, Austin, Texas) according to the manufacturer’s protocol. siRNAs against TGFβ1 
including a 3´-dTdT overhang and matching 5’-triphosphate-modified siRNA were kindly 
provided by Prof. Max Schnurr (Division of Clinical Pharmacology, LMU Munich). Respective 
oligonucleotide sequences are depicted in section 2.1.4. 
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2.6 Statistical Analysis 
All data in this work is given as arithmetic mean values. Variance of mean values is expressed 
as standard error of the mean (SEM). Statistical significance in most experimental finding 
was calculated by independent two-tailed student’s t-test. Comparison of multiple groups 
were performed using 1-way ANOVA with pair-wise Bonferroni posttest. Tumor sizes were 
analyzed using Mann-Whitney U test. Significance was considered at p levels < 0.05, p < 0.01 
and p < 0.001 and were then indicated with *, ** and ***. Statistical analyses and design were 
performed using GraphPad Prism 5 (GraphPad Software), Microsoft Office and Adobe 
Illustrator CS5 (Adobe System).
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3 RESULTS 
3.1 Effect of systemic CpG-DNA administration on Gr1+CD11b+ immature 
myeloid cells (iMC) in tumor-free mice 
3.1.1 iMC numbers in different organs following systemic TLR stimulation 
In our group, we previously demonstrated that activation of the innate immune system with 
the Toll-like receptor (TLR) 9 ligand CpG evokes efficient antitumor immune responses in 
mice bearing subcutaneous CT26 tumors [Heckelsmiller et al., 2002; Bourquin et al., 2008], 
despite a large number of highly immunosuppressive MDSC in this model [Gallina et al., 
2006; Youn et al., 2008]. However, Vaknin and colleagues recently reported that chronic 
activation of innate immunity via TLR2, 4, 7 and 9 using a slow-release delivery system leads 
to immunosuppression in tumor-free mice attributed to the induction of Gr1+CD11b+ 
immature myeloid cells (iMC) or MDSC [Vaknin et al., 2008].  
To address this issue, in a first experiment the capacity of CpG-DNA - our most intensively 
studied TLR ligand - was investigated for its ability to induce Gr1+CD11b+ iMCs in vivo. 
Therefore, mice were challenged with three repeated doses of 100 µg subcutaneous CpG at 
a 3-day interval; the dosage and application resembled typical anti-tumor treatment 
regimens. Indeed, when spleens were analyzed via flow cytometry for the number of 
Gr1+CD11b+ iMC, we saw a two-fold increase in iMC numbers compared to untreated mice 
(Figure 3.1 A,C). This effect was not restricted to splenic Gr1+CD11b+ cells, because the same 
percentage increase of iMCs was observed in other compartments such as blood and bone 
marrow indicating a systemic effect of TLR9 stimulation on iMC accumulation (Figure 3.1 B). 
Lymph nodes did only show minor iMC infiltration in untreated mice or in mice treated with 
CpG (data not shown). In a second step, the effect of other PRR ligands on iMC expansion 
was assessed by in vivo administration of poly(I:C), LPS and complexed triphosphate-RNA 
(3pRNA) using the same treatment protocol. TLR3 and TLR4 stimulation by poly(I:C) and LPS, 
respectively, induced splenic iMC accumulation comparable to CpG. However, systemic 
activation of the pattern recognition receptor RIG-I by 3pRNA did not increase the percentage 
of Gr1+CD11b+ iMCs in tumor free mice (Figure 3.1 C). 
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Figure 3.1. TLR therapy in tumor-free mice leads to expansion of MDSC-like cells. Naïve Balb/c 
mice received either 3 s.c. injections of CpG or PBS (no therapy) as a control at 3-day intervals (n = 5 
per group). 2 days after the last injection mice were sacrificed and the number of Gr1+CD11b+ 
immature myeloid cells (iMC) was determined using flow cytometry. A Representative plot gated on 
viable splenocytes showing the total number of splenic iMC (Gr1+CD11b+) before and after CpG 
treatment. B Histograms showing total numbers of iMC in spleen, blood and bone marrow. C shows 
the percentage of Gr1+CD11b+ iMC in spleens of mice after therapy with different TLR- or RIG-I ligands 
(3p RNA). Treatment protocol was done as mentioned above. Data are the mean + SEM from at least 
three independent experiments. *, p < 0.05; ** p < 0.01; paired Student’s t test. 
3.1.2 Effect of CpG treatment on iMC-mediated suppressivity 
Immune suppression by MDSC is not only a result of their expansion, but in particular due to 
their activation [Gabrilovich et al., 2009]. A hallmark ability of MDSC is inhibiting T-cell 
proliferation by various mechanism (see chapter 1.4.4). Therefore, in a second step the ability 
of splenic Gr1+CD11b+ iMC to suppress the proliferation of T cells ex vivo was examined via 
a BrdU proliferation assay, which is a standard experiment for evaluating MDSC-mediated 
immunosuppression. Naïve mice were treated with CpG again as described above. One day 
after the last injection, spleens were removed and Gr1+CD11b+ cells were separated by 
magnetic sorting. Purified iMC from both untreated and CpG-treated mice showed a 
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moderately suppressive effect on CD3/CD28-stimulated T cells (Figure 3.2), but there was no 
difference when both groups were compared, which was validated in two other independent 
experiments. Thus, in vivo immune stimulation with TLR9 does not result in activation of 
MDSC-like Gr1+CD11b+, which contrasts the results observed by Vaknin and co-workers 
[Vaknin et al., 2008].  
 
Figure 3.2. CpG treatment has no effect on suppressive function of iMC in tumor-free mice. Naïve 
Balb/c mice received either 3 s.c. injections of CpG or PBS (no therapy) as a control at 3-day intervals 
(n = 5 per group). 2 days after the last injection mice were sacrificed and iMCs were purified from 
spleens of untreated or CPG-treated mice by sequential MACS separation (magnetic activated cell 
sorting). Purity was verified via flow cytometry. Degree of suppressivity was assessed with a T-cell 
proliferation assay using CD3/CD28-stimulated splenocytes (SC) as responder cells co-cultured with 
MDSC-like immature myeloid cells for 48 hours (MDSC-splenocyte-ratio 1:8, 1:4, 1:2 with anti-
CD3/CD28-stimulated SC as positive control). p > 0.05 was considered as not significant (n.s.).  
3.1.3 Shifting of myeloid cell subset composition upon CpG-DNA therapy 
As MDSC are comprised of two distinct subpopulations, the effect of TLR9 activation on the 
subset composition was analyzed. The most prominent subset in Balb/c as well as in C57BL/6 
mice are polymorphonuclear iMC or Ly6Ghigh iMC, respectively. When mice were challenged 
with CpG, we observed a strinking change on MDSC-defining markers on the surface: Ly6G, 
the PMN-MDSC defining marker, gets strongly downregulated which is accompanied by a 
significant upregulation of Ly6C (Figure 1 B). More narrowly, the relation of about 70% PMN-
iMC to 30% MO-iMC is reversed when mice were challenged with CpG. This findings 
conclude that the induction of myeloid precursors by innate immune activation via TLR9 is 
mainly due to an increase in monocytic myeloid cells. In addition, this shift was not exclusive 
for splenic iMC, but was again seen in other organs (Figure 1 C). 
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Figure 3.3. Treatment with CpG-ODN results in a shift of splenic iMC subpopulations. Naïve Balb/c 
mice received either 3 s.c. injections of CpG or PBS (no therapy) as a control at 3-day intervals (n = 5 
per group). 2 days after the last injection mice were sacrificed and iMC in different organs were 
analyzed by flow cytometry.  A Pre-gating of splenic myeloid cells was performed via Side-Scatter and 
CD11bhigh inclusion. As an example, the amount of CD11bhigh-myeloid cells is depicted in the right 
upper corner. B CD11bhigh myeloid cells were further divided into two major subpopulations by using 
Ly6G and Ly6C marker expression: Ly6GlowLy6Chigh monocytic iMC and Ly6GhighLy6Clow granulocytic 
iMC, respectively. A representative dot plot shows the shift of those two subpopulations before and 
after in vivo CpG-ODN treatment. C Bar graphs showing the effect of CpG therapy on iMC 
subpopulations in different organs. Data are the mean from at least three independent experiments. 
3.1.4 Alteration of iMC phenotype through systemic TLR9 activation 
One of the defining traits of MDSC compared to their physiologically occurring counterparts 
of immature myeloid cells is that MDSC are prevented from further differentiating whereas 
iMC rapidly mature and home to their target tissue (Kusmartsev and Gabrilovich 2006). To 
address the maturation status of naïve iMC versus iMC following in vivo treatment with CpG-
ODN, splenic Gr1+CD11b+ cells from both groups were analyzed for maturation and 
differentiation marker expression by flow cytometry (Figure 3.4). The macrophage 
differentiation marker F4/80 as well as the DC differentiation marker CD11c and MHCII were 
significantly upregulated on iMC following TLR9 activation (p < 0.05). Additionally, there was 
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a trend towards higher expression of the co-stimulatory molecules CD80 and CD86, even 
though it did not reach statistical significance. Most of the markers analyzed were 
upregulated on both Ly6Glow and Ly6Ghigh subsets (data not shown). Unexpectedly, we 
observed a highly significant upregulation of stem cell antigen-1 (Sca-1) which is also known 
as Ly6A/E and typically expressed by murine hematopoietic stem cells. Moreover, when 
maturation marker expression was compared between in Sca-1+Gr1+CD11b+ iMCs versus 
Sca-1-Gr1+CD11b+ iMCs, Sca-1+ iMCs expressed significantly higher maturation and 
differentiation markers (data not shown). All together, these results show that CpG-ODN 
promotes maturation and differentiation of immature myeloid cells in vivo. 
 
Figure 3.4. CpG therapy induces maturation and differentiation of iMC in tumor free hosts. Naïve 
Balb/c mice received either 3 s.c. injections of CpG or PBS (no therapy) as a control at 3-day intervals 
(n = 5 per group). 2 days after the last injection mice were sacrificed, spleens were harvested and 
examined by flow cytometry. Representative histograms show the expression of different surface and 
maturation markers on pre-gated splenic Gr1+CD11b+ iMC with and without in vivo CpG 
administration. Data analysis was performed using paired Student’s t test comparing mean fluorescent 
intensity (MFI) of each surface marker. p < 0.05 was considered as significant. 
3.2 Myeloid-derived suppressor cells (MDSC) in tumor-bearing mice 
3.2.1 Comparison of MDSC in different mouse tumor models 
Before starting to investigate the effect of innate immune stimulation on MDSC in tumor-
bearing mice, we examined different subcutaneous murine tumor models on their ability to 
drive MDSC accumulation in vivo. Therefore, Balb/c or C57BL/6 mice were inoculated with 
respective tumor cell lines by subcutaneous injection into the left flank and spleens were 
analyzed for the presence of Gr1+CD11b+ MDSC. To exclude an effect of tumor load on the 
number of peripheral Gr1+CD11b+ cells [Pan et al., 2008], mice were sacrificed when tumor 
size reached 150 – 200 mm2 or were 90 – 100 days of age in case of SV40-tumors in the 
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autochtonous CEA424-Tag-model. As expected, in all tumor models examined, the number 
of MDSC was significantly increased compared to naïve mice (Figure 3.5 A). More narrowly, 
in C57BL/6 or Balb/c mice about 3% of splenocytes were Gr1+CD11b+, which is consistent 
with current literature [Gabrilovich and Nagaraj, 2009]. Whereas comparatively low numbers 
of splenic MDSC were observed in mice bearing mGC8, RMA-S and PancO2 tumors ranging 
from 5.0 to 6.5%, MDSC accumulation was more pronounced in the autochtonous SV40 as 
well as EL4 and B16 tumor model (9.8 to 14.6%). Balb/c mice inoculated with CT26 colon 
carcinoma cells, exhibited the highest number of MDSC with around 21% of splenocytes 
(Balb/c background).  
In a second step, Gr1+CD11b+ cells were further investigated for the composition of 
subpopulations by discriminating between Ly6G+ PMN-MDSC and Ly6G- MO-MDSC. PMN-
MDSC were the predominant subpopulation ranging from 40 to 70% in naïve mice and all 
tumor models examined, except for mice bearing subcutaneous B16 melanoma (Figure 3.5 
B). Moreover, tumor induction resulted in significant increase of Ly6G+ PMN-MDSC 
compared to naïve mice (p < 0.05). Notably, in CT26 tumor-bearing mice more than 90% of 
MDSC were granulocytic PMN-MDSC suggesting they play a major role in myeloid-cell 
associated immune suppression in this model.  
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Figure 3.5. The amount of splenic MDSC and the distribution of subpopulations differs in several 
murine models of lymphoma, melanoma, gastric and colon carcinoma. Balb/c or C57/BL6 mice were 
inoculated s.c. with different tumor cells (n = 5 – 20 per group). Mice were sacrificed when 
subcutaneous tumor sizes reached 150 – 200 mm2 or mice were 90 – 100 days of age (SV40). Spleens 
were then removed and Gr1+CD11b+ myeloid-derived suppressor cells (MDSC) quantified via flow 
cytometry. A Percentage of MDSC of viable splenocytes in Black/6 and Balb/c background. MDSC 
numbers of tumor bearing mice were compared with numbers of iMC in naïve mice. All data are 
expressed as mean + SEM. *, p < 0.05; **, p < 0.01; *** p < 0.001, paired student’s t test. B Pre-gated 
Gr1+CD11b+ MDSC were further divided into the two major subpopulations by discriminating via Ly6-
G expression. The histograms show the percentage of Ly6-Glow monocytic MDSCs (MO) and Ly6-Ghigh 
polymorphonuclear/granulocytic MDSC (PMN). Data are the mean from at least 5 – 20 mice per group.  
3.2.2 Surface marker analysis of MDSC in tumor-bearing mice versus iMC in naïve 
mice  
As mentioned above, a hallmark of tumor-induced MDSC is their immature status. In previous 
experiments it was shown that TLR9 activation leads to maturation of immature myeloid cells 
in tumor-free mice (Figure 3.4). Thus we asked, if there are differences in wildtype compared 
to tumor-bearing mice regarding the maturation status of myeloid cells. There are only few 
studies which compared the expression of individual maturation markers between iMC in 
naïve mice and MDSC in tumor-bearing mice and no study that systematically compared a 
set of maturation markers. Thus, the expression of maturation and differentiation markers on 
splenic Gr1+CD11b+ iMC in naïve mice and Gr1+CD11b+ MDSC from CT26 tumor-bearing 
mice was analyzed (Figure 3.6).  
As hypothesized, the expression levels of CD11c and F4/80 were significantly lower in tumor-
induced MDSC as well as co-stimulatory molecules on the cell surface (CD80 and CD86). 
There was also a trend towards lower expression of MHCII even though it did not reach 
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statistical significance. In addition, the expression of Ly6G and Ly6C as subset-defining 
markers was changed contrary to the changes seen after TLR9 activation with upregulation 
of the Ly6G- and downregulation of the Ly6C antigen. That in turn reflects the substantial 
increase in PMN-MDSC and the relative decrease in MO-MDSC during tumorigenesis (Figure 
3.5 B). Summarized, it is shown that MDSC are in fact less matured than their physiological 
counterparts which can objectified by analyzing a set of maturation markers. The same results 
were shown for MDSC and iMC in bone marrow, blood and lymph nodes, even though the 
downregulation of maturation markers in tumor-bearing mice was less pronounced in the 
bone marrow compared to peripheral compartments (data not shown).  
 
Figure 3.6. Tumor-induced MDSC exhibit less maturation markers than naïve iMC. Balb/c mice 
were inoculated subcutaneously with CT-26 colon carcinoma cells. When tumor size reached at least 
150 mm², mice were sacrificed, spleens removed and splenocytes were analyzed by flow cytometry. 
The histograms show representatives of maturation marker expression (MFI) on pre-gated splenic 
Gr1+CD11b+ iMC in tumor free mice (grey curve) vs. Gr1+CD11b+ MDSC in CT26 colon cancer bearing 
mice (black curve). Statistics are calculated from at least 2 – 3 independent experiments (n = 5 mice 
per group in each experiment). Data analysis was performed using paired Student’s t test comparing 
mean fluorescent intensity (MFI) of each surface marker. p < 0.05 was considered as significant. 
3.2.3 Different immunosuppressive activity of MDSC subpopulations  
With previous experiments showing that PMN-MDSC were the main population expanding 
during tumor growth, we decided to investigate the immunosuppressive effect of individual 
subpopulations. Therefore a magnetic-based technique to isolate Ly6Glow MO-MDSC and 
Ly6Ghigh MDSC was developed (see chapter 2.5.3.2). Mice bearing subcutaneous RMA-S 
lymphoma were sacrificed and subpopulations were isolated and separately co-cultured with 
CD3/CD28-stimulated splenocytes for 72 hours. T cell proliferation was analyzed using a 
BrdU proliferation ELISA. 
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Figure 3.7 shows that PMN-MDSC more potently suppress T cell proliferation than MO-
MDSC. That was consistently observed throughout all experiments and was not restricted to 
the RMA-S lymphoma model but also shown for CT26 [Zoglmeier et al., 2011] and B16 tumor-
bearing mice (data not shown). In addition, both tumor-derived MDSC subpopulations were 
significantly more suppressive than their respective counterparts from tumor-free mice (data 
not shown). 
 
 
Figure 3.7. PMN-MDSC bear higher immunosuppressive capacities than MO-MDSC in tumor-
bearing mice. Mice bearing subcutaneous RMA-S lymphoma (at least 150 mm² size) were sacrificed, 
spleens removed and MDSC subpopulations were purified by sequential MACS separation [PMN = 
polymorphonuclear MDSC; MO = monocytic MDSC]. Purity was verified via flow cytometry and was at 
least > 85% in each group. Degree of suppressivity was assessed with a T-cell proliferation assay using 
CD3/CD28-stimulated splenocytes (SC) as responder cells cocultured with either PMN-MDSC or MO-
MDSC for 72 hours (MDSC-splenocyte-ratio 1:8, 1:4, 1:2 with anti-CD3/CD28-stimulated SC as positive 
control). Data are expressed as mean + SEM. *, p < 0.05; **, p < 0.01, paired Student’s t test. 
3.3 Effect of immunotherapy with pattern recognition receptor ligands 
on MDSC in tumor-bearing mice 
3.3.1 MDSC numbers upon TLR ligand therapy in tumor-bearing mice  
In previous experiments, we showed that innate immune activation with CpG-ODN and other 
TLR ligands increases the number of Gr1+CD11b+ immature myeloid cells and concurrently 
induces their maturation without further augmenting their immunosuppressive properties. 
Likewise, it was shown that tumor growth inhibits their differentiation and induces MDSC, 
especially the polymorphonuclear subset which is highly suppressive.  
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In a next step, the effect of innate immune activation on the number, phenotype and function 
of MDSC in tumor-bearing mice was examined. Based on prior experiments, the CT26 colon 
carcinoma model was selected due to high numbers of MDSC and rapid tumor development. 
Therefore, mice bearing subcutaneous CT26 were treated on day 14 and 17 with either 
subcutaneous poly(I:C), CpG or sodium chloride (NaCl) as control. Therapy with TLR ligands 
resulted in a potent tumor reduction compared to control mice (Figure 3.8 A). 48 hours after 
the last therapy, mice were sacrificed and organs were further analyzed by flow cytometry.  
As expected, tumor growth expanded the number of splenic Gr1+CD11b+ MDSC compared 
to non-tumor bearing mice (Figure 3.8 D). Unexpectedly, mice treated with CpG-ODN 
showed no further expansion of splenic Gr1+CD1b+ cells compared to control mice with 12 to 
14% splenic MDSC in both groups (Figure  3.8 C,D). Same results were obtained when mice 
were treated with poly(I:C). Likewise, no changes in absolute MDSC numbers exceeding the 
percentage seen in untreated mice could be observed in peripheral blood or bone marrow 
(data not shown).  
Despite that IFNγ has been associated with MDSC expansion and activation in tumor-free 
mice [Greifenberg et al., 2009], a common surrogate marker for evaluating MDSC-mediated 
immunosuppression is the measurement of IFNγ serum levels, given the fact that MDSC 
directly inhibit IFNγ production by T cells. Additionally, IFNγ is crucial for mounting an 
effective immune response against malignant tumors [Shankaran et al., 2001] and reverses 
the immunosuppressive properties of tumor-associated macrophages [Duluc et al., 2009]. 
Consequently, beside a potent IFNα induction by CpG-ODN and poly(I:C) [Krug et al., 2001; 
Essers et al., 2009], measurement of serum cytokine levels showed that TLR9 activation with 
CpG-ODN restored the CT26-induced IFNγ-depletion (Figure 3.8 B). Because the number of 
MDSC was not altered by innate immune activation, we assessed the function of MDSC by ex 
vivo proliferation assay as described before. It showed that suppressivity of isolated Ly6Ghigh 
MDSC on T-cell proliferation and IFNγ production was significantly inhibited by CpG therapy. 
For the Ly6Glow subpopulation, suppressivity was also reduced by CpG treatment, although 
the effect was not significant [Zoglmeier et al., 2011].  
Thus, we demonstrated that CpG-ODN do not further increase MDSC as key mediators of 
immunosuppression in tumor bearing hosts and, moreover, reverse their immunosuppressive 
capacities they exert on T cells. Moreover, TLR9 stimulation in vivo restores the tumor-
mediated IFNγ-depletion.  
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Figure 3.8. Treatment of established CT26 tumor-bearing mice with TLR ligands does not further 
induce of Gr1+CD11b+ MDSC. Balb/c mice were inoculated subcutaneously with CT-26 colon 
carcinoma cells. Mice bearing established tumors (area at least > 25 mm²) were treated with CpG or 
poly(I:C) on day 14 and 17 after tumor induction (n = 5 per group). A Tumors were continuously 
measured with calipers every day in two dimensions. Mice were sacrificed two days after second 
therapy (day 19) and used for further analysis. B Serum levels of IFNγ in CT26 tumor-bearing mice 
before and after CpG therapy. Naïve Balb/c mice are shown as controls (wt, white bar). Mice were bled 
24 hours after last therapy and serum levels of IFNγ levels were measured via ELISA. C,D 
Representative FACS plot and histograms showing the total number of splenic Gr1+CD11b+ MDSCs in 
untreated (PBS) and CpG-treated mice. The number of MDSC in non tumor-bearing mice is depicted 
as a control (white bar, C). p < 0.05 was considered as significant (paired Student’s t test). 
3.3.2 MDSC subset composition and phenotype following systemic PRR ligation 
Previous studies showed contradicting results regarding the role of different MDSC subsets 
in tumor-mediated immunosuppression. Thus far, we showed that PMN- or Ly6Ghigh - MDSC 
are the most prominent subset induced during tumor growth in various murine tumor models. 
Compatibly, they seem to be the more potent suppressors of T cell proliferation (see chapter 
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3.2). Observing that treatment of tumor bearing mice with CpG-ODN not further induces 
myeloid-derived suppressor cells in total accompanied by a marked reduction in tumor size, 
in a next step we asked whether systemic Pattern recognition receptor ligation might 
influence the subset composition of tumor-induced MDSC. 
Therefore, mice with established CT26 colon carcinoma, B16 melanoma or RMA-S lymphoma 
were challenged with 9.2RNA (TLR7), poly(I:C) (TLR3), CpG-ODN (TLR9) and ppp-RNA (RIG-
I). Mice were than sacrificed and analyzed for MDSC subsets (Figure 3.9 A). As expected, in 
all three tumor models, systemic MDSC expansion was markedly due to a high number of 
Ly6Ghigh PMN-MDSC. This was most prominent in spleens of CT26 colon carcinoma bearing 
mice, but also visible in RMA-S lymphoma and B16 melanoma. Furthermore, when mice were 
challenged with the respective Pattern recognition receptor ligand, we saw a strong and 
significant reduction of PMN-MDSC with augmentation of the Ly6Glow MO-MDSC subset. The 
effect was mostly prominent for CpG but to a lesser extent also seen upon therapy with other 
PRR ligands. However, as described previously, the total number of MDSC remained 
unchanged. Again, the effect was not restricted to spleens alone but was likewise confirmed 
in bone marrow, blood and tumor-draining lymph nodes, even though less pronounced in 
bone marrow (data not shown). 
Splenic Ly6Ghigh PMN-MDSC and Ly6Glow MO-MDSC subsets were than further analyzed for 
maturation and differentiation marker expression by flow cytometry. Given that one of the 
defining traits of MDSC is their immature status and that we could previously show that 
MDSC of tumor-bearing mice challenged with CpG exhibit less immunosuppressive 
capacities, we thus hypothesized that systemic TLR ligation alters their phenotype towards 
matured myeloid cells. Indeed, in vivo treatment with CpG led to an increase in expression of 
the macrophage differentiation marker F4/80, the DC differentiation marker CD11c and the 
co-stimulatory molecule CD80. As shown in wild-type mice before, we observed a highly 
significant upregulation of Sca-1 on both MDSC subsets again. Table 3 summarizes and 
compares different maturation, differentiation and activation marker in naïve and CT26 
tumor-bearing mice with or without CpG therapy. 
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 Naïve vs. CT26 Naïve  vs  naïve + CpG CT26  vs  CT26 + CpG 
Marker Change (p) Change  (p) Change (p) 
Ly6C - < 0.001 + < 0.001 + < 0.001 
Ly6G + < 0.01 
 
- < 0.05 - < 0.01 
CD11b + < 0.05 + < 0.01 + < 0.05 
Sca-1 - < 0.05 + < 0.001 + < 0.001 
CD11c - < 0.05 
 
+ < 0.01 + < 0.05 
MHCII - < 0.05 + < 0.05 + < 0.05 
F4/80 - < 0.05 
 
+ < 0.05 (+) 0.08 
CD80 - < 0.01 
 
(+) 0.07 + < 0.01 
CD86 - < 0.05 (+) 0.09 (+) 0.059 
CD88 (+) 0.088 n.t. n.t. - < 0.01 
CD124 (+) 0.088 
 
- < 0.05 
 
= n.s. 
CD62L = n.s. 
 
= n.s. 
 
= n.s. 
CD31 (+) 0.16 n.t. n.t. (-) 0.09 
Table 3. Comparison of maturation, differentiation and activation marker on Gr1+CD11b+ myeloid-
derived suppressor cells in naïve and tumor-bearing with or without treatment with CpG. n.t. : not 
tested, = : not significant (n.s.), - : significant downregulation, + : significant upregulation, (+) : trend 
towards upregulation, (-) : trend towards downregulation. 
Thus, we demonstrated that challenging tumor-bearing mice with CpG-ODN and other TLR 
ligands, is able to overcome the tumor-induced differentiation block of myeloid cell 
differentiation [Gabrilovich and Nagaraj, 2009], restores expression levels of myeloid cell 
markers to those expressed in Gr1+CD11b+ cells in tumor-free mice and reverses the 
imbalance of Ly6Ghigh/Ly6Glow MDSC to a proportion seen in naïve mice.  
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Figure 3.9. Systemic therapy with TLR ligands induces maturation and MDSC subset shifting 
towards MO-MDSC (Ly6Glow) in tumor-bearing mice. Subpopulations of splenic Gr1+CD11b+ MDSC 
from mice with established C26 colon carcinoma, B16 melanoma or RMA-S lymphoma that were 
treated with different TLR / RIG-I ligands. MDSC subpopulations in spleens were analyzed via flow 
cytometry (n = 4 – 6 per group). A shows the percentage of splenic Ly6Glow monocytic MDSC (Ly6Glow 
MO) and splenic Ly6Ghigh polymorphonuclear MDSC (Ly6Ghigh PMN) with or without prior therapy in 
tumor-bearing mice. The total amount of MDSC in spleens is defined as 100%. B Histograms showing 
representatives of maturation marker expression (MFI) on pre-gated splenic MDSC-subpopulations in 
C26 tumor-bearing mice with (black curve) or without CpG therapy (grey curve). Data analysis was 
performed using paired Student’s t test comparing mean fluorescent intensity (MFI) of each surface 
marker. p < 0.05 was considered as significant. 
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3.3.3 Impact of poly(I:C) therapy on intratumoral MDSC 
MDSC not only play a pivotal role in tumor mediated general immunosuppression, but also 
resemble one of the most important players in the tumor microenvironment, where they can 
potently augment tumor growth, immune escape and where T cell suppression has the most 
profound effect [Umansky and Sevko, 2013]. Due to high practicability, most previous studies 
examined splenic MDSC. Thus, we next investigated, whether the effects on maturation and 
differentiation on tumor-induced MDSC after treatment with TLR ligands were also visible on 
tumor-infiltrating MDSC. 
Therefore, established B16 melanoma tumors of mice received three subcutaneous injections 
of poly(I:C) as described previously. Tumors were explanted and compared with non-treated 
controls using flow cytometry. Analysis of tumor-infiltrating Gr1+CD11b+ MDSC revealed up-
regulation of maturation and differentiation markers comparable with systemically expanded 
MDSC in bone marrow, blood and spleen after treatment with poly(I:C) (Figure 3.10). Higher 
expression of F4/80 and Ly6C resembles differentiation towards macrophages and mature 
monocytes following systemic TLR3 activation, respectively. There was also a trend towards 
DC-differentiation, indicated by upregulation of CD11c with the corresponding co-stimulatory 
molecule CD80, although it did not reach statistical significance. Comparable results were 
obtained when tumor-bearing mice were treated with CpG or ppp-RNA (data not shown). 
Nevertheless, the total amount of tumor-infiltrating MDSC after treatment with poly(I:C) or 
other pattern recognition receptor ligands was not altered (data not shown).  
 
 
Figure 3.10. Poly(I:C) treatment induces maturation and differentiation of intratumoral myeloid-
derived suppressor cells. C57/BL6 mice bearing established B16 tumors (area at least > 25mm²) 
received 3 s.c. injections of poly(I:C) or PBS (no therapy). Two days after the last injection mice were 
sacrificed. The tumors were removed, kollagenase digested and analyzed via flow cytometry. Figure 
10 shows differentiation and maturation marker expression on pre-gated intratumoral Gr1+CD11b+ 
MDSC. Histograms show representative data from individual mice. Data analysis was performed using 
paired Student’s t test. Significances (p) indicate differences in the median marker expression between 
mice with or without prior poly(I:C) injections (n = 5 per group).  
Results  66 
3.3.4 Phenotypical changes on MDSC upon systemic TLR stimulation are IFNα-
dependent 
After establishing that therapy with different TLR agonists and the RIG-I agonist 5’-
triphosphate-RNA is able to induce maturation, differentiation and a population shift of 
myeloid-derived suppressor cell subsets, accompanied by a marked reduction in tumor size, 
we then asked what factors might contribute to the observed effects. 
Maturation of MDSC as well as blocking their immunosuppressive properties was less 
prominent for the TLR7/8 agonist 9.2dr-RNA, R848 and the TLR4 agonist LPS (data not 
shown) and was most prominent for CpG-ODN (TLR9), poly(I:C) (TLR3) and 3p-RNA (RIG-I). 
When comparing differences and similarities of the systemically induced cytokine profile by 
these PRR ligands, a major difference of the latter is their greater ability to induce high 
amounts of IFNα [de Clercq, 1980; Krug et al., 2001; Hornung et al., 2006], suggesting IFNα 
as a major contributor for MDSC maturation and differentiation in vivo. 
To test this hypothesis, we used the immunostimulatory RNA ligand poly(I:C) as one the 
strongest IFNα inducers throughout our experiments. Wildtype and type I IFN-receptor 
deficient mice (IFNαR-/-) were subcutaneously inoculated with B16 melanoma cells and 
treated with one dose of poly(I:C) or PBS as a control. Notably, the sole deficiency of type I 
interferon signaling in IFNαR-/- mice was sufficient to induce a population shift towards 
higher numbers of monocytic Ly6Glow MDSC, accompanied by a decrease in 
polymorphonuclear MDSC (Figure 3.11 A). There were no differences seen when comparing 
MDSC subset composition in wildtype mice bearing B16 tumors after one dose of poly(I:C), 
indicating that the effect of subset recomposition may take longer than the 24 hours. When 
performing maturation marker analysis, one dose of poly(I:C) resulted in phenotypic and 
functional changes in MDSC similar to those induced by CpG. Treatment with poly(I:C) was 
sufficient to significantly upregulate Sca-1 and other maturation markers (Figure 3.11 B). 
Strikingly, this upregulation was completely abolished in IFNαR-/- mice, indicating that type 
I IFN is critically involved in MDSC maturation following innate immune activation. 
Performing flow cytometry analysis of collagenase digested B16 tumors showed comparable 
results with intratumoral maturation and differentiation of tumor-infiltrating MDSC following 
IFNα-induction with poly(I:C), yet without altering the total number of MDSC infiltrating the 
tumor tissue (data not shown).  
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Figure 3.11. Maturation, differentiation and shifting of MDSC subpopulations after treatment with 
TLR ligands is IFNα-dependent. Wild type or type I IFN-receptor deficient (IFNαR-/-) mice bearing 
s.c. B16 tumors (tumor area approximately 50 mm²) were treated once with poly(I:C) or PBS (no 
therapy). One day after injection mice were sacrificed. Organs were removed, tumors collagenase 
digested and analyzed via flow cytometry. A shows the percentage of splenic Ly6Glow monocytic MDSC 
(Ly6Glow MO) and splenic Ly6Ghigh polymorphonuclear MDSC (Ly6Ghigh PMN) with or without prior 
poly(I:C) therapy. The whole amount of MDSC (not shown) is defined as 100%. B shows differentiation 
and maturation marker expression on pre-gated splenic Gr1+CD11b+ MDSC. Surface markers are 
demonstrated and compared in bar graphs as MFI (mean fluorescent intensity). 
3.3.5 Role of ppp-RNA and TGFβ-silencing on MDSC in tumor-bearing mice 
In preceding experiments we have observed that treatment of tumor-bearing mice with 
distinct pattern recognition receptor ligands, especially those that induce high amounts of 
IFNα such as CpG, poly(I:C) and 5’triphosphate-RNA, cause maturation and differentiation of 
systemic and intratumoral myeloid-derived suppressor cells. We showed that even though 
PRR ligation has pleiotropic downstream signaling effects, the effect of abolishing the 
maturation block, changing MDSC subset composition and attenuating their 
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immunosuppressive properties is largely dependent on type I IFN signaling [Zoglmeier et al., 
2011]. 
However, numerous other tumor-derived factors and cytokines may lessen the beneficial 
effect of an IFNα-mediated MDSC maturation following innate immune stimulation. TGFβ has 
been emerged as one of the most crucial cytokines involved in MDSC accumulation in line 
with prevention of DC maturation and polarization of myeloid cells towards immune 
suppressive cells in the tumor microenvironment [Flavell et al., 2010]. In addition, Fridlender 
and colleagues showed that TGFβ-blockage results in polarization of tumor-associated 
neutrophils or Ly6Ghigh MDSC towards an antitumoral neutrophil population.   
Hence, we wanted to investigate whether the maturation and differentiation of MDSC by 
systemic IFNα-induction following innate immune stimulation can be further augmented by 
concurrent blockage of TGFβ. Therefore a bifunctional ppp-siRNA was used that combines 
RIG-I activation for IFNα induction with gene silencing of TGFβ1 and its therapeutic efficacy 
was studied in the orthotopic Panc02 mouse model of pancreatic cancer [Ellermeier et al., 
2013]. 
Treatment of PancO2-bearing mice with si-TGFβ or ppp-TGFβ led to a significant decrease 
of circulating myeloid-derived suppressor cells, illustrated by the percentage of Gr1+CD11b+ 
MDSC found in spleen (Figure 3.12 A). This effect was partially depending on TGFβ-blockage, 
although there was a trend towards further decrease in circulating MDSC with the 
triphosphate moiety and subsequent RIG-I activation. As hypothesized, downregulation of 
TGFβ by siRNA resulted in a highly significant change in subset composition with a decrease 
of polymorphonuclear Ly6Ghigh MDSC and a relative increase of the monocytic subset. A trend 
towards this change in subset composition could also be demonstrated for 3p-RNA alone, 
albeit it lacked significance (data not shown, also see Figure 3.9 A). Again, by combining RIG-
I activation and TGF-blockage with bifunctional ppp-TGFβ-siRNA, the shift in myeloid cell 
subset composition could not be further augmented. When analyzing apoptosis on an 
individual cell basis via measurement of Caspase-9 activity (FLICA), splenic Gr1+CD11b+ 
MDSC showed a significantly higher rate of apoptotic cell death compared to untreated mice. 
A more detailed analysis of MDSC subpopulations revealed, that the induction of apoptosis 
in this experimental setting on PMN-MDSC is largely dependent on TGFβ-blockage, whereas 
apoptosis in the monocytic subset is primarily induced by RIG-I activation via the 5’-
triphosphate moiety (Figure 3.12 B). 
To examine whether TGFβ-blockage alone or in combination with RIG-I activation can also 
promote MDSC differentiation in tumor bearing mice, Gr-1+CD11b+ MDSC were assessed on 
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their expression of CD80, CD11c, Ly6C and Sca-1 (Figure 3.12 C). Knockdown of TGFβ via 
siRNA was sufficient to induce monocytic cell differentiation in MDSC illustrated by 
upregulation of Sca-1 and Ly6C [Serbina et al., 2009]. However, DC differentiation with 
higher expression levels of CD11c and the co-stimulatory molecule CD80 was solely induced 
via the accessory triphosphate moiety with subsequent RIG-I activation.  
MDSC are major inhibitors of cytotoxic T lymphocytes, inducing T cell anergy and negatively 
correlate with the influx of CD8+ tumor-infiltrating cytotoxic T lymphocytes [Gabrilovich and 
Nagaraj, 2009; Curran et al., 2010]. By analyzing tumor slices via fluorescence microscopy 
we examined the influx of cytotoxic CD3+CD8+ T lymphocytes (CTLs) following therapy with 
bifunctional ppp-siRNA against TGFβ (Figure 3.12). We saw a significant increase in CTL-
infiltration following TGF-beta blockage with either siTGFβ or ppp-TGFβ compared to control 
OH-RNA (Figure 3.12 D,E). Systemic RIG-I activation via a –ppp moiety was not able to further 
increase CTL influx, although a trend was visible. This might serve as a proxy of the observed 
pro-apoptotic and differentiating effects of TGFβ blockage and RIG-I activation on MDSC in 
this setting. Nevertheless, a casual link between both has yet to be determined. 
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Figure 3.12. Increased apoptosis and maturation of MDSC by TGFβ blockage and IFNα induction 
via bifunctional 5’triphosphate-siTGFβ RNA. Mice bearing orthotopic PancO2 tumors were 
subsequently treated intravenously with 50 µg RNA on days 12 and 14 with unspecific RNA (control-
OH; white bar), small-interfering RNA directed against TGFβ1 (siTGFβ; grey bar) or bifunctional 
5’triphophosphate-siTGFβ RNA (ppp-TGFβ; black bar). Spleens and tumors were removed on day 15 
and further analyzed by flow cytometry and immunofluorescence. A Percentage of Gr-1+CD11b+ MDSC 
(gated on live cells) and respective subpopulations (gated on MDSC). B Degree of apoptosis in MDSC 
was assessed by measuring Caspase-9 (FLICA) activity via flow cytometry in PMN-MDSC or MO-
MDSC. C Maturation and differentiation of Gr-1+CD11b+ MDSC as assessed by mean fluorescence 
intensity (MFI) of CD80, CD11c, Ly6C and Sca-1, respectively. D Tumor slices were stained with Cy2 
anti-CD8 (green) and Cy3 anti-CD3 (red). Representative pictures of CD3+CD8+ tumor-infiltrating 
cytotoxic T-lymphocytes (CTLs) into tumor tissue. E shows the average number of CTLs per visual 
field. Cell infiltration was averaged measuring at least 15 visual fields per sample out of 3-5 different 
tumor samples. Pooled data of 4 – 6 mice per group are shown as means + SEM. * indicates p < 0.05. 
** indicates p < 0.01. *** indicates p < 0.001. All data are expressed as mean ± SEM. A two-tailed p-
value of < 0.05 was considered significant. 
3.4 Characterization of stem cell antigen-1 (Sca-1) on MDSC 
Following innate immune stimulation and therapy of tumor-bearing mice with different PRR 
ligands, the Ly6 protein family member Sca-1 (Ly6A/E) has been shown to be one of the most 
significantly upregulated proteins on MDSC among the surface proteins throughout our 
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experiments. Stem cell antigen-1 (Sca-1) or lymphocyte activation protein-6A (Ly6A) is a GPI-
anchored protein and is localized to lipid rafts of the plasma membrane [Curran et al., 2010]. 
It has been originally identified as an antigen upregulated on activated lymphocytes more 
than 30 years ago [Yutoku et al., 1974]. 
In prior experiments we had shown for the first time that Sca-1 is strongly upregulated by 
MDSC in response to CpG-ODN, poly(I:C) or 5’triphosphate-RNA and that it represents a 
highly sensitive activation/differentiation markers for this cell population. Furthermore, its 
upregulation inversely correlates with the suppressive activity of MDSC. Therefore, we aimed 
to further dissect the role of Sca-1 on MDSC mediated immunosuppression and tumor 
development.  
3.4.1 Expression of Sca-1 in different tissues and MDSC subpopulations 
Using flow cytometry, we first started to analyze the expression of Sca-1 on Gr1+CD11b+ 
immature myeloid cells (iMC) in non-tumor-bearing mice. Mean fluorescence intensity of 
Sca-1 on iMC was lowest in bone marrow with induction of its expression after peripheral 
homing of immature myeloid cells into spleen, lung and peripheral lymph nodes with the 
highest measurable Sca-1 expression in lymphoid tissue (Figure 3.13 A). Surprisingly, when 
comparing tumor-induced splenic MDSC and tumor-associated MDSC in CEA424-TAg mice 
bearing spontaneous gastric tumors, tumor-associated MDSC showed three-fold higher 
expression levels of Sca-1 in comparison to splenic MDSC (Figure 3.13 C). In a next step, we 
compared Sca-1 expression on splenic immature myeloid cells in tumor-free mice versus 
tumor-induced myeloid derived suppressor cells showing that MDSC express significantly 
lower levels of Sca-1 than their naïve counterparts. In addition, when comparing MDSC 
subpopulations on their differential expression of Sca-1, monocytic Ly6Chigh MDSC express 
higher amounts of Sca-1 on their cell surface than granulocytic PMN-MDSC (Figure 3.13 B). 
We thus show that Sca-1 is upregulated during homing of Gr1+CD11b+ myeloid cells into 
peripheral organs and even tumor tissue. Furthermore, Sca-1 seems to be downregulated on 
MDSC via tumor-derived factors, which complements previous results showing Sca-1 
upregulation via TGFβ-blockage (Figure 3.12 C). In addition, when performing detailed flow 
cytometry analysis of Sca-1+Gr1+CD11b+ cells compared to Sca-1-Gr1+CD11b+ cells, the 
expression of Sca-1 strongly correlated with a more mature and differentiated MDSC 
phenotype in both naïve and tumor-bearing mice (data not shown). 
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Figure 3.13. Sca-1 expression on MDSC is tissue-dependent and differs between naïve iMC, 
MDSC-homing site and MDSC subpopulations. A Naïve Balb/c mice (n = 3) were sacrificed and Sca-
1 expression on Gr1+CD11b+ iMCs was analyzed via flow cytometry in indicated tissues (pLN: 
peripheral lymph nodes). Histograms display an example of representative individual mice. B Balb/c 
mice were inoculated subcutaneously with CT26 colon carcinoma cells. Mice bearing established 
tumors (area at least > 50 mm²) are compared with non-tumor bearing mice (n = 5 per group). Bar 
graphs show the amount of Sca-1+ MDSC in spleen (left) and Sca-1 expression on MDSC 
subpopulations (right) displayed as Mean Fluorescent intensity (MFI). C MDSC in CEA424-TAg mice 
bearing spontaneous gastric tumors (SV40; mice aged 90 – 100 days; n = 3 per group) were analyzed 
via flow cytometry. Bar graphs show the mean fluorescent intensity (MFI) of Sca-1 on splenic and 
intratumoral Gr1+CD11b+ MDSC. Analysis was performed using paired Student’s t test. Significances 
are depicted in the left upper corners. 
3.4.2 Role of Sca-1 in tumor development and MDSC-mediated immunosuppression 
To further evaluate the role of Sca-1 in tumor formation and to evaluate a functional role in 
MDSC-mediated immune escape, wild type C57/BL6 mice and mice deficient in stem cell 
antigen-1 (Sca-1-/-) were subcutaneously inoculated with PancO2 cells. Tumor formation was 
then continuously measured. When mice were sacrificed, we purified Gr1+CD11b+ MDSC 
from spleens as described previously and performed a T cell suppression assay.  Based on 
73 Results 
 
prior experiments, we hypothesized that Sca-1 may act as a negative regulator of MDSC-
mediated tumor tolerance, thereby promoting a more efficient immune answer.  
To our surprise, when we compared Sca-1-/- MDSC with wild type MDSC on their capability 
to suppress CD3/CD28-activated splenocyte proliferation ex vivo, MDSC lacking Sca-1 were 
significantly less suppressive than their naïve counterparts (Figure 3.14 B). In addition, Sca-
1-/- mice showed a trend towards slower tumor growth, even it did not reach statistical 
significance (p = 0.11). In contrast to what we had expected, we thus show for the first time 
that Sca-1 functionally fosters the capability of myeloid-derived suppressor cells to suppress 
T cell proliferation and thereby might attenuate immune surveillance of malignant tumors.  
 
Figure 3.14. Sca-1-/- mice have less immunosuppressive MDSC without significant alteration of 
tumor growth. A C57/BL6 and Sca-1-/- mice were inoculated subcutaneously with PancO2 pancreatic 
carcinoma cells (n = 5 – 8 per group). Tumors were continuously measured with calipers in two 
dimensions. Mice were sacrificed on day 32 after tumor inoculation when tumor size reached at least 
> 75 mm2 in each group. B MDSC were purified from spleens of wildtype and Sca-1-/- PancO2-bearing 
mice by sequential MACS separation. Purity was verified via flow cytometry and was > 80% in each 
group. Degree of MDSC-mediated suppressivity was assessed with a T-cell proliferation assay using 
CD3/CD28-stimulated splenocytes (SC) as responder cells cocultured with MDSC for 48 hours [MDSC-
splenocyte-ratio 1:16, 1:8, 1:4, 1:2 with anti-CD3/CD28-stimulated SC as positive control (SC, act)]. p 
< 0.05 was considered as significant.  
3.4.3 Induction of Sca-1 on MDSC via TLR ligands in vivo and in vitro 
Preceding experiments using immunotherapy with different TLR ligands in vivo showed a 
significant upregulation of Sca-1 on MDSC in tumor bearing mice, concurrent with an inverse 
relation of Sca-1 expression with immunosuppressive properties of Gr1+CD11+ MDSC. 
Throughout our experiments, especially PRR ligands known for their potential to induce high 
amounts of type I interferons after receptor ligation such as CpG-ODN (TLR9), poly(I:C) 
(TLR3) and 3p-RNA (RIG-I) were the most efficient inducers of Sca-1 on MDSC in vivo.  
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To validate this finding, CT26 tumor-bearing mice received three repeated injections of CpG-
ODN and poly(I:C) again, as we and others have shown a major type I interferon response in 
vivo following treatment with these immunostimulatory oligonucleotides [de Clercq, 1980; 
Krug et al., 2001]. Indeed, Sca-1 expression on myeloid derived suppressor cells was 
upregulated four- to tenfold as compared to untreated mice (Figure 3.15 A).  
In a next step, we used B16 melanoma-bearing IFNαR-/- mice and injected poly(I:C) as it 
appeared to be the strongest inducer of IFNα with subsequent upregulation of Sca-1 on 
Gr1+CD11b+ cells (Figure 3.15 B). Whereas poly(I:C) treatment of wild type mice led to Sca-
1 upregulation on splenic as well as intratumoral MDSC, its expression was completely 
abrogated in IFNαR-/- mice. This is supported by recent literature by Essers and colleagues, 
showing that Sca-1 is inducible via IFNα in a STAT1 dependent fashion in vivo [Essers et al., 
2009]. 
In parallel experiments we found that abrogation of MDSC suppressivity, their maturation 
and Sca-1 induction following CpG treatment, is mainly mediated by type I IFN induction via 
plasmacytoid dendritic cells, rather than a direct effect of TLR9 activation on MDSC 
[Zoglmeier et al., 2011]. To test whether direct stimulation of Gr1+CD11b+ immature myeloid 
cells with different Toll-like receptor ligands is able to induce Sca-1 expression, we purified 
Gr1+CD11b+ immature myeloid cells from bone marrow via magnetic sorting. Cell purity was 
greater than 98% which was validated via flow cytometry. As hypothesized, IFNα induces 
the highest Sca-1 expression on immature myeloid cells, at the same time proving that 
iMC/MDSC express a functional type I interferon receptor (Figure 3.15 C). Neither CpG-ODN 
or poly(I:C) were able to induce Sca-1 expression in vitro. In contrast, LPS (TLR4) and R848 
(TLR7) as well as the combination of Pam3CysK (TLR2) and Curdlan, a beta-1,3-glucan-
polymer binding to Dectin-1, significantly induced Sca-1 expression in immature myeloid 
cells. Neither Pam3CysK nor Curdlan alone were able to upregulate Sca-1 alone, which 
supports findings of Ferwerda and colleagues in 2008, showing that dectin-1 amplifies TLR2-
dependent induction of cytokines [Ferwerda et al., 2008]. 
Thus, we show that upregulation of Sca-1 on Gr1+CD11b+ immature myeloid cells upon 
stimulation with CpG and poly(I:C) in vivo is mainly mediated via indirect induction of IFNα 
as direct stimulation of their corresponding Toll-like receptor on iMC did not result in a 
significant upregulation of Sca-1. Concurrently, we show that immature myeloid cells express 
functional TLR2, TLR4, TLR 7 and Dectin-1 and to a certain extent, Sca-1 expression is also 
inducible via their direct activation. 
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Figure 3.15. TLR ligands induce Sca-1 on MDSC in vivo and in vitro with an essential role for IFNα.  
A CT26 tumor-bearing mice received 3 s.c. injections of CpG, poly(I:C) or PBS (no therapy). Two days 
after the last injection mice were sacrificed and Sca-1 expression on splenic myeloid-derived 
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suppressor cells was analyzed via flow cytometry (MFI = mean fluorescent intensity). Pooled data of 4 
– 6 mice per group are shown as means + SEM. **** indicates p < 0.0001. ***** indicates p < 0.00001. 
B Wildtype or IFN-I receptor deficient (IFNαR-/-) mice bearing s.c. B16 tumors (tumor area 
approximately 50 mm²) were treated once with poly(I:C) or PBS (no therapy). Organs were removed, 
tumors kollagenase digested and analyzed via flow cytometry. Histograms show the changes in the 
expression of Sca-1 on splenic and intratumoral MDSC two days after treatment; an example of 
representative individual mice is depicted [gray, no therapy; black line, poly(I:C)]. Significances (p) 
indicate differences in median expression (n = 5 per group). C Gr1+CD11b+ iMC from bone marrow of 
naïve C57/BL6 mice were purified, plated in 96-well and cultured in vitro with indicated stimuli. Purity 
of Gr1+CD11b+ was greater than 98% (validated via FACS). Sca-1 expression (MFI) on iMC was 
evaluated after 24 hours of stimulation via flow cytometry. [CpG:TLR9; R848:TLR7; IFNα:IFNαR; 
Flagellin:TLR5; Curdlan:Dectin-1; Pam3CysK:TLR2; TGFβ:TGFβR; LPS:TLR4; poly(I:C):TLR3]. 
Significances (p) indicate differences in the median marker expression (n = 3 per group). A two-tailed 
p-value < 0.05 was considered significant (Student’s t test). 
3.4.4 Analysis of cytokine induction in Sca-1-/- mice upon PRR ligation  
On the one hand we found out that the induction of IFNα via innate immune receptors is 
critically involved in maturation, differentiation and attenuation of MDSC suppressivity, along 
with a highly significant increase in the expression of stem cell antigen-1. In addition, we 
unexpectedly found that myeloid-derived suppressor cells deficient for Sca-1 exhibit less 
immunosuppressive properties in tumor-bearing mice in conjunction with a trend towards 
slower tumor growth in vivo. On the other hand, increasing evidence in the literature 
implicated that Sca-1 might not only be a bystander protein indicating T cell activation or 
serving as a phenotypical marker for lineage determination in haematopoietic stem cells [Ma 
et al., 2002; Holmes and Stanford, 2007], but may also play a functional role in distinct 
signaling pathways, e.g. type I interferon and TGFβ signaling [Essers et al., 2009, Upadhyay 
et al., 2011].  
Based on that findings and in order to dissect functional differences between Sca-1-/- and 
wildtype mice, C57/BL6 and Sca-1-/- mice received one injection of poly(I:C). Twenty hours 
later mice were bled and serum was tested for cytokine levels. Based on findings of other 
groups that Sca-1 may prohibit downstream type I interferon signaling, we hypothesized 
lower levels of IFNα upon systemic TLR3 activation via poly(I:C). To our surprise, serum levels 
of IFNα were comparable in wild type and Sca-1-/- mice (Figure 3.16 A, left column). When 
we further screened for serum levels of other cytokines, no differences in the induction of IL-
6, IL12p70, TNFα or IL1β could be detected (data not shown). Incidentally, we detected high 
levels of IP-10/CXCL-10 in Sca-1 deficient mice upon therapy with poly(I:C) (Figure 3.19 A, 
right column). IFNγ-inducible protein of 10 kDa or IP-10/CXCL10 is an early response gene 
mainly induced by Interferon-γ but also type I interferons, LPS or CpG-ODN [Neville et al., 
1997; Imaizumi et al., 2013] and is critically involved into effector T cell trafficking to sites of 
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inflammation [Dufour et al., 2002]. Experimental models also demonstrated that CXCL10/IP-
10 has antitumorigenic properties and reduces angiogenesis [Narvaiza et al., 2000].  
Next, we wanted to evaluate if this pronounced induction of IP-10 in vivo is either an indirect 
effect of TLR3 activation via other soluble mediators/cytokines and likewise, if stimulation of 
other pattern recognition receptor pathways also triggers a more pronounced IP-10 
induction. Therefore, bone marrow-derived macrophages (BMDM) from wild type and Sca-
1-/- mice were generated as previously described [Manzanero, 2012], cultivated, plated in 96-
well plates and stimulated with various pattern recognition receptor ligands available in our 
laboratory. BMDM were used because they resemble a common tool when analyzing innate 
immune receptor signaling and cytokine production [Kobayashi et al., 2002]. 
Direct stimulation of wild type macrophages with poly(I:C), LPS, poly(dA:dT), 5’ppp-RNA and 
IFNα/γ induced moderate levels of IP-10 secretion into the supernatant (Figure 3.16 B). In 
this experimental setting, IP-10 induction via IFNγ at 100 U/ml was lower as expected after 
24 hours of stimulation. When we repeated the same experimental setting with higher 
concentrations of IFNγ (up to 500 U/ml), IP-10 induction was markedly increased in a dose 
dependent manner (data not shown). When we measured IP-10 levels in the supernatant of 
pattern recoginiton receptor stimulated Sca-1-/- BMDM, a highly significant increase in its 
production compared to wildtype mice was observed. Especially stimulation of TLR3, TLR4, 
the AIM2-inflammasome and RIG-I resulted in a three- to sixfold increase in IP-10 production 
as compared to macrophages posessing the Sca-1 antigen. Comparable results (only less 
pronounced) were obtained when bone marrow, splenocytes and magnetically sorted 
Gr1+CD11b+ immature myeloid cells from wild type and Sca-1-/- mice were used in the same 
experimental setting (data not shown). 
Thus, we show for the first time that mice deficient for Stem cell antigen-1 show a pronounced 
IP-10 production following innate immune stimulation with various PRR ligands in vivo and 
in vitro. Whether that observation has a biological significance, or might even explain 
reduced MDSC suppressivity of Sca-1-/- mice, needs to be elucidated in further studies.  
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Figure 3.16. Pronounced IP-10 induction in vivo and in vitro following PRR ligation in Sca-1-/- mice. 
A Naive C57/BL6 and Sca-1-/- mice (n = 5 per group) received one s.c. injection of 250 µg poly(I:C). 20 
hours later mice were bled and serum was analyzed for the amount of IFNα, IL-6 and IP-10 via ELISA. 
B Bone marrow-derived macrophages (BMDM) from wildtype (wt) and Sca1-/- mice were cultured, 
plated in 96-well and stimulated for 24 hours with indicated PRR ligands. Supernatant was measured 
for the amount of IP-10 via ELISA. ** indicates p < 0.01. *** indicates p < 0.001. **** indicates p < 
0.0001. All data are pooled of w wells per group and expressed as mean ± SEM. A two-tailed p-value 
of < 0.05 was considered significant. 
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4 DISCUSSION 
4.1 MDSC subpopulations 
4.1.1 Differentiated view on MDSC subpopulations in tumor-bearing hosts 
In recent years, the role of MDSC in tumor-associated immune suppression has been 
established in a large number of clinical and preclinical studies. It quickly became apparent 
that MDSC do not represent a single cell population, but are rather comprised of myeloid 
cells at different stages of cell differentiation [Almand et al., 2001: Bronte, 2009]. Tumor-
induced MDSC are further dichotomized into two major subpopulations, in mice based on 
their differential expression of Ly6G and Ly6C on the cell surface: polymorphonuclear 
Gr1+CD11b+Ly6GhighLy6Clow MDSC and monocytic Gr1+CD11b+Ly6GnegLy6Chigh MDSC (MO-
MDSC) [Movahedi et al., 2008]. However, with more studies on MDSC biology, it becomes 
more and more apparent that this classical dichotomy is more complex than originally 
thought. Based on their differential expression of Gr-1, CD11b, scatter-appearance, other 
surface expression markers such as CD115 and morphologic appearance, Greifenberg and 
colleagues could identify six different populations in the Gr1+CD11b+ compartment with 
varying immunosuppressive properties [Greifenberg et al., 2009]. Other groups made 
attempts to further subdivide polymorphonuclear and monocytic MDSC in more or less 
immunosuppressive phenotypes by using additional surface markers such as CD49d, CD115 
or CD124/IL-4Rα [Mandruzzato et al., 2009; Haile et al., 2010].  
Due to feasibility and the lack of clearly defined additional subpopulations of myeloid-derived 
suppressor cells other than Ly6Ghigh PMN and Ly6Glow MO-MDSC, we have adopted the 
classical division of MDSC in this work. All tumor models examined in this study showed a 
variable but significant increase in the whole population of MDSC. Intriguingly, PMN-MDSC 
were the most abundant cell type induced by tumor growth in vivo. This finding is supported 
by the literature showing the granulocytic subset as a predominant population of MDSC in 
tumor-bearing mice [Youn et al., 2008; Gabrilovich and Nagaraj, 2009]. However, in other 
pathologic conditions, such as experimental autoimmune encephalitis, a mouse model of 
multiple sclerosis, a significant increase in the number of CD11b+Ly6G-Ly6Chigh cells 
resembling monocytic MDSC was observed that limited the course of disease. At the bottom 
line, the basis for this subset dichotomy remains elusive as the exact nature of tumor-derived 
factors that drive MDSC accumulation and define the expansion of a specific subset.  
Likewise, in the context of tumor development, there is still ongoing debate whether 
granulocytic or monocytic MDSC exploit more immunosuppressive features. In this work, we 
consistently observed that the Ly6Ghigh fraction (when purified and compared to Ly6Glow 
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MDSC) was substantially more suppressive. This was validated in the murine B16 melanoma, 
CT26 colon carcinoma, RMA-S lymphoma and orthotopic SV40 gastric carcinoma model.  In 
contrast, a study using EL-4 lymphoblastic lymphoma, MO-MDSC have shown to inhibit T 
cell proliferation more potently than PMN-MDSC [Movahedi et al., 2008]. Likewise, another 
study by Dolcetti and colleagues proposed an inverse correlation of Gr1-brightness to the 
immunosuppressive power of MDSC on Ag-stimulated CD8+ T cells in a C26-GM and 4T1 
tumor model [Dolcetti et al., 2010]. On the contrary, our data is strengthened by a recent 
study analyzing MDSC subpopulations from mice bearing 3LL, MCA-38 and EL-4 tumors that 
shows that PMN-MDSC had higher ability to impair proliferation and expression of effector 
molecules in activated T cells, thus inducing T cell anergy [Raber et al., 2014]. Regarding 
human MDSC, a recent NIH study by Tim Greten and colleagues analyzed monocytic (CD14+) 
and granulocytic (CD15+) MDSC in patients with gastrointestinal malignancies and found the 
granulocytic fraction to be more suppressive than their counterparts [Duffy et al., 2013].  
However, defining the exact differences between MDSC subsets in mice and particularly in 
human has not reached a consensus yet. For the future studies of MDSC biology it will be 
crucial to further dissect molecular pathways and mechanisms of immunosuppression which 
are partially substantially different between MDSC subsets. Even though, these variations are 
not overly surprising since the factors driving MDSC accumulation vary between different 
tumor models and human cancers: If a tumor of a given type will produce a particular set of 
MDSC driver molecules that induce a MDSC phenotype of a given type, another tumor entity 
will produce other driver molecules that induce a different MDSC phenotype. 
In addition, variations between different study groups regarding MDSC suppressivity and 
their behavior following pharmacologic therapy may be explained by different isolation 
techniques used for MDSC purification as well as the functional readout used for estimation 
of their immunsosuppressive properties. In this study we used different magnetic-bead based 
technologies to sort MDSC subpopulations with high purity. Nevertheless, by histologic 
evaluation, purified Ly6Ghigh MDSC were exclusively polymorphonuclear, whereas the 
nuclear morphology of Ly6Glow MDSC was more heterogeneous, comprising both monocyte-
like and polymorphonuclear cells [Zoglmeier et al., 2011]. That may limit the direct transfer 
of our data when compared to studies in which other isolation techniques have been utilized. 
Furthermore it may clarify that these cells do not represent a defined subset of cells but a 
group of phenotypically heterogenous myeloid cells sharing common biological activity 
rather than specific phenotypical characteristics. 
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4.1.2 Shift in subset composition upon TLR activation 
In non-tumor bearing mice, the proportion of polymorphonuclear Ly6Ghigh to monocytic 
Ly6Glow immature myeloid cells is relatively stable varying from 1:1 up to 3:2 in favor of 
granulocytic myeloid cells with minor distinctions between different mouse strains. In vivo 
treatment with the TLR ligands CpG and poly(I:C) mainly increases the frequency of 
monocytic immature myeloid cells in naive mice, whereas the total number of PMN-MDSC 
remains relatively stable, ultimately resulting in a so-called “shift” in subset composition with 
the majority of Gr1+CD11b+ cells being monocytic in their nature. As discussed before, 
granulocytic MDSC outnumber monocytic MDSC in numerous mouse tumor models and our 
data show them to be the major players of immunosuppression in tumor-bearing mice. In 
addition, when tumor-bearing mice were treated with CpG, poly(I:C) and to a lesser extent 
with 3pRNA, a strong reduction of PMN-MDSC accompanied by a significant increase of MO-
MDSC could be observed, resulting in a proportion of MDSC subsets observed in naïve mice. 
This shift was almost completely abrogated in IFNα-deficient mice and nor could we observe 
it in tumor-bearing mice treated with LPS as it lacks potent type I IFN induction in vivo 
without prior priming [Richez et al., 2009].  
As hypothesis, this may be a reflection of the effects of IFNα on (1) the induction of monocyte 
differentiation and proliferation [Paquette et al., 1998; Svane et al., 2006] and (2) the negative 
influence of type I interferons on myelo-/granulopoiesis [Koren and Fleischmann, 1993; 
Paquette et al., 1998] thus shutting down the pool of subsequent granulocytic MDSC from 
the bone marrow. That hypothesis is further strengthened by our observation that the 
decrease of PMN-MDSC in tumor bearing mice is equally observed in bone marrow. In 
addition, PMN-MDSC are not capable of proliferating and have a substantial shorter lifespan 
than MO-MDSC [Condamine et al., 2014].  
Interestingly, work by the group of Dimitry Gabrilovich recently assessed one of the 
underlying mechanisms of PMN-MDSC abundance in tumor-bearing hosts [Youn et al., 
2013]. By performing detailed fate-mapping experiments in tumor-bearing mice, their results 
suggest that in cancer, a large proportion of MO-MDSC can convert into PMN-MDSC instead 
of differentiating into macrophages and dendritic cells. This process was tightly regulated by 
epigenetic transcriptional silencing of the retinoblastoma gene (RB). Our data, illustrating a 
decrease in PMN-MDSC with a relative increase in more mature and differentiated MO-
MDSC, suggests that systemic activation of distinct TLRs might overcome this fate decision 
of pathologic myeloid differentiation in cancer. Of note, induction of the RB protein by 
Interferon-α has been described more than 20 years ago, although it was shown in human 
Burkitt lymphoma cells rather than in the myeloid compartment [Kumar and Atlas, 1992].  
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If the individual proportion of PMN-MDSC to MO-MDSC displays a prognostic or even 
predictive value upon therapy remains elusive as well as a potential interplay within MDSC 
subsets as no studies exist that have investigated the effect of granulocytic MDSC on 
monocytic MDSC and vice versa. If at all, the significance of our finding may only be conferred 
to tumor models in which PMN-MDSC display the major immunosuppressive subset as well.  
4.2 Myeloid-derived suppressor cells and pattern recognition receptor 
ligands 
4.2.1 Expansion and activation of MDSC by Toll-like receptor ligands 
Myeloid-derived suppressor cells accumulate under certain pathological conditions in bone 
marrow, blood, peripheral lymphoid organs, in case of malignancy at the tumor site itself or 
even in premalignant lesions [Tu et al., 2008]. Whether the stimulus for MDSC expansion 
concurrently triggers their activation to gain fully immunosuppressive MDSC remains 
questionable. In fact, research in the last years suggests a so-called “two-signal-model” 
proposing that MDSC expansion and activation is mediated by several different factors with 
molecules driving MDSC accumulation and other factors involved in direct activation of 
MDSC [Gabrilovich and Nagaraj, 2009; Condamine and Gabrilovich, 2011].  
The significance of Toll-like receptor activation and other pattern recognition receptors in 
MDSC activation has not been fully elucidated yet. If MDSC expanded by innate immune 
stimulation acquire immunosuppressive properties remains largely elusive. In a model of 
polymicrobial sepsis, Delano and colleagues demonstrated that MDSC expansion is 
dependent on the TLR adaptor protein MyD88 but does not require TLR4, suggesting other 
PRRs/TLRs to be responsible for MDSC accumulation during systemic inflammation [Delano 
et al., 2007]. The above described “two-signal-model” with LPS as TLR4 agonist involved in 
the expansion of MDSC, has been nicely demonstrated by Greifenberg and colleagues. They 
showed that the combined treatment of mice with LPS and IFNγ activating the JAK/STAT axis 
enhanced immunosuppressive MDSC functions and impaired the capacity of Gr1+CD11b+ to 
mature into dendritic cells. Recently, membrane bound heat-shock protein 72 (Hsp72) 
expressed on tumor-derived exosomes has shown to be involved in triggering MDSC 
expansion in a STAT-3 and TLR2-dependent manner [Chalmin et al., 2010]. In fact, evidence 
for an activation of MDSC suppressivity has so far only been provided for TLR2 and TLR4, 
which may therefore hold a unique position among TLRs. 
In 2008, with the use of a slow-delivery system, Vaknin and colleagues showed that chronic 
immune stimulation with TLR2, 3, 4, and TLR 9 ligands leads to systemic expansion of MDSC-
like cells [Vaknin et al., 2008]. They proposed that TLR stimulation in this setting also delivers 
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the second signal required to activate MDSC suppressivity. Because TLR9 ligands are used 
in cancer vaccines, where MDSC activation would be deleterious for the clinical outcome, we 
investigated the effect of systemic TLR stimulation on accumulation and suppressive function 
of MDSC in naïve mice.  
Indeed, our own data support the expansion of Gr1+CD11b+ immature myeloid cells via 
systemic activation of Toll-like receptors in vivo. More specific, TLR9 activation with CpG-
ODN, TLR3 activation with poly(I:C), TLR7 activation with R848 (data not shown) and TLR4 
activation with LPS resulted in a significant increase of iMC in naïve mice. This induction was 
systemic as it has been shown in different organs. We propose it is probably due to a higher 
proliferation rate and systemic induction of myelopoiesis, given that we also found a two- to 
threefold increase of iMC numbers in the bone marrow. This consequence upon TLR-
stimulation is not overly surprising, as short term TLR stimulation mimics an acute infection 
of the host and triggers the mobilization of myeloid cells, in particular neutrophils and 
monocytes, from the bone marrow to infected tissue. This process in particular has been 
termed “emergency myelopoiesis” [Takizawa et al., 2012]. In addition, we could not see 
induction of myelopoiesis and immature myeloid cells upon RIG-I stimulation via 5’ppp-RNA 
in vivo. Early studies on the suppression of myelopoiesis by type I IFNs and work published 
in 2008 demonstrate a critical role of RIG-I by negatively regulating granulopoiesis, support 
this finding [Platanias et al., 1999; Zhang et al., 2008]. 
It is important to note that in the context of acute infection or a short immunogenic stimulus, 
an increase in the generation or recruitment of immature myeloid cells does not necessarily 
reflects an expansion of an immunosuppressive MDSC population. Albeit we observed a 
reproducible and significant increase in immature myeloid cells upon TLR stimulation, CpG- 
and poly(I:C)- expanded cells were not activated towards higher suppressivity. Thus, whereas 
expansion of immature myeloid cells in tumor-free mice can be triggered by several TLR 
ligands, activation of suppressivity may be limited to selected TLR ligands or the duration of 
immune stimulation. Especially in the case of endosomal TLRs such as TLR3, 7 and TLR9, no 
convincing study has yet shown the accumulation of immunosuppressive MDSC via induction 
and concurrent activation by the same TLR ligand. 
4.2.2 Pattern recognition receptor expression on MDSC 
The fact that myeloid-derived suppressor cells and immature myeloid cells can be induced 
by systemic activation of Toll-like receptors does not necessarily mean that MDSC are directly 
expanded by ligand-receptor activation. Several known factors and cytokines which have 
been shown to be involved in MDSC accumulation such as IL-1β, IL-6, IL-10, IL-12, IFNγ, 
TNFα and others are also effector molecules of innate immune stimulation by PRR ligands.  
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Besides a number of studies analyzing TLRs in the context of MDSC biology, Dectin-1 and 
the NLRP3 inflammasome as other innate immune receptors have been attributed to play a 
role in regulating the immunosuppressive function of MDSC [Li et al., 2010; Bruchard et al., 
2013]. Regarding the function of Toll-like receptors on MDSC, by using transcriptomic 
analysis, Fridlender and colleagues could show an upregulation of Toll-like receptor signaling 
genes in granulocytic MDSC when compared to neutrophils in naïve mice [Fridlender et al., 
2012]. Nevertheless, the expression Toll-like and other innate immune receptors on myeloid-
derived suppressor cells has not been systematically assessed yet. In fact, only TLR2, TLR4 
and TLR5 have been described to be expressed in MDSC [Bunt et al., 2006; Ostrand-
Rosenberg and Sinha, 2009; Chalmin et al., 2010; Rieber et al., 2013].  
By using rtPCR, the work of former doctoral students in our laboratory confirmed that MDSC 
express high levels of TLR4 [Zoglmeier et al., 2011]. On the contrary, when we stimulated 
isolated MDSC with CpG, we did not observe changes in their ability to suppress T cell 
proliferation nor a change in maturation marker expression, suggesting that CpG cannot 
directly activate MDSC. Likewise, TLR9 on MDSC was only expressed at minor levels when 
compared to plasmacytoid dendritic cells. This contrasts a recent work by Shirota and 
colleagues; they showed that monocytic MDSC express TLR9 and can be actively maturated 
into tumoricidal macrophages by direct TLR9 activation with CpG in vitro. Of interest, they 
also described TLR2, 3, 4, 7 and 8 expression by monocytic MDSC [Shirota et al., 2012]. By 
measuring Sca-1 expression levels on Gr1+CD11b+ cells following stimulation with a set of 
pattern recognition receptor ligands in vitro, we could show significant upregulation of Sca-
1 by Pam3CysK, LPS, R848 and Dectin-1. Of course, that finding does not necessarily exclude 
the presence of other TLRs and PRRs on immature myeloid cells nor it addresses the issue of 
up- or downregulation of pattern recognition receptor ligands on MDSC in the course of 
disease, though it demonstrates that immature myeloid cells at least express functional TLR2, 
TLR4, TLR 7 and Dectin-1. 
Taken together at least for the majority of TLRs it appears probable that MDSC induction is 
rather mediated by secondary effector molecules than a consequence of direct TLR 
stimulation on MDSC in an in vivo experimental setup. Nevertheless, more systematic studies 
are needed to clarify direct and indirect effects of pattern recognition receptor activation and 
their relevance for MDSC function in the context of disease.  
4.3 MDSC in the context of cancer immunotherapy with PRR ligands  
Current efforts bringing TLR agonists in the focus of cancer immunotherapy are mainly 
focused on TLR3, TLR7 and TLR9 [Krieg, 2007; Nicodemus et al., 2010, Hotz et al., 2012]. 
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During the last years, our own group could demonstrate potent antitumoral activity for the 
TLR3/MDA-5 ligand poly(I:C), TLR7 ligand R848 and the TLR9 ligand CpG in murine tumor 
models [Bourquin et al., 2006; Bourquin et al., 2009; Bourquin et al., 2011].  
MDSC strongly rely on the local NF-κB driven inflammatory milieu for their suppressive 
capabilities [Karin and Greten, 2005]. In addition, proinflammatory cytokines, in particular 
TNFα, IL-1 and IL-6, drive MDSC accumulation and further lead to NF-κB activation 
[Gabrilovich and Nagaraj, 2009]. On the other hand, NF-κB as a center molecule in TLR-
signaling cascades and its activation by TLR ligands in vivo leads to the induction of many 
proinflammatory cytokines, most of which are also known for MDSC induction [Medzhitov, 
2001; Gabrilovich and Nagaraj, 2009]. Thus, it may seem counterintuitive to use TLR and 
other innate immune receptor ligands to break MDSC induced tumor tolerance and 
immunosuppression. Indeed, we demonstrated that in vivo activation of TLRs with poly(I:C), 
R848 and CpG resulted in a potent induction of MDSC-like cells. But in contrast to recent 
findings by Vaknin and colleagues they lacked immunosuppressive properties [Vaknin et al., 
2008]. 
Nevertheless, tumor formation alters the local and systemic cytokine-milieu, enabling MDSC 
accumulation as well as their attraction to the tumor-site. For a number of murine tumor 
models, we and others could demonstrate that MDSC numbers are already substantially 
higher than in naïve mice. For example, the use of a monoclonal antibody binding IL-6 has 
been shown to eliminate MDSC in mice and ovarian cancer patients [Coward et al., 2011; 
Sumida et al., 2012]. We hypothesize that innate immune sensing in tumor-bearing mice 
induces additional antitumoral cytokines (such as IFNα and IL-12 which will further discussed 
below) that were not present in the tumor-induced local and systemic cytokine profile and 
thus break MDSC-mediated immunosuppression. In that case, the additional induction of 
“bystander” cytokines such as IL6 or TNFα might be dispensable.  
4.3.1 MDSC as a target of cancer immunotherapy with CpG 
Specifically in mice bearing subcutaneous CT26 tumors we could previously demonstrate that 
activation of the innate immune system with the TLR9 ligand CpG evokes efficient antitumor 
immune responses, despite the presence of large numbers of highly immunosuppressive 
MDSC in this model [Gallina et al., 2006; Youn et al., 2008]. By showing that systemic therapy 
with CpG, and to a lesser extent with poly(I:C), cannot further increase immunosuppressive 
MDSC populations and mitigates their T-cell suppressive activity in line with initiating their 
maturation, we demonstrate that immune modulators such as CpG and poly(I:C) are capable 
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of converting the immunosuppressive tumor microenvironment and are able to overcome 
MDSC-mediated immunosuppression.  
Our findings are complemented by a recent study of Shirota and co-workers, demonstrating 
that intratumoral injection of CpG oligonucleotides results in differentiation of monocytic 
MDSC in line with a decrease of their immunosuppressive properties [Shirota et al., 2012]. 
We show that CpG induced maturation and especially the loss of suppressivity is most 
pronounced on the Ly6Ghigh polymorphonuclear subset of MDSC, that displays the dominant 
population associated with immunosuppression in our murine tumor models. Instead, Shirota 
and colleagues show monocytic MDSC as the main target population of TLR9 activation. One 
explanation for these divergent results may be different isolation techniques as well as 
differences in the experimental setup regarding the analysis of MDSC subsets versus the 
entire MDSC population. For in vitro experiments we used the whole population of 
Gr1+CD11b+ magnetically sorted MDSC, whereas Shirota and colleagues used FACS-sorted 
monocytic MDSC. Of note, by analyzing PMN-MDSC they could only detect minor expression 
of TLR9 and failed to elicit further maturation of PMN-MDSC by direct stimulation with CpG 
in vitro.  Given that we assessed the maturation potential and suppressive activity in the total 
population of MDSC in vitro, a possible effect on monocytic MDSC may be superimposed by 
PMN-MDSC that make up to 90% of Gr1+CD11b+ cells in CT26 tumor-bearing mice.  
Although we did not find direct effects of CpG on tumor-associated MDSC [Zoglmeier et al., 
2011], another group described a direct effect of TLR agonists affecting influenza-associated 
MDSC differentiation [De Santo et al., 2008]. In their work, the TLR3 agonist poly(I:C), TLR7/8 
agonist R848 and the TLR9 agonist CpG, were all individually able to attenuate the 
suppressive capacity of isolated MDSC on T cells. Interestingly, this could be further 
augmented by co-incubation with invariant NKT (iNKT) cells, thereby maximizing IL-12 
production. Notably, whereas we used splenic MDSC, De Santo and colleagues used bone 
marrow-derived MDSC by culturing bone marrow with GM-CSF followed by depletion of 
CD11c+ cells and positive selection via Gr1+ purification. If these cells represent tumor-
associated MDSC, that have been “in vivo – generated” by a variety of tumor-derived factors, 
remains questionable. Besides, an oncolytic adenovirus engineered for increased TLR9 
stimulation in a xenograft model of lung cancer has recently achieved similar TLR9-
dependent, MDSC-modulating and T-cell immunity-stimulating results. Furthermore, in mice 
bearing orthotopic  renal cell carcinomas, CpG was used as an adjuvant for a TRAIL-encoding 
recombinant adenovirus, CpG modulated phenotype and function of MDSC and enabled a 
more vigorous antitumoral response [Cerullo et al., 2012; James et al., 2014].  
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Despite ambiguities regarding a direct or indirect effect of TLR9 activation on MDSC in 
tumor-bearing mice, our data as well as work by others clearly support the role of systemic 
TLR9 activation in order to overcome MDSC mediated immunosuppression. 
4.3.2 MDSC as a target of cancer immunotherapy with poly(I:C) 
Our data also demonstrate comparable results for the TLR3/MDA5 ligand poly(I:C) in 
maturation, differentiation and attenuation of MDSC-mediated immune suppression upon in 
vivo therapy of tumor-bearing mice. In addition, poly(I:C) treatment induced maturation of 
intratumoral MDSC. Due to methodical difficulties regarding the purification of intratumoral 
MDSC we could not confirm a lack of suppressivity as it has been demonstrated for splenic 
MDSC upon poly(I:C) treatment. Data on the effect of TLR3 activation on myeloid-derived 
suppressor cells are even more seldom than with TLR9 activation. A study by Liu and 
colleagues in 2011 showed that in addition to GM-CSF and IL-4, poly(I:C) can induce bone 
marrow precursors to differentiate into cells with MDSC-like properties [Liu et al., 2011]. 
However, the acquisition of these results is restricted to in vitro studies and lacks validation 
in a clinically relevant setting in vivo. In contrast, our data are further strengthened by 
unpublished data presented by Forghani and Waller at the annual ASH meeting in 2014; in a 
4T1 murine breast cancer model they show a poly(I:C)-induced polarization of MDSC into M1 
macrophages. As proof of principle, by performing in vitro studies they demonstrate antigen-
presenting properties of splenic MDSC when stimulated with poly(I:C). In addition, they also 
observe a significant reduction in tumor-infiltrating MDSC upon TLR3 activation in vivo. This 
could not be validated by our data – despite intratumoral MDSC differentiation we did not 
see a reduction in B16 melanoma-infiltrating MDSC upon poly(I:C) treatment which might be 
explained by different murine tumor models used. 
4.3.3 MDSC as a target of cancer immunotherapy with 5’-triphosphate-RNA 
The innate cytosolic immune receptor RIG-I has recently gained interest as a target for tumor 
immunotherapy. Importantly, in contrast to TLRs, RIG-I is expressed in all nucleated cells in 
the body, including tumor cells. By sensing double-stranded RNA structures it serves as a 
sensor of viral infection of the host cell, inducing apoptosis accompanied by a pronounced 
type I IFN induction in immune, non-immune and tumor cells [Yoneyama et al., 2004; Kawai 
et al., 2005]. The hallmark activating structure of RIG-I, a short and blunt-ended 5’-
triphosphate dsRNA (3pRNA), has been used in vivo in a humanized mouse model of 
melanoma where it induced high amounts of type I interferons and IL-12, thereby mediating 
an effective antitumor immunity [Poeck et al., 2008].  
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Previous work in our laboratory showed that in vivo treatment of tumor-bearing mice with 
3pRNA is able to overcome MDSC-mediated immunosuppression on T cells (data 
unpublished). When we identified IFNα as key player for Toll-like receptor induced 
maturation and differentiation of MDSC, we were interested whether 3pRNA may be equally 
able to induce maturation and differentiation of MDSC in vivo. By using bifunctional siRNA 
with RIG-I triggering and silencing of TGFβ (which will further be discussed below) 
(Ellermeier et al., 2013], we could indeed see maturation of MDSC by introducing a 
triphosphate group at the 5’ end of siRNA. In addition, we observed that ppp-TGFβ-siRNA 
reduced the frequency of Gr1+CD11b+ MDSC more significantly that TGF-blockage alone. 
That finding could not be demonstrated for other IFN-inducing TLR ligands in vivo. 
Surprisingly, we also found that the RIG-I triggering part of the bifunctional siRNA, was able 
to induce apoptosis in PMN- and MO-MDSC. Interestingly, by downregulating the Fas-
signaling pathway, MDSC have been shown to have a higher apoptotic resistance than their 
non-inflammatory counterparts [Ostrand-Rosenberg et al., 2012]. Only few studies addressed 
the induction of apoptosis in myeloid-derived suppressor cells. Cimetidine has been shown 
to suppress lung tumor growth in mice through the induction of apoptosis in MDSC and the 
anthracycline doxorubicine has been shown to deplete MDSC by mediating their apoptosis 
in a ROS-dependent fashion [Zheng et al., 2013].  
We thus demonstrate a potential novel antitumoral mechanism of 3pRNA by inducing 
maturation as well as apoptosis in tumor-associated myeloid-derived suppressor cells. Our 
data on the IFNα-dependent differentiation of MDSC upon TLR activation support the 
hypothesis that RIG-I induced maturation of MDSC is as well caused by the strong type I IFN 
induction upon 3pRNA therapy in vivo. Whether the induction of apoptosis is caused by direct 
RIG-I activation in Gr1+CD11b+ cells or a secondary result via Interferon-dependent apoptotic 
pathways remains to be determined in future studies.  
4.4 Maturation of myeloid-derived suppressor cells 
Myelopoiesis is a tightly regulated hierarchical process of cell lineage commitment. This 
process is altered in cancer, skewing myeloid differentiation to the expansion and activation 
of myeloid-derived suppressor cells. Most importantly, a hallmark feature of MDSC is their 
immaturity as they lack specific markers expressed by mature monocytes, macrophages or 
dendritic cells. Early studies showed that only a minor portion of tumor-induced MDSC have 
the ability to form myeloid-cell colonies in vitro and about one third can differentiate into 
major macrophages and dendritic cells upon appropriate cytokine stimulation in vitro and in 
vivo [Bronte et al., 2000; Kusmartsev and Gabrilovich, 2002; Li et al., 2004]. It is assumed 
that MO-MDSC and PMN-MDSC develop along different pathways involving 
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monocyte/macrophage and granulocyte progenitors, respectively. Increasing evidence 
additionally suggests, that even this process of tightly controlled myelopoiesis in naïve mice, 
is altered and disturbed in tumor-bearing hosts with MO-MDSC preferentially differentiating 
into PMN-MDSC, thus resembling an even more complex system that might be targeted for 
therapeutical benefit [Youn et al., 2013]. 
Maturation of myeloid cells involves the upregulation of known differentiation markers for 
macrophages and dendritic cells. F4/80 (with its human homologue EMR1) is a typical 
macrophage differentiation marker in mice [Austyn and Gordon, 1981]. CD11c serves as a 
marker for myeloid differentiation towards dendritic cells in mice and human, although it has 
been shown to be expressed by neutrophils, macrophages and some B cells as well [Corbi 
and Lopez-Rodriguez, 1997]. Ly6C is differentially expressed on activated circulating 
monocytes [Gordon and Taylor, 2005]. Some other maturation markers used to 
phenotypically assess the maturation status of MDSC in this study were the co-stimulatory 
molecules CD80 and CD86, that are both indispensable for an effective T cell priming [Acuto 
and Michel, 2003], MHC II as an antigen-presenting molecule and indicator of immature to 
mature dendritic cell conversion [Shin et al., 2006] and Stem cell antigen-1 which will further 
be discussed below.   
Indeed, when we compared immature myeloid cells and tumor-induced myeloid-derived 
suppressor cells, these and other markers assessed for evaluating the maturation status were 
significantly downregulated on tumor-associated myeloid cells, indicating a tumor-induced 
differentiation block and its measurability by these surface molecules. In contrast, here we 
show for the first time, that systemic activation of distinct Toll-like receptors (TLR3/9) and 
RIG-I in tumor-bearing mice is able to overcome altered features of myelopoiesis by reversing 
the population shift as well as promoting differentiation and maturation of MDSC into 
antigen-presenting and functionally non-immunosuppressive cells. Notably, we observed a 
comparable upregulation of CD11c, CD80, Ly6C and to a lesser extent F4/80 on intratumoral 
MDSC following systemic TLR activation. This may seem counterproductive as Ly6Chigh 
monocytes have been suggested to represent tumor-associated macrophage precursors may 
tipping the balance back towards tumor promotion [Movahedi et al., 2010]. However, our 
data regarding loss of suppressivity and the practical outcome of efficient tumor regression 
demonstrate that microenvironmental changes are maintained in favor of antitumor 
immunity. Supporting evidence comes from more recent studies, showing that the 
emergence of Ly6Chigh inflammatory myeloid cells in a murine model of colon cancer, using 
cyclophosphamide/anti-CD25-mAb and IL-12 as chemoimmunotherapy, coincides with the 
emergence of effector T cells into the tumor microenvironment [Medina-Echeverz et al., 
2011]. In addition, the group around Laurence Zitvogel discovered intratumoral 
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CD11b+CD11c+Ly6Ghigh myeloid cells, which displayed dendritic cells and granulomonocytic 
precursors as crucial mediators in anthracycline-induced immunogenic cell death and 
priming of antitumoral T cells [Ma et al., 2013].  
Not only MO-MDSC, with further capabilities of differentiating into macrophages and 
dendritic cells, but also PMN-MDSC express co-stimulatory molecules such as CD80 and 
CD86 [Movahedi et al., 2008; Talmadge et al., 2013]. Interestingly, we observed an 
upregulation of the dendritic cell differentiation marker CD11c as well as the co-stimulatory 
molecules CD80, CD86 and MHC class II on PMN-MDSC following TLR stimulation in vivo. 
Especially maturation of PMN-MDSC was associated with decreased immunosuppressive 
properties, as Ly6Ghigh cells from non-treated tumor-bearing mice represented the major 
suppressors of T cell stimulation in our tumor models. This may seem counterintuitive, 
because PMN-MDSC as granulocytic cells are principally thought to be terminally 
differentiated [Gabrilovich and Nagaraj, 2009; Condamine et al., 2014]. Accordingly, F4/80 
expression was not altered indicating that redifferentiation into monocytic cells, as it has 
been demonstrated vice versa [Youn et al., 2013], was not occurring following systemic TLR 
stimulation. Based on phenotypical assessment of PMN-MDSC, alongside with abolishment 
of their immunosuppressive function exerted on T cells, our results reinforce the notion that 
neutrophils (and in that case granulocytic MDSC) can acquire antigen-presenting cell (APC) 
- like properties. In accordance with this, neutrophils have shown to act as antigen-presenting 
cells via co-expression of MHC II and upregulate CD80 and CD86 in the presence of 
appropriate cytokines and bystander cells [Radsak et al., 2000; Ashtekar and Saha, 2003]. In 
the presence of GM-CSF, immature and mature neutrophils can differentiate into a “hybrid” 
population exhibiting phenotypical und functional features of both neutrophils and dendritic 
cells [Matsushima et al., 2013]. Thus, upregulation of co-stimulatory molecules on PMN-
MDSC and their interaction with corresponding ligands on T cells may impart a loss of 
immunosuppressive properties. 
Of course, more work is needed to distinguish between “immature” and “mature” PMN-
MDSC in tumor-bearing hosts and to further dissect antigen-presenting properties of IFNα- 
or TLR ligand-stimulated PMN-MDSC in an appropriate in vivo setting. Currently there is no 
reliable marker such as morphologic appearance or flow cytometry analysis to distinguish 
PMN-MDSC from their natural counterparts. As naïve neutrophils and PMN-MDSC share 
distinct morphological features, PMN-MDSC might just represent a different functional state, 
rather than a separately occurring cell subset. Here we show, besides significant maturation 
of MO-MDSC, that at least a part of tumor-associated PMN-MDSC further differentiates into 
granulocytes with an antigen-presenting phenotype following in vivo stimulation with type I 
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IFN inducing pattern recognition receptor ligands. Thus, we propose a new mechanism by 
which CpG, and other type I IFN-inducing TLR ligands, exert their anti-tumoral effect in vivo. 
4.4.1 Interferon-α as key effector molecule in differentiation and maturation of MDSC 
upon stimulation of pattern recoginition receptor ligands 
As inhibition of MDSC suppressivity and maturation by stimulation with CpG could not be 
observed in vitro [Zoglmeier et al., 2011], we tried to identify factors that might be crucial for 
the seen effects. A hallmark of stimulation through TLR3 and TLR9 is, however, the induction 
of high levels of IFNα [Uematsu and Akira, 2007; Matsumoto and Seya, 2008].  In addition, 
3pRNA that is known for its potent induction of type I Interferons results in differentiation 
and maturation of MDSC when administered to tumor-bearing mice as well. Indeed, the 
positive effects on MDSC maturation and subset recomposition by poly(I:C) could not be 
observed in IFNαR-/- mice. When we compared B16-melanoma induced MDSC in wild type 
and IFNαR-/- mice, MDSC already expressed lower baseline levels of common maturation 
markers such as CD80, CD86 and MHC II, thus indicating that endogenous Interferon-α may 
serve as a baseline stimulus for MDSC maturation and differentiation. Indeed, one of the 
myriad of immunological functions of IFNα is the activation of dendritic cells with 
upregulation of MHC proteins and co-stimulatory molecules such as CD80 and CD86 as well 
as their maturation from monocytes [Santini et al., 2000; Baccala et al., 2005]. Interestingly, 
IFNα has been reported to synergistically cooperate with all-trans retinoic acid to induce 
maturation and differentiation of promyelocytic blasts in acute promyelocytic leukemia 
[Gallagher et al. 1987; Nason-Burchenal et al., 1996].  Our observations are complementary 
to findings by Jablonska and colleagues that showed endogenous Interferon-β as major 
negative regulator of GR1+CD11b+ granulocytic MDSC driven tumor angiogenesis. 
Considering that Interferon-β and Interferon-α as type I Interferons bind to the very same 
receptor (IFNαR), we would expect comparable results following a potent Interferon-α 
induction. In adoptive transfer experiments, granulocytic MDSC deficient for the IFNα-
receptor dramatically increased tumor growth in contrast to PMN-MDSC from wild type mice. 
Simultaneously, this proves the expression of a functional IFNαR on Gr1+CD11b+ and thus 
matches our results showing that co-incubation of purified MDSC with IFNα significantly 
upregulates Sca-1 as an interferon-response gene [Bamezai et al., 1995; Pietras et al., 2014]. 
Although Jablonska and colleagues did not analyze the maturation status of L6Ghigh MDSC, 
nor did we examine tumor angiogenesis, their results strengthen our data as a proof of 
principle [Jablonska et al., 2010].  
Further validation of interferon-induced maturation of MDSC was gained by other students 
in our laboratory demonstrating that stimulation of isolated MDSC with recombinant IFNα 
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induces a significant upregulation of F4/80. Accordingly, short-term treatment of tumor-
bearing mice with IFNα significantly reduced MDSC-mediated immune suppression 
accompanied by their differentiation [Zoglmeier et al., 2011]. We could further identify 
plasmacytoid dendritic cells as the major source of Interferon-α upon stimulation of TLR9 
with CpG [Siegal et al., 1999], closing the gap between TLR9, type I interferons and 
maturation of myeloid-derived suppressor cells in vivo. 
Several biological functions of type I IFNs, including their modulating function of innate and 
adaptive immunity as well as their proapoptotic and antiangiogenic effects, make them an 
attractive molecule in anti-cancer immunity. Indeed, type I IFNs have been used with success 
in a number of human cancers, including hematological malignancies and solid tumors 
[Ferrantini et al., 2007; Moschos and Kirkwood, 2007]. However, the mechanism of its 
antitumor effect remains largely elusive. Interesting results come from the group of Robert 
Schreiber, identifying IFNα/β as critical components in cancer immunoediting [Dunn et al., 
2005]. Surprisingly, not tumor cells, but hematopoietic and in particular IFNα/β-responsive 
NK cells were the main targets of type I IFNs and sufficient for mediating tumor rejection.  
A recent study revealed interferon-regulatory-factor-8 (IRF-8) as a critical transcriptional 
component in the control of tumor-induced MDSC development [Waight et al., 2013]. IRF-8 
enhancement ameliorated granulocytic MDSC accumulation and slightly increased 
monocytic MDSC in IRF8-transgenic mice which was accompanied by a significant reduction 
of tumor-size. Notably, the same effects were notified when tumor-bearing mice were 
injected with CpG, poly(I:C) or Interferon-α. In addition, several tumor-induced factors 
inhibited IRF-8 expression leading to expansion of granulocytic and, to a lesser extent, 
monocytic MDSC. IRF-8 also seems to act as a positive regulator of IFN signaling in the 
murine system. In addition, IRF8-/- mice display a general defect in pro-inflammatory cytokine 
induction and upregulation of co-stimulatory molecules such as MHCII and CD40 in splenic 
DCs stimulated with CpG [Tsujimura et al., 2002; Tsujimura et al., 2003]. Since IRF-8 is tightly 
involved in the TLR- and interferon response of the host, these findings provide an interesting 
cross-point between our results and possible mechanistic actions of TLR stimulation and 
IFNα treatment on MDSC maturation and subset shifting in vivo.  
STAT3 has been generally accepted as one of the main transcription factors that regulate 
expansion and activation of MDSC [Gabrilovich and Nagaraj, 2009; Rebe et al., 2013; 
Vasquez-Dunddel et al., 2013] and has been recognized as a negative regulator of type I IFN 
responses in vivo [Kirkwood et al., 1999; Vasquez-Dunddel et al., 2013]. In turn, systemic 
Interferon-α treatment leads to STAT3-inactivation, which has been demonstrated in 
melanoma precursor lesions. Interestingly, a number of studies has shown that MDSC perturb 
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endogenous anti-tumor immunity effects of IFNα by downregulation of IFNα-induced STAT1 
phosphorylation in effector immune cells. This has been demonstrated in mice as well as in 
human malignancies [Mundy-Bosse et al., 2011; Mundy-Bosse et al., 2011]. Notably, the 
ability of MDSC to interfere with IFN responses, suggests the importance that IFN-α might 
have in converting their immunosuppressive phenotype and function. 
Taken together, our findings suggest that IFNα plays a major role in mediating the functional 
and phenotypic changes in MDSC following TLR activation.  Here we describe a new potential 
antitumor-mechanism of type I IFNs and TLR3/9-mediated IFNα-induction, namely by 
maturating and differentiating myeloid-derived suppressor cells hence mitigating their 
immunosuppressive properties. Regarding the underlying mechanism, definitely further 
studies are needed to dissect associated signaling pathways that may be involved. 
4.4.2 MDSC maturation is not due only to IFN-α 
Like IFNα, the cytokine IL-12 can potently induce MDSC differentiation and promote tumor 
immunity. IL-12 triggers a programmatic change in MDSC maturing them into antigen-
presenting cells as displayed by upregulation of costimulatory markers such as CD80, CD86 
and differentiation markers F4/80 and MHC-II [Steding et al., 2011] and forces them to 
support rather than suppress proliferation of CD8+ cytotoxic T lymphocytes [Kerkar et al., 
2011]. The immunostimulatory effect of IL-12 is further enhanced by a MDSC-reducing 
combinatory treatment with oxaliplatin in a murine model of liver metastasis [Hernandez-
Alcoceba and Berraondo, 2012]. When used together with cyclophosphamide, IL-12 even 
shows the ability of converting MDSC into immunostimulating myeloid cells that facilitate 
tumor rejection [Medina-Echeverz et al., 2011]. 
TGFβ is an essential mediator of immunosuppressive effects within the tumor 
microenvironment, allowing tumors to usurp its homeostatic effect for promoting tumor 
growth, invasion and metastasis [Massague, 2008]. As a naturally occurring suppressor of 
the immune system, tumors alienate its function to facilitate their immune escape. A number 
of studies has tightly linked TGFβ as a crucial cytokine involved in MDSC-mediated 
immunosuppression. For instance, depletion of GR1+CD11b+ cells in a murine mammary 
model of breast cancer, diminishes the antitumor effect of TGFβ neutralization [Li et al., 
2012]. Fridlender and colleagues showed that tumor-associated inflammation polarized 
granulocytic MDSC from an anti-tumoral G1 to a pro-tumoral G2 phenotype. By inhibiting 
the TGFβ-receptor with a kinase inhibitor, SM16, they could reprogram PMN-MDSC from G2 
to G1 [Fridlender et al., 2009]. Accordingly, anti-TGFβ antibody can drive a shift from the M2 
to M1 monocytic/macrophage phenotype in myeloid cells [Gong et al., 2012]. Moreover, in 
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murine colon adenocarcinoma and murine glioma, tumor-infiltrating MDSC are the main 
producers of TGFβ within the tumor microenvironment [Umemura et al., 2008]. 
When we found IFNα as the main driver of MDSC maturation in TLR3 and TLR9 stimulated 
hosts, we were interested whether this is an exclusive mechanism for IFNα or might also be 
achieved by targeting factors detrimentally involved in MDSC-mediated immune evasion of 
tumors, as it has been shown for TGFβ. Indeed, siRNA-mediated knockdown of TGFβ resulted 
in differentiation of GR1+CD11b+ MDSC in vivo, though the effect was not as significant as 
seen with additional RIG-I activation and subsequent type I IFN induction  [Ellermeier et al., 
2013]. Interestingly, TGFβ gene silencing led to a significant decrease in circulating MDSC 
and resulted in a comparable shift in MDSC subset composition as seen after treatment of 
tumor-bearing mice with CpG or poly(I:C), respectively. In accordance with our findings, 
TGFβ partially exerts its pro-tumoral activity by preventing DC maturation within the tumor-
microenvironment, thus limiting an efficient CD8+ T cell response [Flavell et al., 2010]. 
Although Interferon-α plays a crucial role in mediating maturation of MDSC upon 
pharmacological therapy with distinct TLR ligands, overcoming the tumor-induced 
differentiation block of myeloid cells can also be achieved by targeting other cytokines such 
as TGFβ. 
4.5 Stem cell antigen-1 (Sca-1) as a possible marker for MDSC maturation 
4.5.1 General aspects of Sca-1 
The Ly6 protein family member Sca-1 (Ly6A/E), has been originally identified on activated 
lymphocytes [Yutoku et al., 1974]. Since then, for more than 20 years it has been widely used 
as a marker for hematopoietic stem cells (HSCs) and their enrichment ex vivo [Spangrude et 
al., 1988]. Its expression during hematologic maturation is regulated in a complex fashion: 
When HSCs further differentiate into myeloid/lymphoid progenitors, Sca-1 expression is 
downregulated [Akashi et al., 2000], becoming upregulated in colony-forming unit 
progenitors, mature thymocytes and peripheral T cells again [Bamezai et al., 1995]. Outside 
the hematopoietic system, Sca-1 is similarly expressed by stem- and progenitor cells as well 
as differentiated cell types in a variety of tissues and organs as well as on some murine tumors 
including retinoblastoma, mammary gland tumors and prostate cancer [Seigel et al., 2005; 
Xin et al., 2005; Batts et al., 2011].  
Nonetheless, little is known about its biological function. Recent studies suggest that it might 
be more than just a convenient marker for enrichment of adult murine HSCs [Holmes and 
Stanford, 2007]. Interestingly, Sca-1 is a glycosyl phosphatidylinositol–anchored protein 
(GPI-AP) and thus lacks an individual cell signaling pathway upon ligand-receptor interaction. 
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In addition, no specific Sca-1 ligand could be identified yet. As GPI-APs are localized to lipid 
rafts of the plasma membrane, Sca-1 rather seems to affect signaling pathways of other cell 
surface receptors [Stefanova et al., 1991; Lingwood and Simons; 2010]. Indeed, Upadhyay 
and colleagues could demonstrate that Sca-1 attenuates GDF10-dependent TGFβ signaling 
by disrupting TGFβ-receptor heterodimerization [Upadhyay et al., 2011]. In addition, Sca-1 
seems to be involved in myeloblast/cardiomyogenic differentiation as mice lacking Stem cell 
antigen-1 display mild defects in self-renewal of hematopoietic and stem cell progenitor cells 
[Ito et al., 2003; Mitchell et al., 2005]. Notably, Sca-1 has been linked to tumorigenesis; in the 
prostate, selective AKT overexpression in Sca-1+ cells initiates tumorigenesis and cancer 
progression correlated with increased Sca-1-positivity. Similarly, repression of Sca-1 in 
mammary gland tumor affected proliferation and migration of malignant cells and high Sca-
1 levels in tumor cells were significantly associated with a more aggressive phenotype [Katz 
et al., 1994; Xin et al., 2005; Batts et al., 2011]. However, none of the studies depicted above 
has evaluated the role of Sca-1 on tumor-associated bystander cells or systematically 
analyzed its function on tumorigenesis in an appropriate in vivo model.  
4.5.2 Sca-1 induction via innate immune receptor activation 
We demonstrated that Sca-1 is highly upregulated on Gr1+CD11b+ myeloid-derived 
suppressor cells following innate immune stimulation with different Toll-like receptor 
ligands. However, whereas LPS, R848, Dectin-1, Curdlan as well as IFNα significantly 
induced Sca-1 expression in vitro, CpG and poly(I:C) did not. In contrast, the most significant 
Sca-1 induction in vivo was seen following treatment with poly(I:C), CpG and to a lesser extent 
3pRNA. Notably, upregulation of Sca-1 upon TLR3 activation with poly(I:C) in vivo was 
abolished in IFNαR-/- mice, suggesting a pivotal role for type I Interferons in Sca-1 induction. 
Indeed, early work and some newer studies suggested Sca-1 as an Interferon-response gene 
[Ma et al., 2001; Pietras et al., 2014]. Moreover, in a widely acclaimed work by Essers and 
colleagues in 2009, they not only confirm our results of impaired Sca-1 induction following 
poly(I:C) treatment in IFNαR-/- mice, but also demonstrate that IFNα-induced proliferation of 
HSCs is also dependent on Sca-1 itself [Essers et al., 2009]. However, our results and work 
by other groups support the notion that Sca-1 can also be induced by other cytokines and 
innate immune receptors as shown for LPS and E. coli bacteremia [Shi et al., 2013].  
4.5.3 Sca-1 as a possible differentiation marker on myeloid-derived suppressor cells 
Throughout our experiments, we observed a highly significant upregulation of Stem cell 
antigen-1 (Sca-1) on myeloid-derived suppressor cells following innate immune activation 
with TLR and RIG-I ligands in naïve as well as tumor bearing mice. Sca-1 is known to be 
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highly expressed on HSCs as highly undifferentiated cells and immaturity is a hallmark of 
MDSCs, this may seem counterintuitive. But given the complexity of Sca-1 up- and 
downregulation during hematopoietic ontology, branding Sca-1 as an overall marker for 
undifferentiated cells may be oversimplified. One could also hypothesize, that this 
upregulation may just be a result of IFN-induced gene expression on target cells, including 
Sca-1 with no further use in drawing conclusions from phenotype to function.  
Nevertheless, we hypothesize Sca-1 can serve as a highly sensitive marker for MDSC 
maturation. First and foremost, tumor-associated MDSC express significantly lower levels of 
Sca-1 than their naïve, non-immunosuppressive counterparts. This finding is further 
supported by Movahedi and colleagues that could not detect measurable Sca-1 expression 
on tumor-induced untreated mice [Movahedi et al., 2008]. Second, upon TLR stimulation, the 
strength of Sca-1 expression was inversely correlated with their immunosuppressive activity 
on T cells. Third, Sca-1 expression also correlated to the specific “homing-site” - whereas 
immature myeloid cells in bone marrow and blood showed minor levels of Sca-1, its 
expression was significantly upregulated during homing into peripheral organs and lymph 
nodes, where undifferentiated myeloid cells will be without use. In line with this, recent work 
by a German group showed that Sca-1 expression on plasmacytoid dendritic cells defines 
their developmental stage as Sca-1- pDC are mainly found in the bone marrow and represent 
an early developmental stage, whereas Sca-1+ pDC are mainly located in secondary lymphoid 
organs and show higher MHC class II expression [Niederquell et al., 2013]. Accordingly, 
when we performed detailed flow cytometry analysis, Sca-1+ MDSC had significantly higher 
expression levels of other maturation/differentiation marker such as CD11c, F4/80, CD80 and 
CD86 when compared to Sca-1- MDSC. Finally, knock-down of TGFβ in PancO2 tumor-
bearing mice by siRNA, also led to upregulation of maturation and differentiation marker, 
including Sca-1. Although we did not test for MDSC suppressive activity in this experimental 
setting, given the crucial role for TGFβ in mediating immune suppression via MDSC (as 
discussed previously), we would expect a loss of their immunosuppressive potential as it has 
been demonstrated previously [Fridlender et al., 2009]. 
Although we propose Sca-1 as a new marker for less immunosuppressive and more maturated 
MDSC, it does not necessarily reflect an anti-tumoral role of Sca-1 in tumor-bearing mice. 
Moreover, when we challenged Sca-1-/- and wildtype mice with syngenic PancO2 tumor cells, 
we unexpectedly found that myeloid-derived suppressor cells deficient for Sca-1 exhibit less 
immunosuppressive properties in conjunction with a trend towards slower tumor growth in 
vivo. Thus, in addition to prior studies that have demonstrated a detrimental role for Sca-1 
expression on tumor cells, we find that Sca-1 and seem to foster the capability of myeloid-
derived suppressor cells to suppress T cell proliferation and might attenuate immune 
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surveillance of malignant tumors. Unravelling the underlying mechanism will be work of 
future projects and should include bone-marrow chimeras in order elucidate relevant in vivo 
effects of tumor-associated and tumor-infiltrating myeloid cells.  
When increasing evidence also suggested a role for the involvement of Sca-1 into distinct 
signaling processes, as it has been suggested for TGFβ and IFNα, respectively [Essers et al., 
2009; Fridlender et al., 2009; Upadhyay et al., 2011] we aimed to further dissect functional 
differences between Sca-1-/- and wildtype mice treated with the TLR3 ligand poly(I:C). 
Incidentally, we detected high levels of IP-10/CXCL10 in Sca-1-/- mice upon therapy with 
poly(I:C), whereas other cytokine levels, especially Interferon α, remained stable. Comparable 
results were observed in vitro with a pronounced IP-10 induction following stimulation of 
bone marrow-derived macrophages with various PRR ligands. IFNγ-inducible protein of 10 
kDa or IP-10/CXCL10 is an early response gene,  induced by type I and type II interferons, 
LPS or CpG-ODN, attracts effector T lymphocytes to infectious sites and serologically serves 
as a proxy for a TH1 skewed immune response [Neville et al., 1997; Dufour et al., 2002]. Sca-
1 obviously dampens IP-10 induction in vivo. Our in vitro studies suggests that this effect is 
mediated on cellular basis. These results are hard to interpret as there is scarce literature on 
how Sca-1 might be involved in cell signaling pathways and nothing is yet published about a 
relationship of Sca-1 and IP-10/CXCL10 [Holmes and Stanford, 2007]. Given the anitumoral 
properties of IP-10 [Narvaiza et al., 2000], this pronounced IP-10 response might explain why 
tumor formation in Sca-1-/- might be slower than in wild type mice. Interestingly, MDSC have 
shown to significantly affect IP-10/CXCL10 mediated tumor infiltration of CTLs [Fujita et al., 
2011]. However, these results have to be carefully interpreted and validated (1) for their 
reproducibility in other tumor models and mouse strains other than C57/BL6 and (2) for their 
biological significance.  
4.6 MDSC as therapeutic targets in cancer 
Since MDSC are still poorly defined and the knowledge of their molecular mechanisms of 
action is still in its infancy, they are difficult to target. Significantly, only two clinical trial have 
launched yet that selectively target myeloid-derived suppressor cells in cancer patients, albeit 
various approaches that have undertaken in murine tumor models and cancer patients aiming 
to boost the host’s immune response by targeting MDSC [Greten et al., 2011]. Our findings 
in this work provide further evidence for the concept that overcoming the maturity block of 
MDSC is a highly promising approach to abrogate MDSC-related immunosuppression and to 
improve the success of cancer vaccines.  
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Apart from multiple strategies that target MDSC-associated immunosuppression in cancer 
including depletion, inactivation and inhibition of their development, a major strategy 
pursued by cancer immunologists is initiating MDSC differentiation. Besides individual 
molecules/cytokines that have been studied in preclinical murine studies, a number of 
commercially available drugs including all-trans retinoic acid (ATRA), 25-hydroxy-vitamin D 
(D3) and 5-Aza-2'-deoxycytidin (Vidaza®) lead to maturation and hence less-
immunosuppressive MDSC in human [Lathers et al., 2004; Mirza et al., 2006; Daurkin et al., 
2010]. ATRA, that showed groundbreaking results in facilitating the differentiation of 
leukemic promyelocytes in acute promyelocytic leukemia, has already entered randomized 
phase II trials that employ ATRA to modulate MDSC (NCT0060179, NCT00618891). 
Interestingly, in some studies murine as well as human MDSC morphologically matched 
promyelocytes [Greten et al., 2011; Youn et al., 2013]. Vitamin D3 has also shown efficacy in 
human studies by increasing HLA-DR expression on PBMC and decreased CD34+ circulating 
myeloid cells in patients with HNSCC [Wiers et al., 2000]. Tyrosine-kinase inhibitors used for 
the therapy of a variety of human cancers have also shown to decrease the number of 
circulating MDSC and to block their T cell suppressive activity. Sunitinib, used for the 
treatment of renal cell carcinoma, leads to a decline of CD33+HLA-DR- and CD15+CD14- 
MDSC paralleled by an increase in IFNγ-release by T cells stimulated with anti-CD3 
antibodies ex vivo [Rodriguez et al., 2009]. In addition, Vemurafenib, a selective blocker of 
the serine/threonine-protein kinase B-Raf decreases both PMN- and MO-MDSC as well as 
reverses their suppressing effect on autologous T cell proliferation in patients with malignant 
melanoma [Schilling et al., 2013]. Even conventional chemotherapy drugs such as 
doxorubicin, gemcitabine and 5-FU reduced the number of circulating MDSC in both murine 
tumor models and cancer patients [Le et al., 2009; Vincent et al., 2010; Alizadeh et al., 2014]. 
Some compounds that are already FDA approved (e.g. ATRA, PDE5 inhibitors, COX-2 
inhibitors and bisphosphonates) will likely be the first to enter late phase clinical trials to test 
their ability to suppress MDSC and improve the efficacy of other immunactivating agents. 
However, the precise mechanisms leading to abnormal differentiation of myeloid progenitor 
cells into MDSC remain largely elusive and will provide a goal and more tailored 
pharmacological starting point for future studies. Table 4.1 features some selected available 
strategies and interventions targeting MDSC in murine and human cancer. 
Therapeutic agent Effect on MDSCs (mouse / human) Reference 
ATRA 
Differentiation of immature myeloid 
cells to mature leukocytes, partially via 
ROS neutralization (m/h) 
[Mirza et al., 2006; Nefedova 
et al., 2007] 
5-Aza-2'-deoxycytidin 
(Vidaza®) 
Differentiation into APCs (m) [Daurkin et al., 2010] 
Vitamin D3 
Differentiation and inhibition of 
expansion (m/h) 
[Lathers et al., 2004; Wiers et 
al., 2000] 
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Interleukin-12 
Differentiation and reduction of tumor-
infiltration (m)  
[Steding et al., 2011; Kerkar et 
al., 2011] 
Paclitaxel 
Differentiation in small doses, 
inhibition of immunosuppression in 
higher doses (m/h) 
[Naiditch et al., 2011; Sevko et 
al., 2013] 
Sunitinib 
Inhibition of proliferation, STAT-3 
inhibition, reduction of tumor-
infiltration, induction of apoptosis? 
(m/h) 
[Rodriguez et al., 2009; Ko et 
al., 2009; Xin et al., 2009] 
N-Bisphosphonates 
Inhibition of expansion, decreased 
immunosuppression via prenylation of 
MMP9 (m) 
[Heissig et al., 2002; Melani et 
al., 2007] 
STAT-3 inhibitors 
Differentiation, reduction of MDSC 
numbers, inhibition of apoptosis, 
proliferative and pro-angiogenic gene 
expression (m/h) 
[Nefedova et al., 2005; Lu et 
al., 2012] 
Doxorubicin Reduction of MDSC numbers (m/h) 
[Alizadeh et al., 2014; Diaz-
Montero et al., 2009] 
Gemcitabine  
Reduction of MDSC numbers by 
apoptosis, direct mitigation of T cell 
suppression (m/h) 
[Le et al., 2009; Suzuki et al., 
2005] 
5-Fluoruracil 
Reduction of MDSC numbers by 
apoptosis (m) 
[Vincent et al., 2010] 
PDE-5 inhibitors 
Downregulation of IL4Rα and reduced 
immunosuppressive function (m) 
[Serafini et al., 2008] 
COX-inhibitors Inhibition of iNOS and Arg2 (m) 
[Sinha et al., 2007; Rodriguez 
et al., 2005] 
CXCR2/4 antagonists 
Altered recruitment to the tumor site 
(m/h) 
[Porvasnik et al., 2009] 
PPARγ inhibitor Induces proliferation of MDSC (m) [Wu et al., 2012] 
Very small size proteo-
liposomes 
Differentiation of MDSC into mature 
APCs, changes in MDSC subset 
distribution (m) 
[Fernandez et al., 2014] 
Table 4.1. Selected pharmacological agents targeting MDSC in murine and human tumors. 
Adapted from [Gabrilovich et al., 2007; Greten et al., 2011; Talmadge et al., 2013; Wesolowski et al., 
2013].  
Although MDSC have gained increasing interest by cancer immunologists and oncologists, 
their biological significance in other disease has also been recognized. They are intimately 
involved in regulating immune responses during viral, bacterial and parasitic infections, 
sepsis and trauma. Notably, given their immunosuppressive nature, they do not exclusively 
exert detrimental effects on the host but possibly bear a distinct therapeutic potential under 
certain pathological conditions for which dampening the immune response will be of benefit. 
Indeed, a number of studies implicated beneficial effects of MDSC in preclinical models of 
multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus and described 
their occurrence and prognostic impact in human autoimmune disease [Drujont et al., 2014]. 
Furthermore, recent work using therapeutic administration of MDSC in mouse models of 
multiple sclerosis, rheumatoid arthritis and type I diabetes has shown promising results in 
delayed onset or reduction of disease severity [Chou et al., 2012; Ioannou et al., 2012; Fujii 
et al., 2013].  
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Interestingly, endosomal TLRs such as TLR3, 7 and 9 as well as type I IFNs have been closely 
connected to the pathogenesis of both systemic and organ-specific autoimmune disease. 
[Baccala et al., 2007; Theofilopoulos, 2012]. Congruent findings implicate the innate immune 
system as culprit for subsequent auto-antibody and T cell-mediated tissue damage of the 
host. Via recognition of self-antigens, especially when sensed by nucleic acid-sensing TLRs, 
elicit a strong production of IFNα. Moreover, IFNα in lupus patients promoted the maturation 
of monocytes to efficient antigen-presenting cells [Blanco et al., 2001]. Although previous 
studies did not analyze the occurrence and significance of MDSC in these patients and 
experimental models of autoimmunity, based on our data it is tempting to speculate that TLR- 
and type I IFN-elicited maturation of MDSC may play a disease-perpetuating and -promoting 
role. Future studies will provide additional insights regarding a potential interplay between 
MDSC, Toll-like receptors and type I IFNs in autoimmune diseases. Nevertheless, our 
findings emphasize the role of MDSC as crucial disease modulators and the promotion of 
their maturation as a promising goal in order to restore immunosurveillance of malignant 
tumors. Likewise, our work underlines the potential of distinct Toll-like receptor ligands such 
as CpG and poly(I:C) in cancer immunotherapy. 
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4.7 Summary 
Neoplastic growth triggers the induction of highly immunosuppressive myeloid cells that 
have been termed myeloid-derived suppressor cells (MDSC). MDSC disrupt local and 
systemic immunosurveillance, enable and sustain malignant growth and represent a major 
obstacle for effective cancer immunotherapy. A hallmark of MDSC is their immaturity due to 
a tumor-induced differentiation block reflecting the abnormal nature of myelopoiesis in 
cancer. Restoring a disrupted myelopoiesis and blocking MDSC-related immunosuppression 
in cancer patients might attenuate disease progression and open the path for more effective 
immunotherapy protocols. Existing immunotherapy protocols use Toll-like receptor ligands 
such as the TLR3 ligand poly(I:C) or the TLR9 ligand CpG-DNA. However, some studies 
suggest a pivotal role of Toll-like receptor activation in the expansion and activation of MDSC, 
calling the clinical utility of such approaches into question. 
Using flow cytometry and ex vivo T-cell suppression assays, in the first part of this study we 
could demonstrate that in vivo treatment of tumor-free mice with CpG or poly(I:C) indeed 
causes systemic accumulation of immature myeloid cells, but these cells lack 
immunosuppressive features. In tumor-bearing mice, we show that PMN-MDSC are the most 
abundant MDSC subset in nearly all tumor models examined and exhibit significantly 
stronger immunosuppressive properties than MO-MDSC. Moreover, in vivo treatment with 
CpG and poly(I:C) leads to a significant reduction of PMN-MDSC, reverses the paramalignant 
differentiation block and reestablishes the subset composition to a proportion seen in naïve 
mice, thus enabling a more vigorous anti-tumor immune response. Using IFNαR-/- mice, we 
could further identify IFNα as a key effector molecule upon stimulation with TLR ligands in 
vivo. In addition, by performing siRNA experiments in vivo, we could demonstrate that TGFβ 
might be another detrimental cytokine rendering MDSC in an immature immunosuppressive 
state. Finally, we show that stem cell antigen-1 (Sca-1) serves as a highly sensitive maturation 
marker on MDSC, its upregulation significantly correlating with maturation and 
differentiation status and inversely correlating with their suppressive activity as measured by 
their capacity to suppress T cell proliferation ex vivo. 
Taken together, our findings provide further evidence for the concept that targeting the 
disrupted myelopoiesis during tumorigenesis and overcoming the maturation block of MDSC 
is a highly promising approach in cancer immunotherapy. Here we describe a new potential 
antitumor-mechanism of type I IFN and of TLR3- and TLR9-mediated IFNα-induction, namely 
by maturating and differentiating myeloid-derived suppressor cells hence mitigating their 
immunosuppressive properties. Thus, our work further underlines the potential of distinct 
Toll-like receptor ligands such as CpG and poly(I:C) in cancer immunotherapy. 
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4.8 Zusammenfassung 
Die Unterdrückung der immunologischen Tumorabwehr wird wesentlich durch die Induktion 
sogenannter myeloider Suppressorzellen (MDSC) bedingt. Durch Umgehung der 
Immunüberwachung des Wirtes fördern MDSC nicht nur progredientes malignes Wachstum 
und die Entstehung einer metastasierenden Erkrankung, sondern stellen auch ein 
wesentliches Hindernis für effektive Immuntherapien dar. Bedingt durch einen tumor-
induzierten Differenzierungsblock, ist die hämatologische Unreife ein zentrales Merkmal 
myeloider Suppressorzellen. Die Wiederherstellung einer gestörten Myelopoese mit 
konsekutiver Aufhebung der MDSC-assoziierten Immunsuppression bietet daher einen 
attraktiven Ansatz für effektivere Immuntherapien. Ein Element experimenteller 
Tumorimmuntherapien ist der Einsatz von Toll-like Rezeptor-Liganden wie dem TLR3-Ligand 
poly(I:C) oder dem TLR9-Ligand CpG-DNA. Einige Studien schreiben Toll-like Rezeptoren 
jedoch eine zentrale Rolle in der Aktivierung und Expansion myeloider Suppressorzellen zu, 
was deren klinischen Nutzen in Frage stellt.  
Im ersten Teil dieser Arbeit konnten wir mittels Durchflusszytometrie und ex vivo T-Zell 
Suppressions-Assays zeigen, dass eine CpG- und poly(I:C)-vermittelte Toll-like-Rezeptor-
Aktivierung in tumorfreien Mäusen zu einer Akkumulation von myeloiden Vorläuferzellen 
führt, diesen jedoch immunsuppressive Eigenschaften fehlen. Weiterhin stellten tumor-
assoziierte PMN-MDSC nicht nur zahlenmäßig die dominierende Subpopulation dar, sondern 
wiesen auch eine signifikant höhere antiproliferative Wirkung auf T-Zellen als MO-MDSC auf. 
Die in vivo Therapie tumortragender Mäuse mit CpG oder poly(I:C) führte sowohl zur 
signifikanten Reduktion von PMN-MDSC, als auch zur Aufhebung des paramalignen 
Differenzierungsblockes. Mittels IFNαR-/- Mäusen, ließ sich Interferon-α als ein 
Schlüsselmolekül der Toll-like Rezeptor-induzierten Maturierung von MDSC identifizieren. 
Eine entgegengesetzte Rolle konnten wir durch siRNA-basierte in vivo Experimente TGF-β 
als differenzierungsblockierendem Molekül myeloider Zellen zuschreiben. Zuletzt konnten 
wir zeigen, dass stem cell antigen-1 (Sca-1) einen hochsensitiven Differenzierungsmarker für 
die Ausdifferenzierung myeloider Suppressorzellen darstellt, dessen 
durchflusszytometrisches Expressionslevel hochsignifikant mit dem Maturierungsstatus von 
MDSC, sowie invers mit deren antiproliferativer Wirkung auf T-Zellen korreliert. 
Zusammengefasst unterstützen die Ergebnisse dieser Arbeit, dass die Wiederherstellung 
einer normalen Hämatopoese und das Überwinden des Differenzierungsblockes myeloider 
Suppressorzellen einen vielversprechenden Ansatz in der Tumorimmuntherapie darstellen. 
Weiterhin unterstreichen unsere präklinischen Daten den potentiellen Nutzen einer TLR3- 
und TLR9-Liganden vermittelten IFNα-Induktion zur Überwindung einer tumorassoziierten 
Immunsuppression sowie deren klinisches Potenzial.
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6 APPENDIX 
6.1 Abbreviations  
3p Triphosphate 
3pRNA 5‘-triphosphate 2.2 dsRNA 
5-FU 5-Fluoruracil 
A 
AIM2 Absent in melanoma 2 
AKT Protein kinase B 
AP-1 Activated protein 1 
APC  Allophycocyanin 
APC Antigen-presenting cell  
Arg1 Arginase 1 
ASH American society of hematology 
ATRA All-trans retinoic acid 
B 
B7-H1 B7 homolog 1 
BCG Bacillus Calmette-Guerin 
Bcl-2 B-cell lymphoma 2 protein 
BiTE Bi-specific T-cell engager 
BMDM Bone marrow-derived macrophages 
BrdU 5-bromo-2’-deoxyuridine 
Breg Regulatory B cell 
C 
C5a Complement factor 5a  
CARD Caspase recruitment domain 
Cardif CARD adapter inducing IFN-β 
CCL Chemokine C-C motif ligand 
CD Cluster of differentiation  
cDC Conventional dendritic cell 
cDNA  Copy-desoxyribonucleic acid 
CLR C-type lectin receptor 
COX-2 Cyclooxygenase-2 
CpG Oligonucleotide with cytosine-(phosphate)-guanine motifs 
CTL Cytotoxic T lymphocyte 
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CTLA4 Cytotoxic T-lymphocyte antigen 4 
CXCL10 C-X-C motif chemokine 10 
D 
DAMP Damage-associated molecular pattern 
DMEM  Dulbecco's modified Eagle´s medium 
DNA Desoxyribonucleid acid 
DOTAP Dioleoyl trimethylammonium propane 
dsRNA Double-stranded RNA 
dsRNA Double-stranded RNA 
ELISA Enzyme-linked immunosorbent assay 
F 
F4/80 Macrophage-differentiation marker 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
FITC  Fluorescein isocyanate 
FLICA Fluorochrome-labeled inhibitor of caspases 
Foxp3 Forkhead box p3 
FSC Forward scatter 
G 
GM-SCF Granulocyte/macrophage colony-stimulating factor 
GPI-AP Glycosyl phosphatidylinositol–anchored protein 
Gr-1 Granulocyte-differentiation antigen-1 
H 
H2SO4 Sulfuric acid 
HIF Hypoxia inducible factor 
HLA Human leukocyte antigen 
HMGB1 High-Mobility-Group-Protein B1 
HMW High molecular weight 
HNSCC Head and neck squamous cell carcinoma 
HRP Horseradish peroxidase 
HSC Hematopoietic stem cell 
HSP72 Heat-shock protein 72 
I 
ICD Immunogenic cell death 
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ICI Immune checkpoint inhibitor 
IDO Indoleamine 2,3-dioxygenase 
IFN Interferon 
IFNαR Interferon α receptor 
IL Interleukin 
IL-1R Interleukin-1 receptor 
IL-1β Interleukin-1β 
iMC Immature myeloid cell 
iNOS Inducible nitric oxide synthase 
IP10 Interferon gamma-induced protein 10 
IPS-1 Interferon promoter stimulator 1 
IRAK Interleukin-1 receptor associated kinase 
IRF Interferon regulatory factor 
IRF-8 Interferon regulatory factor 8 
IκB  NFκB inhibitor 
J 
JAK2 Janus kinase 2 
K 
k.o. Knockout 
kDa Kilodalton 
L 
LCM L929-conditioned medium 
LGP2 Laboratory of genetics and physiology 2 
LMW Low molecular weight 
LPS Lipopolysaccharide 
LRR Leucin-rich repeat 
Ly6G/C Lymphocyte antigen 6G/C 
M 
mAb Monoclonal antibody 
MACS Magnetic Activated Cell Sorting 
MAL  MyD88-adaptor-like 
MAPK Mitogen-activated protein kinase  
MAVS Mitochondrial anti-viral signaling 
MDA5 Melanoma differentiation-associated factor 5 
MDSC Myeloid-derived suppressor cell 
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MHC Major histocompatibility complex 
MMP9 Matrix metalloproteinase 9 
MO-MDSC Monocytic myeloid-derived suppressor cell 
mRNA Messenger RNA 
MyD88 Myeloid differentiation primary response gene 88 
N 
NEMO NFκB essential modulator 
NFκB Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
NK cell Natural killer cell 
NLR NOD-like receptor 
NLRP3 NOD-like receptor family, pyrin domain containing 3 
NOD Nucleotide-binding oligomerization domain 
O 
ODN Oligodesoxyribonucleotide 
ONOO- Hydrogen peroxide H2O2 and peroxynitrite 
P 
PacBlue Pacific blue 
PacOrange Pacific orange 
PAM3CSK4 Synthetic triacylated lipopetide 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood monocytes 
PBS Phosphate buffered saline 
PD-1  Programmed cell death protein 1 
pDC Plasmacytoid dendritic cell 
PD-L1 Programmed cell death protein 1 ligand 
PE  Phycoerythrin 
PE-Cy7 Phycoerythrin-cyanine dye 7 
PerCP  Peridinin chlorophyll protein 
PGE Prostaglandine E2 
PI Propidium iodine 
PI3K  Phosphoinositide 3-kinase 
PMN-MDSC Polymorphonulcear myeloid-derived suppressor cell 
poly dA:dT Poly(deoxyadenylic-deoxythymidylic) acid 
Poly(I:C) Polyinosinic:polycytidylic acid 
PPARγ Peroxisome proliferator-activated receptor gamma 
PRR Pattern recognition receptor 
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PTO Phosphorothioate 
R 
R848 Resiquimod 
RAGE Receptor for advanced glycation endproducts 
Rb Retinoblastoma 
RIG-I Retinoic acid inducible gene 
RLR RIG-I like receptor 
rlu relative light units 
RNA Ribonucleic acid 
ROS reactive oxygen species 
rtPCR Real-time PCR 
 
S 
s.c. Subcutaneous  
SARM Sterile-alpha and Armadillo motif-containing protein 
Sca-1 Stem cell antigen-1 
SDF Stem-cell derived factor 
SEM Standard error of the mean 
siRNA Small-interfering RNA 
SSC Sideward scatter 
ssRNA Single-strand RNA 
STAT Signal transducer and activator of transcription 
SV40 Simian vacuolating virus 40 
T 
TAA Tumor-associated antigen 
TAM Tumor-associated macrophage 
TAN Tumor-associated neutrophil 
TAP-1 Transporter associated antigen 1 
TBK 1 TANK-binding kinase 1 
TCR T cell receptor 
tDC Tolerogenic dendritic cell 
TGF-β Transforming growth factor beta 
TH1/2 T helper cell 1/2 
TIR  Toll/IL-1 receptor 
TIRAP TIR-associated protein 
TLR Toll-like receptor 
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TMB 3,3’,5,5’ – tetramethylbenzidine 
TNFα Tumor necrosis factor α 
trAb Trifunctional bispecific antibody 
TRAF TNF receptor-associated factor 
TRAM TRIF-related adapter molecule 
Treg Regulatory T cell  
TRIF TIR-containing adapter inducing IFN-β 
V 
VEGF Vascular endothelial growth factor 
VISA Virus-induced signaling adapter 
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